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Abstract
Thromboembolic disorders are a major cause of morbidity and mortality. Therapeutic
intervention with anticoagulants and antiplatelets greatly reduces the risk of arterial and
venous thrombosis. However, the observed large interindividual variation in responsiveness
to these drugs indicates that subsets of patients are not attaining optimal therapy, resulting in
either lack of antithrombotic effect or elevated bleeding risk. Recently, single nucleotide
polymorphisms (SNPs) have been linked to the variation observed in efficacy and toxicity for
many cardiovascular drugs.

Warfarin has been the gold standard anticoagulant for prevention of stroke and
thromboembolism in atrial fibrillation (AF) and venous thromboembolism (VTE) patients.
SNPs in genes that affect warfarin metabolism (CYP2C9) and response (VKORC1) have an
important influence on response and dose, particularly during initiation. Accordingly, we
developed and evaluated the clinical utility of a pharmacogenetics-based initiation nomogram
in AF and VTE patients which provides safe and optimal anticoagulation therapy irrespective
of genetic variation.

The new oral anticoagulant (NOAC) rivaroxaban is highly dependent on the kidney for
elimination through glomerular filtration and active tubular secretion. Importantly,
interindividual variation in exposure and response to rivaroxaban has been reported. Using
cell-based and animal models, we demonstrated that rivaroxaban is a dual substrate of the
ii

efflux transporters MDR1 and BCRP, which played a synergistic role in modulating
rivaroxaban clearance and brain accumulation. The contribution of interindividual variation
in transport and metabolism to the efficacy of rivaroxaban as well as other NOACs requires
to be addressed in patients.

Clopidogrel has been the gold standard antiplatelet for prevention of acute coronary
syndromes and stent thrombosis following percutaneous coronary intervention. Two
enzymes, CYP2C19 and PON1, have been proposed to affect clopidogrel bioactivation and
efficacy. We showed that CYP2C19 but not PON1 is capable of bioactivating clopidogrel to
its active metabolite. This is in line our finding that CYP2C19 genetic variation is a predictor
of clopidogrel pharmacokinetics and antiplatelet response while PON1 is not.

Taken together, these studies demonstrate the contribution of SNPs to the variation in
efficacy and toxicity of cardiovascular drugs, enabling personalized medicine for patients,
where an individual’s genetic makeup is used to guide drug selection and dosing.

Keywords
Oral anticoagulant therapy, antiplatelet therapy, warfarin, clopidogrel, rivaroxaban,
cytochrome P450 enzymes, single nucleotide polymorphisms, pharmacogenomics,
pharmacogenetics, metabolism, pharmacokinetics, pharmacodynamics, thromboembolic
disorders, efflux drug transporters
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1

THROMBOEMBOLIC DISORDERS: PATHOGENESIS
AND RATIONALE FOR ANTICOAGULANT AND
ANTIPLATELET THERAPY

2

1.1

Introduction

Maintenance of blood fluidity within the vasculature is an important human physiological
process. Under normal conditions, there is a fine equilibrium between pathological states
of hypocoagulability and hypercoagulability. Hemostasis refers to a series of normal
physiological processes that confine blood to the vascular spaces, maintain blood fluidity,
and importantly, clot formation to limit hemorrhage following vascular injury.
Thrombosis is pathological clot formation when hemostasis is inappropriately activated
in the absence of a bleeding event. In the 1800s, Rudolf Virchow postulated a triad of
causes for thrombosis formation: changes in the composition of blood, alterations in the
vessel wall, and disruption of blood flow (1). Indeed, in the event of a vascular vessel
injury, a sequence of events is generated in response: vessel constriction to reduce blood
flow, hemostatic platelet plug formation at the trauma site following platelet adhesion,
activation, and aggregation, formation of a fibrin clot to stabilize the platelet plug by
activation of a series of proteins in the coagulation cascade. As such, a thrombus forms in
the presence of alterations in the hemostatic system leading to inappropriate platelet
aggregation and coagulation. A thrombus in a large blood vessel will decrease blood flow
through that vessel while a thrombus in a small blood vessel may completely cut-off
blood flow resulting in an occlusive thrombus. An embolism is the dislodging of the
thrombus from the site of formation that travels to a distal vessel leading to blood flow
blockage in a distant part of the body.
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Thromboembolic disorders are a significant source of mortality and morbidity. There are
two types of thrombosis, arterial and venous thrombosis, whereby the clinical and
therapeutic management differs, reflecting the distinct pathogenesis of the two
classifications. Arterial thrombosis usually occurs after the erosion or rupture of an
atherosclerotic plaque, potentially leading to ischemic events. Cardiac ischemia and
stroke are the most devastating clinical manifestations of atherothrombosis. Venous
thromboembolism (VTE) is represented by two main manifestations, deep venous
thrombosis (DVT) and pulmonary embolism (PE). The most devastating clinical
consequence of VTE is PE where majority of PEs result from DVT that have dislodged
from site of formation in the lower extremities and traveled to the pulmonary circulation.

Understanding the pathogenic processes leading to either arterial or venous thrombosis is
crucial for selecting effective and safe antithrombotic agents for management of patients
with thromboembolic disorders. While arterial thrombosis undoubtedly involves the
coagulation cascade, platelet activation and aggregation plays a more prominent role in
the rapidly flowing arteries. As such, arterial thrombosis is often referred to as white clot,
rich in platelets and little red blood cells. On the other hand, venous thrombosis is
associated with venous stasis and hypercoagulability. Thus, the coagulation cascade plays
a prominent role in formation of a venous thrombus, often referred to as red clot due to
the abundance of red blood cells and little platelets.
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1.2

Hemostasis

The endothelium of blood vessel walls plays an important role in maintaining vasculature
integrity. Vessel wall damage or disruption of the endothelium leads to exposing the
collagen present in the subendothelial matrix, resulting in platelet activation, aggregation,
and formation of a primary platelet plug. Concurrently, subendothelial tissue factor (TF)
is also exposed on the damaged endothelium leading to activation of the coagulation
cascade, resulting in formation of a fibrin mesh to stabilize the platelet plug (2).

1.2.1

Platelet activation

Platelets are small disk shaped colorless cells present in the blood that play a vital role in
hemostasis and are the key factor in the pathogenesis of arterial thrombosis. Vascular
injury may cause the rupture of an atherosclerotic plaque and denudation of the
endothelium (Figure 1.1). The exposure of subendothelial collagen bound to a protein
known as von Willebrand factor (vWF) facilitates platelet adhesion to the vessel wall. At
the site of injury, vWF binds platelets via the glycoprotein Ib/IX/V receptor complex on
the platelet membrane (3). At low shear rates, platelets can also bind to subendothelial
collagen through other receptors such as the glycoprotein IV, VI, and Ia/IIa. Upon
adhering to the vessel wall, platelets release the granules of platelet agonist thromboxane
A2 and adenosine diphosphate (ADP), initiating an autocrine/paracrine signaling cascade
of platelet activation. Activated platelets undergo a change in morphology from smooth
disks to irregular spheroids with filopodia, allowing platelets to bind to one another for
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platelet aggregation. The formation of this hemostatic plug is essential for wound healing.
However, formation of a thrombotic occlusion in coronary arteries can cause tissue
ischemia leading to conditions known as acute coronary syndromes (ACS), in the form of
either unstable angina or myocardial infarction (MI).
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Figure 1.1 Schematic representation of arterial thrombosis.
An atherosclerosis plaque develops through the accumulation of lipid deposits. The
rupture of an atherosclerotic plaque is the primary trigger for arterial thrombosis by
promoting platelet activation and fibrin generation.
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1.2.2

Coagulation cascade

The coagulation cascade plays a pivotal role in forming the fibrin mesh to reinforce the
hemostatic platelet plug. The ultimate formation of fibrin is dependent on two distinct
pathways: the extrinsic and intrinsic pathway. It was previously thought that both
pathways were equally crucial to hemostasis. However, it is evident now that the
extrinsic pathway is the predominant pathway for initiation and activation of the
coagulation cascade during hemostasis and response to vascular injury. The intrinsic and
extrinsic pathways are activated by distinct factors but merge into a common pathway to
activate thrombin and form fibrin. The ultimate generation of fibrin is governed by
initiation, amplification, and propagation of coagulation (4). The ability to form a fibrin
clot is dependent on a series of serine proteases that are clotting factors and/or cofactors
(Figure 1.2). These clotting factors are chronologically activated producing thrombin by
stepwise activation of a series of proenzymes.

During initiation phase, the extrinsic cascade is activated by tissue injury or trauma
triggering the exposure of TF on subendothelial cells, an essential cofactor for factor VII
(4). Activated factor VII, a serine protease will subsequently cleave factor X and factor V
to Xa and Va, respectively, to combine with phospholipid and calcium to form the
prothrombinase complex. The complex then cleaves a small amount of prothrombin
(factor II) to active thrombin (factor IIa). In addition to activating platelets, this small
amount of thrombin amplifies the coagulation reactions by positive feedback. Thrombin
activates factor V and VIII on the platelet surface leading to a burst of activated clotting
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factors ready to generate thrombin. On activated platelets, factor XIa activates IX to IXa,
which forms the tenase complex with factor VIIIa to activate factor X. Finally, factor Xa
and factor Va forms the prothrombinase complex in abundance to produce the thrombin
burst. The propagation of thrombin generation converts fibrinogen to fibrin for forming
the mesh.

The intrinsic pathway begins with the formation of a primary complex of coagulation
factors, including high molecular weight kininogen, prekallikrein, and factor XII, driven
by the collagen exposed on the damaged blood vessel wall (4). Prekallikrein is converted
to kallikrein and factor XII is activated to factor XIIa through a process called
autoactivation, resulting in the activation of factor XI to factor XIa. Subsequently, factor
XIa activates factor IX to factor IXa, which associates with factor VIIIa to form the
tenase complex to activate factor X to factor Xa. Lastly, the intrinsic pathway merges
with the extrinsic pathway in the common pathway where factor Xa activates
prothrombin to thrombin to form fibrin. The minor role that the intrinsic pathway plays in
hemostasis is evident in the fact that patients with deficiencies in primary proteins
prekallikrein, high molecular weight kininogen, and factor XII do not have lifethreatening bleeding disorders.
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Figure 1.2 Schematic representation of the coagulation cascade.
The coagulation cascade can be activated by intrinsic and extrinsic factors to ultimately
generate thrombin and fibrin.
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1.3
1.3.1

Thrombosis
Arterial thrombosis

Arterial thrombosis (Table 1.1) typically occurs in conjunction with vascular
abnormalities that are the result of atherosclerosis (buildup of cholesterol and fatty
plaques on the inner walls of arteries), leading to coronary artery disease (CAD). ACS
reflects the clinical manifestations attributed to CAD, thrombus formation, and occlusion
of the coronary arteries. It has been suggested that thrombotic coronary occlusion
accounts for 50 - 70% of sudden deaths caused by ischemic heart disease (5). The three
types of ACS are unstable angina, non-ST segment elevation MI (NSTEMI), and ST
segment elevation MI (STEMI). An arterial thrombus that is fibrin-rich is often fully
occlusive, results in STEMI as characterized by clinically significant changes on an
electrocardiogram (ECG). Platelet-rich thrombus is likely partially occlusive, resulting in
unstable angina and NSTEMI, with little change on an ECG. Antiplatelet therapy is the
primary therapy for prevention of ACS recurrence.

1.3.2

Atrial fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting a significant
portion of the elderly population. Statistics show that there are currently 5.2 million
individuals with AF in North America and this number is expected to increase
substantially by 2050 as a consequence of the aging population (6). The incidence of AF
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increases from 2.3% among individuals over age 40 to 5.9% among individuals over 65.
The most devastating complication of AF is stroke, resulting from cardioembolization to
the central nervous system. In all age groups of AF patients, the incidence of stroke is
increased by four to five fold with a high mortality rate (7). Furthermore, stroke risk may
increase up to seven fold in presence of additional risk factors such as hypertension,
diabetes, and heart failure.

The pathophysiology of AF is such that the abnormal electrical charges from the atria
reduce the ability to pump blood into the ventricles resulting in stagnant blood flow
particularly in the left atrial appendage. The stasis in this area in individuals with
prolonged or insufficiently treated AF is a significant contributing factor to thrombus
formation. Indeed, more than 90% of the thrombi associated with nonvalvular AF
(absence of mitral valve disease) have been found in the left appendage (8). Emboli
carried away from thrombus formation site to the brain cerebral vessels may result in an
ischemic stroke or a transient ischemic attack (TIA).

AF has been associated with markers of coagulation and platelet activation that reflects
its hypercoagulable state. It has been shown that both vWF and TF are overexpressed in
the atrial endothelium of AF patients (9). Based on available evidence, pathogenesis of
thromboembolism in AF patients follows Virchow’s triad for thrombogenesis (9).
Although a thrombus formed in the left atrial appendage is considered as an arterial
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thrombus, the characteristics of an AF thrombus appear to be more similar to a venous
clot. Therefore, anticoagulation therapy is recommended as the primary therapy for
stroke risk reduction.

CHADS2 Score
The risk of stroke in AF patients is compounded with co-existing risk factors. The
CHADS2 score is a clinical prediction tool for estimating the risk of stroke in patients
with nonvalvular AF, where the annual stroke risk significantly increases in individuals
with higher CHADS2 scores (10). This system also allows for determining the
recommended treatment regimen, in terms of whether to initiate therapy with an
antiplatelet or oral anticoagulant. Components of the CHADS2 score include congestive
heart failure, hypertension, age ≥ 75, diabetes, and prior history of stroke or TIA (Table
1.3.2).
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Table 1.3.1 Risk factor and characteristic differences between arterial thrombosis
and venous thrombosis.
Arterial Thrombosis

Venous Thrombosis

Artery

Vein

Atherosclerosis

Stasis

Underlying cardiovascular disease

Irregular thrombin generation

Platelet rich

Red blood cell rich

Platelet aggregation dominates

Coagulation cascade dominates
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Table 1.3.2 CHADS2 scoring system for determining stroke risk in atrial fibrillation
patients.
Condition

Points

C

Congestive heart failure

1

H

Hypertension

1

A

Age ≥ 75

1

D

Diabetes mellitus

1

S2 Prior stroke or transient ischemic attack

2
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1.3.3

Percutaneous coronary intervention

Percutaneous coronary intervention (PCI) is often part of the standard of care for ACS
patients, particularly those presented with STEMI or NSTEMI. The PCI procedure has
evolved dramatically since its introduction with bare-metal stents (BMS) to the
availability of drug-eluting stents (DES). The development of DES was to incorporate the
release of pharmacological agents in the stent design to inhibit responses to injury, a
primary contributor to restenosis after BMS implantation (11). However, although
restenosis rates are evidently reduced with DES, stent thrombosis (ST) rate has not
decreased. ST is the sudden occlusion of a stented coronary artery as a result of thrombus
formation, a severe complication after implantation owing to its high mortality (12). A
number of trials have observed occurrence of acute, subacute, and late ST following DES
implantation, and the rate is suspected to be substantially greater in the real-world
population (12). Moreover, ST as long as three years after stent implantation has been
noted with DES, which was rarely seen with BMS.

The pathogenesis of ST has not been completely delineated; however, factors increasing
risk of ST include the procedure itself, patient and lesion characteristics, and premature
cessfation of antiplatelet drugs (13). Stent implantation itself induces platelet adhesion
and activation of the coagulation cascade, as it is the introduction of a foreign object in
the vessel wall. DES were developed to prevent restenosis by reducing vascular smooth
muscle

cell

proliferation

and

migration

(13).

However,

they

also

impair

reendothelialization, which prolong arterial healing and in fact, have been found to
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induce TF expression and thereby thrombogenesis (14). Lastly, DES impair the
endothelial function of coronary arteries, promoting risk of ischemia and coronary
occlusion (13).

1.3.4

Venous thrombosis

In contrast to arterial thrombosis, venous thrombosis is typically not associated with
underlying vascular pathology (Table 1.3.1). VTE comprises of DVT and PE; DVT
occurs most often in the large veins of the lower extremities and when part of the
thrombus dislodges, the embolism can travel to the lungs to block blood flow to the
pulmonary artery resulting in PE. Venous stasis is an important risk factor for VTE by
promoting thrombus formation with reduced ability to clear activated coagulation factors
away from the site of injury (15). In fact, majority of venous thrombi is formed in regions
of slow blood flow (15). Stasis may be caused by immobility, orthopaedic surgery, and
increased venous pressure. Overall, prolonged impairment of venous function, sustained
hypercoagulability, and imbalance in the endogenous anticoagulant and fibrinolytic
systems all contribute to the risk of developing a clinically significant thrombus.

As previously noted, venous thrombi mostly consist of red blood cells and fibrin and
activation of the coagulation cascade is the primary contributor to venous thrombosis.
Thus, anticoagulant therapy is the primary therapy for prevention and management of
VTE.
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1.4
1.4.1

Therapeutic interventions
Oral anticoagulant therapy

For many decades, the vitamin K antagonist warfarin has been the gold standard of
therapy for prevention of ischemic stroke in AF patients. The mechanism of action of
warfarin is inhibition of vitamin K dependent clotting factor (II, VII, IX, X) activation in
the liver. In 1994, it was demonstrated in a group 3,692 patients that warfarin treatment
reduced stroke risk by 68% compared to individuals without treatment, along with
minimal bleeding risk (16). Indeed, pooled-analysis of six large randomized clinical trials
(RCTs) comparing aspirin with warfarin demonstrated superiority of warfarin in
reduction of ischemic stroke rate compared to aspirin (17). Furthermore, a meta-analysis
of 29 trials incorporating 28,044 AF patients demonstrated that warfarin improved the
incidence of stroke outcomes by 40% compared to antiplatelet therapy (18).

Anticoagulation therapy is also crucial for prevention of recurrent DVT and PE. Oral
anticoagulant therapy with warfarin has been the mainstay of long-term treatment and
prophylaxis of VTE (19). However, warfarin has an indirect pharmacological mode of
action whereby it inhibits the vitamin K epoxide reductase (VKOR) enzyme to prevent
the formation of coagulation factors in the liver (20). Thus, the onset of warfarin’s
anticoagulation activity is typically delayed up to 48 hours following initiation. In the
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setting of VTE, immediate anticoagulantion is necessary for minimizing risk of
recurrence. Accordingly, subcutaneous low-molecular-weight heparin (factor Xa
inhibitor) is the anticoagulant of choice to be used concurrently with warfarin during the
initial days of overlapping therapy.

We note here that although warfarin has been the gold standard of therapy for the past 60
years, its shortcomings (including the wide interindividual variation in responsiveness
and the need to titrate dose to therapeutic response using continuous monitoring) have led
to the development and market approval of several new oral anticoagulants. These new
agents exert therapeutic efficacy by directly inhibiting the coagulation cascade in the
systemic circulation. The new oral anticoagulants include direct thrombin inhibitors such
as dabigatran, and factor Xa inhibitors such as rivaroxaban and apixaban. The clinical
implications of the new agents to oral anticoagulation therapy will be discussed in the
forthcoming chapters.

1.4.2

Antiplatelet therapy

Antiplatelet therapy has emerged as a major success in reducing the risk for MI
associated with CAD. Currently, dual antiplatelet therapy with clopidogrel and aspirin is
the mainstay of therapy for prevention of recurrent cardiovascular events in patients with
ACS, and prevention of ST following PCI (21). The rationale for the dual therapy is to
block two important pathways involved in platelet aggregation. Clopidogrel is a
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thienopyridine drug, which inhibits ADP-mediated platelet activation by irreversibly
binding to P2Y12 G-protein coupled receptors on platelets (22). Aspirin exerts its
antiplatelet effect by inhibiting the activity of cyclooxygenase-1 (COX-1), preventing the
production of thromboxane A2 from arachidonic acid (22). Dual antiplatelet therapy has
been demonstrated to be effective in reducing arterial thrombosis and ischemic events in
large RCTs such as CURE and PCI-CURE (23, 24).

1.5

Conclusions

Thromboembolic disorders are major causes of morbidity and mortality. Failure to
provide optimal therapeutic intervention to reduce risks of stroke, ACS, and recurrent
VTE will undoubtedly be a significant health burden. As outlined earlier, the therapeutic
treatment of thromboembolic disorders heavily depends on the pathogenesis of the
disease. In conditions of high blood flow (arterial thrombosis), the dominant role of
platelets in the formation of a thrombus is the basis for use of antiplatelets in primary
treatment. On the other hand, the coagulation cascade plays a more prominent role in low
blood flow conditions (venous thrombosis) and anticoagulant therapy is more
appropriate. However, review of hemostasis demonstrates that platelet activation and
coagulation cascade play a synergistic role in thromboembolic events. Accordingly,
combination therapy with anticoagulants and antiplatelets cannot be ruled out for better
prevention of thromboembolic events compared to each therapy alone for high-risk
patients. Finally, it is important to note that antithrombotic therapy represents a double-
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edged sword such that greater prevention of thrombosis is also associated with greater
risk of bleeding. Thus, delivering optimal antithrombotic therapy to individual patients at
risk for thrombosis will not only augment therapeutic prevention of thromboembolic
events but also minimize drug-related hemorrhagic risk.
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PHARMACOGENETIC ADVANCES IN
CARDIOVASCULAR MEDICINE: RELEVANCE TO
PERSONALIZED MEDICINE1

____________________________

1

Portions of this chapter is reprinted with permission from Gong IY, Kim RB. 2013.
Pharmacogenetic advances in cardiovascular medicine: Relevance to personalized
medicine. Current Genetic Medicine Reports 1(1) 1:14. Copyright 2013 Springer.
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2.1

Introduction

Clinical trials have clearly demonstrated the therapeutic benefit for many cardiovascular
agents; however, some patients, even on the same dose, exhibit loss of efficacy or higher
risk of toxicity. We know that while an average dose of a medication can benefit a large
proportion of the patient population, the one-size-fits-all dosing regimen disregards the
importance of identified variation in drug metabolism, transport, and response pathways
known to exist in any given population. Not surprisingly, preventable adverse drug
reactions (ADRs) often occur in subsets of susceptible patients. Interindividual
differences in drug response are multifactorial and may be explained by an array of
factors including environmental, genetic, comorbidities, and drug-drug interactions.

Advances in the field of pharmacogenetics over the past decade have dramatically
improved our understanding of the impact of genetic variability to observed variation in
drug response and toxicity. Accordingly, we now have the capability to use an individual
genetic makeup in combination with clinical variables to choose appropriate drug therapy
and dosages in an a priori fashion. Therefore, the field of pharmacogenetics has
significant implication for optimizing cardiovascular drug therapy, considering the large
proportion of patients with cardiovascular disease requiring pharmacotherapy.
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Associations of genetic variations with drug response largely fall within two categories
(Figure 2.1): and polymorphisms that affect drug pharmacokinetics by introducing
variability in systemic drug exposure; polymorphisms that affect pharmacodynamics by
affecting the drug’s ability to act at the target site. Not surprisingly, for the most part,
candidate gene approaches have been used to identify single nucleotide polymorphisms
(SNPs) in genes suspected to influence variation in response. On the other hand, genomewide association studies (GWAS) for drug response represent an unbiased screen across
the entire genome and may inform novel pathways of relevance to ADRs or therapeutic
response.

We now see a number of pharmacogenetic linkages for a number of medications, some of
which have resulted in FDA label changes to incorporate guidance on consideration of
genetic information during treatment. The present review highlights the genetic
determinants of commonly used cardiovascular drugs (Table 2.1), and how the use of
such information may enhance patient care in a clinical setting.

27

Non-Responders:
Increase dose or
alternative therapy

Gut
Wall

Adverse Drug Reactions:
Decrease dose or
alternative therapy

Portal
Vein
Drug
Transporter

Enzyme

Drug
Transporter

Responders
Metabolism

Target Site of
Action
Enterocyte

Hepatocyte

Figure 2.1 Pharmacogenetic determinants of interindividual variability in
cardiovascular therapy.
Genetic variability in drug transporter and metabolizing enzymes expressed at the level of
enterocytes and hepatocytes affect pharmacokinetics and overall disposition. Genetic
variability in the gene(s) encoding the drug’s pharmacological target affects
pharmacodynamics. Identified genetic variants confer altered drug sensitivity, response
and toxicity, allowing classification of patients as responders or nonresponders.
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Table 2.1.1 Summary of current evidence in cardiovascular pharmacogenetics.

Drug

Warfarin

Drug
Class

Description

Gene(s)

Catego
ry

Clinical
Problem

tion

Variation in

CYP2C9*2,

dose

CYP2C9*3,

requirement

VKORC1 -

Anti-

for achieving

1639G>A

coagula

and

nt

maintaining

CYP2C9,
VKORC1

PK, PD

carriers
have

INR in

increased

therapeutic

sensitivity

range

to warfarin
CYP2C19*
2 and

Clopido

Anti-

grel

platelet

Variation in

CYP2C19*

antiplatelet

3 carriers

response

have

leading to

CYP2C19

PK

Implementa

insufficient

resistance in

active

a subset of

metabolite

patients

formation
leading to
resistance

Dose
reduction for
loss-offunction
variant
carriers

Dose
increase or
consider
newer
antiplatelet
agents for
loss-offunction
variant
carriers

CYP, cytochrome P450; PD, pharmacodynamics; PK, pharmacokinetics; VKORC1,
vitamin K epoxide reductase subunit 1.
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2.2
2.2.1

Oral Anticoagulants
Warfarin

The vitamin K antagonist warfarin is a common oral anticoagulant prescribed in North
America for stroke prevention in atrial fibrillation (AF) patients and thromboembolism
prophylaxis in venous thromboembolism (VTE) (1). However, warfarin therapy is
particularly challenging due to marked and often unpredictable interindividual dosing
variation (up to 20-fold) to reach and maintain adequate anticoagulation. Not
surprisingly, its clinical use is associated with ADRs, mainly in the form of bleeding
events; in fact, warfarin was recently reported to account for one-third of hospitalizations
in the elderly (2). For most indications, optimal warfarin therapy is achieved by
maintaining the international normalized ratio (INR) within a narrow therapeutic range of
2-3. An insufficient warfarin dose leads to a lack of antithrombotic effect while overanticoagulation is associated with elevated bleeding risk. Aside from demographic (age,
gender, weight) and clinical variables (renal or hepatic disease, diet, drug-drug
interactions), pharmacogenetics explains a large portion of the observed variability in
warfarin dose requirement (3).

2.2.1.1

CYP2C9

Warfarin is administered as a racemic drug; S-warfarin is 3-5 times more potent than Rwarfarin. The clearance and thus pharmacokinetics of warfarin is largely dependent on
the metabolic pathways of each enantiomer. While CYP1A2, CYP3A4, and CYP2C19
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are enzymes that convert the R-warfarin to its inactive metabolite in varying extents,
CYP2C9 is the primary enzyme responsible for metabolism of S-warfarin. As such,
candidate gene studies have consistently shown that CYP2C9 polymorphisms
significantly affect warfarin sensitivity (4). In particular, common CYP2C9*2 and *3
variant alleles result in decreased enzymatic activity (30 and 90 % reduction,
respectively) compared to the wild-type allele (5). The clinical implication for these
SNPs is lower therapeutic dose requirement, increased time to stable anticoagulation and
increased bleeding risk due to greater rate of over-anticoagulation (6). A large metaanalysis of 39 studies (n = 7,907) demonstrated that maintenance dose for CYP2C9*2 and
*3 homozygous patients were 36 and 78 % lower, respectively, as compared to wild-type
patients (7).

2.2.1.2

VKORC1

S-warfarin inhibits the vitamin K epoxide reductase, encoded by VKORC1, the enzyme
responsible for recycling oxidized vitamin K to the reduced form, an essential cofactor
for γ-glutamyl-carboxylase carboxylation (GGCX) in clotting factor II, VII, IX and X
activation (8). Common genetic variants in VKORC1 result in altered warfarin sensitivity
while rare polymorphisms result in warfarin resistance (9). Of note, the common
promoter SNP (VKORC1 -1639G>A, rs9923231) is thought to be the causative variation
responsible for the greater warfarin sensitivity, resulting in lowered dose requirement
(10).
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2.2.1.3

Other SNPs

In addition to CYP2C9 and VKORC1 polymorphisms, SNPs in other genes have been
studied as potential contributors to warfarin response. These genes include GGCX,
calumenin (CALU), apolipoprotein E (ApoE) as well as multidrug resistance protein
(ABCB1) (11). However, the impact of these polymorphisms on warfarin response has
generally been minimal or none at all. An exception to this is the growing importance of
the CYP4F2 1297C>T genotype, whereby several retrospective studies have
demonstrated that variant T carriers (rs2108622) require 1 mg more than wild-type C
carriers (12). Moreover, CYP4F2 is the metabolizing enzyme of vitamin K accounting for
the pharmacological basis of the dose difference (13). However, CYP4F2 genotype only
accounts for a small portion of the observed maintenance dose variability (0-4%) (14).
These findings were confirmed by recent GWASs, where polymorphisms in CYP2C9 and
VKORC1 were the only genetic markers identified to influence warfarin dosing, while the
CYP4F2 genotype was only significant after adjusting for CYP2C9 and VKORC1 (15).

2.2.1.4

Clinical Applicability of SNPs

CYP2C9*2, CYP2C9*3 and VKORC1 -1639G>A variant carriers are at an increased risk
of over anticoagulation (INR > 4) and bleeding as well as delayed time to therapeutic
efficacy. Based on these findings, the FDA approved a new label for warfarin in 2007
advising physicians to consider pharmacogenetic testing for patients requiring warfarin.
Many dosing algorithms have been developed to predict warfarin dose requirement using
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CYP2C9, VKORC1, and CYP4F2 SNPs and clinical parameters (16). The majority of
these studies have focused on the effect of genetic variation on warfarin dose during
maintenance phase of anticoagulation. However, warfarin initiation is arguably the most
challenging therapeutic phase where risk of hemorrhage and recurrent VTE are greatest
(17). Moreover, we and others demonstrated that CYP2C9 and VKORC1 modulate
wafarin response even during early anticoagulation (18).

2.2.1.5

Clinical Implementation

There is a strong association between CYP2C9 and VKORC1 SNPs with warfarin
response and dose. However, the widespread use of pharmacogenetics-based warfarin
dosing remains has not yet been achieved, in part related to concerns regarding costs
associated with pharmacogenetic testing and additional clinical evidence to support
superiority of a pharmacogenetics-based approach. Recently, the COUMAGEN-II trial
showed clear superiority of pharmacogenetics-based warfarin dosing over standard care
with respective to time spent in therapeutic range and reduced occurrence of ADRs (19).
Additionally, a recent large scale community-based study found that genotyping during
warfarin therapy reduced the hospitalization rate for bleeding or thromboembolic event
by 30 % compared to a historical control group (20). A number of RCTs
(www.clinicaltrials.gov; COAG, GIFT, EU-PACT) involving larger sample sizes are
currently underway to more fully confirm such findings focusing on safety and efficacy
of pharmacogenetics-based dosing compared to standard dosing. Given the extent of
supportive evidence to date for warfarin, pharmacogenetics-based warfarin dosing is
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likely to be widely implemented, particularly given the rapid improvement in genotyping
technologies that has resulted in greater accuracy, turn-around time, and lower cost.

2.2.2

New oral anticoagulants: dabigatran, rivaroxaban, and
apixaban

Dabigatran, a direct thrombin inhibitor, and factor Xa inhibitors rivaroxaban and
apixaban, are new oral anticoagulants recently approved for AF and VTE. Dabigatran
etexilate is a pro-drug, requiring bioactivation to active dabigatran by esterases while
rivaroxaban undergoes metabolism predominantly by CYP2J2 and CYP3A4 (21).
Interestingly, all agents are substrates of P-glycoprotein (ABCB1) while rivaroxaban and
apixaban are also substrates of breast cancer resistance protein (BCRP) (22). Very
recently, a genome-wide subanalysis of the RE-LY trial demonstrated that a common
variant in the carboxylesterase 1 (CES1) gene (rs2244613) was associated with
dabigatran-related bleeding events. The polymorphism is thought to attenuate dabigatran
formation resulting in lowered systemic exposure and reduced bleeding risk, indicating
the potential for pharmacogenetics-based dosing. Further studies are needed to confirm
these findings in addition to identification of additional genetic variations in candidate
genes such as ABCB1 and BCRP to determine SNPs capable of modulating the efficacy
and toxicity of these new agents.
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2.3
2.3.1

Antiplatelets
Aspirin

Aspirin is commonly prescribed for prevention of cardiovascular events. Aspirin
irreversibly binds and inactivates cyclooxygenase (COX) 1 and 2 in platelets, and thereby
reduce platelet aggregation (23). The term of aspirin resistance has been coined to note
the occurrence of cardiovascular events, presumably related to suboptimal antiplatelet
inhibitory effect in patients prescribed with therapeutic doses of aspirin. However,
classification of aspirin resistance has been highly controversial with prevalence of 5 – 60
% depending on the population and ex vivo response measurement used; a patient defined
as a non-responder in one test would be normal in another (24). Therefore, it has been
challenging to interpret the relevance of genetic markers associated with aspirin response.

2.3.1.1

PTGS1

Since COX1 is the direct pharmacological target of aspirin, considerable amount of focus
has been on the COX1 encoding gene, PTGS1. However, results of such studies have
been variable. Although genetic polymorphisms in this gene have been linked to greater
platelet aggregation in some studies, many others failed to replicate such an effect or find
an association with cardiovascular events such as myocardial infarction (MI) (25).
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2.3.1.2

Other SNPs

Several other genes encoding platelet activation pathway proteins have been linked to
aspirin antiplatelet response. The ITGB3 gene encodes GPIIIa protein and carriers of the
risk allele (rs5918) appear to confer elevated risk of MI, arterial and venous thrombosis.
However, other studies in this regard have been conflicting (25). A recent study found
carriers of an intronic SNP in the PEAR1 gene (rs12041331) corresponded to higher
aspirin response (26). Additionally, a SNP in the LPA gene (rs3798220) determined
plasma levels of apolipoprotein A and associated with differential aspirin efficacy in a
large placebo-controlled trial (27).

2.3.1.3

Clinical Implementation

The extent of clinically relevant genetic markers and their role to aspirin response remain
to be defined. The lack of consistent associations indicates it may be premature to include
genetic testing for aspirin therapy, at least based on currently published genetic markers.
It addition, a key impediment has been the lack of a standardized antiplatelet response
measurement assay for aspirin prescribed patients.

36

2.3.2

Clopidogrel

Antiplatelet therapy with thienopyridine is an important therapeutic intervention for the
prevention of ischemic events in patients with high-risk cardiovascular disease,
particularly for those undergoing percutaneous coronary intervention (PCI) (28).
Clopidogrel is the most widely prescribed thienopyridine known to exert its
pharmacological effect by irreversibly binding to P2Y12 receptors on platelets, thereby
diminishing platelet aggregation (29). Although benefits from clopidogrel has been
widely documented in large clinical trials, marked interpatient variation in platelet
responsiveness has meant that 21 % of patients (termed nonresponders) remain at risk for
coronary artery and stent thrombosis (30).

2.3.2.1

CYP2C19

Clopidogrel is a prodrug and its clinical efficacy is a function of the amount of
enzymatically derived active thiol metabolite formed (H4) (31). While most of the
prodrug undergoes hydrolysis to an inactive metabolite, clopidogrel bioactivation is a
two-step process catalyzed by several CYP isozymes (32). Both metabolic steps leading
to H4 formation have been shown to be predominantly dependent on CYP2C19, and to a
lesser extent CYP3A4 (32).
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A number of studies have examined the influence of genetic variation in CYP enzymes
on clopidogrel antiplatelet response. The most consistent finding is that CYP2C19*2
(rs4244285) and CYP2C19*3 (rs4986893) loss-of-function SNPs results in lower platelet
inhibition, high on-treatment platelet reactivity and consequently, an increased risk of
major cardiovascular events, particularly stent thrombosis in PCI patients (33). A metaanalysis including nine studies (n = 9,685) reported a gene-dose effect for variant
carriers; one reduced function allele carrier had a hazard ratio of 1.57 (95 % confidence
interval, 1.13-2.16) for a composite of cardiovascular endpoints while carriers of two
reduced function alleles had an even greater risk (hazard ratio 1.76, 1.24-2.5) (33).
Another common CYP2C19 polymorphism (*17, rs3758581) results in increased enzyme
activity, greater efficacy, and better cardiovascular outcomes at the expense of increased
bleeding risk (34). These findings prompted the FDA to update the clopidogrel label with
a boxed warning for cautious use amongst CYP2C19 reduced function carriers.

2.3.2.2

ABCB1

Clopidogrel has been demonstrated to be a substrate of P-glycoprotein, which limits the
extent of its bioavailability. Not surprisingly, the ABCB1 3435C>T SNP (rs1045642) has
been shown to result in lower peak concentrations of clopidogrel and its active metabolite
(35). However, the definitive role of this SNP on clopidogrel antiplatelet response
remains controversial. While Mega et al. reported that the elevated cardiovascular risk of
CYP2C19 variant allele carriers was accentuated in presence of homozygous 3435C>T
genotype, other studies could not replicate this finding (36, 37).
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2.3.2.3

P2Y12

Clopidogrel exerts its pharmacodynamics effects by inhibition of P2Y12 receptor on
platelets. Recently, Ziegler et al. reported a fourfold increase in cerebrovascular events in
patients possessing the 34C>T (rs6809699) variant while another variant, 52G>T
(rs6785930), confers clopidogrel resistance following PCI (38). However, other studies
have failed to show the same trend for antiplatelet response and cardiovascular events
(39).

2.3.2.4

Other SNPs

CYP2C19 undoubtedly predicts cardiovascular outcomes in patients treated with
clopidogrel following PCI, yet it is thought to represent only a portion of the observed
variation in antiplatelet response. A GWAS demonstrated that clopidogrel platelet
aggregation was highly heritable (r2 = 0.73) in an Amish population (40). However, the
CYP2C19*2 SNP only accounted for 12 % of the interindividual variation, indicating that
other genetic markers affecting efficacy remain to be identified to explain the large
heritable component of clopidogrel response. More recently, the Scripps Clinic conducted
whole genome sequencing in 392 patients on clopidogrel and found two novel genes
ATP2B2 and TIAM2 to predict poor platelet response (unpublished data).
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2.3.2.5

Clinical Implementation

Clopidogrel resistance and the lack of adequate therapeutic efficacy is a major concern,
thus identification of resistant patients prior to treatment is of great value for favorable
outcomes. Although there is ample evidence linking CYP2C19 with cardiovascular
outcomes in PCI patients, RCTs assessing the benefit of genotyping for CYP2C19 over
standard care has yet to be conducted. One recent RCT using point-of-care CYP2C19*2
genotyping showed that such genetic information led to better prediction of antiplatelet
response in a real world setting, indicating that personalized clopidogrel therapy may be
effective in improving efficacy (41). Accordingly, a number of institutions (Vanderbilt
University Medical Centre, Scripps Clinic) adopted routine CYP2C19 genotyping for
patients undergoing PCI (42). Conversely, although several small prospective trials have
restored diminished H4 exposure and poor antiplatelet response in CYP2C19 variant
carriers by increasing clopidogrel loading and maintenance dose (43), recent larger
studies failed to overcome the reduced antiplatelet response in individuals harboring
CYP2C19*2 variant alleles (44). This indicates that clopidogrel potency at the P2Y212
receptor is likely inadequate for CYP2C19 variant carriers. Accordingly, the Clinical
Pharmacogenetics Implementation Consortium suggested that newer antiplatelet agents
with greater affinity and potency (prasugrel and ticagrelor) should be considered for
carriers of one or two loss-of-function variant alleles (45). Indeed, CYP2C19*2 carriers
were more likely to switch to prasugrel due to high on-treatment platelet reactivity (46).
Current ongoing studies include the GIANT trial which will assess the clinical efficacy of
using high-dose clopidogrel for CYP2C19*2 carriers and the RAPID-STEMI trial that
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will evaluate efficacy of either high-dose clopidogrel or switching to prasugrel for
CYP2C19*2 and ABCB1 3435TT carriers.

2.3.2.6

New Antiplatelets: Prasugrel and Ticagrelor

Neither agents require extensive bioactivation by CYP2C19. Thus, CYP2C19 genetic
variation has not been demonstrated to affect cardiovascular outcomes in subanalysis of
the TRITON-TIMI (prasugrel) or the PLATO (ticagrelor) trial (47). However, we note
that CYP3A4 and CYP2B6 are responsible for bioactivation of prasugrel to its active
form, and the influence of polymorphisms in these enzymes to prasugrel platelet efficacy
remains to be delineated. An important consideration of prasugrel use over clopidogrel is
that, although it proved more efficacious than clopidogrel, this is at the price of increased
bleeding risk. Similarly, ticagrelor use over clopidogrel is complicated by the finding that
ticagrelor was as effect as clopidogrel across all international centres of PLATO trial
except for North America.

2.4

Conclusions

Interindividual variation in drug exposure and efficacy lead to subsets of patients
experiencing drug-related toxicities or inadequate therapeutic benefit. The one-dose-fitsall paradigm for drug therapy is increasingly recognized as inappropriate for many drugs
in clinical use. Alternative paradigm for pharmacotherapy pertains to individualized

41

therapies. In the past decade, substantial progress has been made linking commonly
occurring genetic variants to cardiovascular treatment response. Despite this,
pharmacogenetics-guided care is still in its infancy, as most centres have not
implemented this approach to routine clinical practice. However, as the cost of
genotyping continues to decline while the extent of clinical evidence supporting
pharmacogenetics-based approach rises, there is little doubt that implementation of
pharmacogenetics-guided personalized medicine will result in reduced incidence of
ADRs, and greater likelihood of therapeutic benefit. Indeed, for drugs where
pharmacogenetics-guided care has been shown to be noninferior, and potentially superior
to standard care, such an approach should be implemented and further studied in a
prospective fashion to show the overall merit of pharmacogenetics to enhancing patient
care, reducing ADRs and health care costs in the real-world setting. We also recognize
that, for many drugs, clinical decision support algorithms that integrate patient-specific
pharmacogenetic data along with environmental and clinical variables will be essential to
realizing the promise of personalized medicine.
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3

SPECIFIC AIMS AND HYPOTHESES
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3.1

Specific aim 1

1. To develop a novel pharmacogenetics-based initiation protocol that incorporates
loading and maintenance doses calculated based on individual patient genetics,
clinical variables, and anticoagulation response.
2. To evaluate the clinical utility of the novel initiation protocol in a prospective
cohort of atrial fibrillation (AF) and venous thromboembolism (VTE) patients.

Variable warfarin response poses a significant challenge to providing optimal
anticoagulation therapy. Single nucleotide polymorphisms in genes that affect warfarin
metabolism (cytochrome P450 2C9 gene, CYP2C9) and response (vitamin K epoxide
reductase complex 1 gene, VKORC1) have an important influence on warfarin
responsiveness, particularly during initiation. A number of algorithms have been
proposed which incorporate genetics as well as clinical parameters to predict
individualized maintenance dose with the intent of improving warfarin anticoagulation
therapy (1-3). However, there is a paucity of information with respect to optimal
pharmacogenetics-based warfarin initiation, arguably the most clinically challenging
therapeutic phase where the risk of haemorrhage and recurrent thromboembolism is
greatest (4-7). Accordingly, the use of a pharmacogenetics-based warfarin initiation
algorithm may prove useful in maximizing therapeutic efficacy while minimizing
bleeding risk during this critical period by diminishing interindividual variation in
response.
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We hypothesized that the use of a novel pharmacogenetics-based dosing algorithm
for initiating patients requiring new anticoagulation therapy should effectively
eliminate genotype-driven differences in anticoagulation response to provide a safe,
rapid, and uniform anticoagulation response in AF and VTE patients. To test this
hypothesis, we conducted a prospective cohort study in which patients requiring warfarin
therapy for AF or VTE were initiated with a novel pharmacogenetics-initiation protocol
(WRAPID, Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing) that
incorporates loading and maintenance doses based on genetics, clinical variables, and
response (n = 167, followed up for 90 days), to assess the influence of genetic variations
on anticoagulation responses. As described in Chapter Four, application of the WRAPID
algorithm resulted in negligible influence of genetic variation in VKORC1 or CYP2C9 on
time to achievement of therapeutic response as measured by international normalized
ratio (INR), risk of overanticoagulation, and time to stable anticoagulation. Overall, we
demonstrate the clinical utility of genetics-guided warfarin initiation with the WRAPID
protocol to provide safe and optimal anticoagulation therapy for patients with AF or
VTE.

3.2

Specific aim 2

To elucidate the genetic and nongenetic determinants of interindividual variability
in warfarin pharmacokinetics and pharmacodynamic responses.
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Many of the factors influencing the required warfarin maintenance dose such as age,
body surface area, drug interactions and importantly, CYP2C9 genotype relate to their
effects on S-warfarin pharmacokinetic (PK) parameters, such as volume of distribution
and clearance (1, 8-10). However, the influence of genetics and clinical parameters on Swarfarin pharmacodynamics (PD) variability is less clear.

We hypothesized that genetic variation in CYP2C9 and VKORC1, as well as clinical
variables contribute to interindividual variation in warfarin PK and PD
parameters. To test this hypothesis, we investigated the determinants of warfarin
kinetics and responses during initiation of warfarin therapy in the cohort of 167 patients.
During the first nine days of treatment with pharmacogenetics-guided dosing, S-warfarin
plasma levels and INR were obtained to serve as inputs to a pharmacokineticpharmacodynamic (PK-PD) model. Individual patient PK (S-warfarin clearance) and PD
(Imax) parameter values were estimated. As described in Chapter Five, regression analysis
demonstrated that CYP2C9 genotype, kidney function, and gender were independent
determinants of S-warfarin clearance while the estimated Imax variability was dependent
on VKORC1 and CYP4F2 genotypes, vitamin K status, indication for warfarin, and
weight.
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3.3

Specific aim 3

To determine the efflux transporters expressed at the apical side of renal tubular
cells capable of secreting rivaroxaban into the urine.

Rivaroxaban is a new oral anticoagulant (factor Xa inhibitor), recently approved for the
treatment and prevention of thromboembolic diseases. However, adverse events
associated with its use, namely bleeding risk, continue to be an important concern,
particularly in patients with renal impairment. Rivaroxaban disposition is governed by
hepatic metabolism and renal excretion, whereby 30-40% of the administered
rivaroxaban is excreted unchanged through the kidney via a combination of glomerular
filtration and active tubular secretion. The renal excretion is greater than glomerular
filtration rate, suggesting a significant contribution of active transport processes to
rivaroxaban elimination (11). Indeed, tubular secretion is the predominant pathway as the
ratio of active tubular secretion to glomerular filtration of unchanged rivaroxaban was
estimated to be 4-to-1 in a population pharmacokinetics model (11). Furthermore, there
has been a growing appreciation of drug transporters expressed in various tissues in
determining the disposition and excretion of a wide range of clinically used drugs.

We hypothesized that the efflux transporters P-glycoprotein (MDR1) and breast
cancer resistance protein (BCRP) are capable of transporting rivaroxaban and
contribute to the overall disposition of rivaroxaban. As described in Chapter Six, the
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ability of MDR1 and BCRP efflux transporters to mediate rivaroxaban transport in vitro
was assessed in polarized cell monolayers. Indeed, rivaroxaban is a shared substrate of
MDR1 and BCRP. Following oral administration of rivaroxaban (2 mg/kg), plasma
concentrations did not significantly differ between wild-type and Mdr1adef or Bcrp-/- mice
(n = 6 per group). However, rivaroxaban clearance was significantly reduced in
Mdr1a/Mdr1b-/-/Bcrp-/- mice. Interestingly, rivaroxaban brain to plasma ratio did not
differ in mice lacking only Mdr1a or Bcrp, but was more than two times higher in the
Mdr1a/Mdr1b-/-/Bcrp-/- mice. Our results demonstrate that MDR1 and BCRP function
synergistically to modulate rivaroxaban disposition and appear to be particularly relevant
to limiting its central nervous system entry. As clinically relevant polymorphisms exist in
both MDR1 and BCRP, genetic variations in these efflux transporters may play an
important role in determining rivaroxaban exposure and anticoagulation efficacy.

3.4

Specific aim 4

To systematically elucidate the mechanism and relative contribution of PON1 in
comparison to CYP2C19 to clopidogrel bioactivation and antiplatelet response.

The marked interindividual variation in clopidogrel antiplatelet responsiveness results in
a subset of patients at sustained risk for atherothrombosis. It is thought that antiplatelet
response to clopidogrel is highly heritable, but the precise genetic determinants of its
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metabolism and response remain controversial. Polymorphisms in cytochrome P450
2C19 (CYP2C19) have been correlated with clopidogrel antiplatelet response and clinical
outcomes in a number of cohort studies and clinical trials, accounting for 12% of
interindividual variation. However, a recent study challenged this notion by proposing
CYP2C19 as wholly irrelevant, while identifying paraoxonase-1 (PON1) and its Q192R
polymorphism as the major driver of clopidogrel bioactivation and efficacy. Given the
breadth of data supporting the importance of CYP2C19 to clopidogrel bioactivation and
clinical outcomes, additional studies are required to evaluate the validity and relevance of
these findings.

We hypothesized that both CYP2C19 and PON1 contribute to clopiodgrel
metabolism and antiplatelet response at varying extents. To test this hypothesis, we
administered a single 75 mg dose of clopidogrel to a cohort of healthy subject (n = 21)
and assessed the influence of CYP2C19 and PON1 polymorphisms and plasma
paraoxonase activity on clopidogrel active metabolite (H4) plasma levels and antiplatelet
response. As described in Chapter Seven, CYP2C19 but not PON1 genotype was
predictive of H4 levels and antiplatelet response. Moreover, metabolic profiling of
clopidogrel in vitro confirmed the role of CYP2C19 in bioactivating clopidogrel to H4.
Conversely, PON1 cannot generate H4, but mediates the formation of another thiol
metabolite, termed Endo. Our results demonstrate that PON1 does not contribute to
clopidogrel active metabolite formation or antiplatelet action, while CYP2C19 activity
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and genotype remains a predictor of clopidogrel pharmacokinetics and antiplatelet
response.
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4.1

Introduction

The vitamin K antagonist warfarin is an oral anticoagulant commonly prescribed in North
America to treat venous thromboembolism (VTE) and decrease the risk of stroke in atrial
fibrillation (AF) (1). Warfarin therapy is challenging because of marked and often
unpredictable interindividual dosing variation to reach and maintain adequate
anticoagulation. For most indications, optimal warfarin therapy is achieved by
maintaining the international normalized ratio (INR) within a narrow therapeutic range of
2.0 to 3.0. An insufficient warfarin dose leads to a lack of antithrombotic effect, whereas
overanticoagulation is associated with elevated bleeding risk (2).

Although warfarin has been in use for the past 60 years, genetic control of warfarin
response has only recently been appreciated (3). In this regard, among the most studied
genetic determinants are the single-nucleotide polymorphisms (SNPs) in genes that
encode cytochrome P450 2C9 (CYP2C9) (4), and vitamin K epoxide reductase complex
subunit 1 (VKORC1) (5, 6). CYP2C9 is the primary enzyme responsible for metabolism
of the active S-enantiomer of warfarin, and its polymorphisms contribute significantly to
variability in warfarin response (7). Possession of the common CYP2C9*2 (c.430C>T,
rs1799853) and *3 (c.1075A>C, rs1057910) variant alleles results in lower dose
requirement, increased time to stability and a higher risk of overanticoagulation (8).
VKORC1 is the target of warfarin that recycles oxidized vitamin K to the reduced form,
an essential cofactor for activation of clotting factors II, VII, IX, and X, through γglutamyl carboxylation (9). Harboring common genetic variants of VKORC1, such as the
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functional promoter SNP -1639G>A (rs9923231), results in enhanced warfarin
sensitivity, whereas rare mutations have been linked to warfarin resistance (5, 6, 10). In
addition to VKORC1 and CYP2C9 polymorphisms, several studies have reported
recently that a functional SNP in CYP4F2 (c.1297G>A, rs2108622), the metabolizing
enzyme for vitamin K (11), also determines warfarin dose requirement (12).

Since the Food and Drug Administration revised the label for warfarin to note the
importance of VKORC1 and CYP2C9 polymorphisms (13), several groups have
proposed genotype-guided maintenance dose algorithms that incorporate both genetics
and demographic parameters, such as age, weight, and body surface area (14, 15).
However, there is a paucity of information with respect to dosing during warfarin
initiation, arguably the most clinically challenging therapeutic phase, during which the
risk of hemorrhage and recurrent thromboembolism is greatest (16, 17). Standardized
loading dose nomograms developed to date have not considered genetics and other
patient-specific characteristics and have not been applied to indications other than VTE,
such as AF (18-20). We and others have recently shown that VKORC1 and CYP2C9
genetic variations modulate early and stable response to warfarin during initiation when
dosing by traditional means is used (21-24). Thus, in the present, a novel and practical
VKORC1- and CYP2C9-based loading and maintenance dose algorithm (WRAPID,
Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing protocol) was
developed and evaluated in AF and VTE patients with the aim of providing a safe, rapid,
and uniform anticoagulation response.

60

4.2
4.2.1

Experimental Section
Study sample and eligibility

This was a prospective cohort study of outpatients conducted at the London Health
Sciences Center (LHSC) and The Ottawa Hospital (TOH). The study was approved by
research ethics boards at both institutions. Patients requiring initiation of warfarin therapy
were screened for eligibility. The requirement for warfarin therapy was determined on the
basis of current American College of Chest Physicians guidelines (1). Patients who met
the eligibility criteria were enrolled on provision of written informed consent in
accordance with the Declaration of Helsinki. Table 4.1 summarizes patient
characteristics.

Study eligibility was determined by the following inclusion criteria: (1) at least 18 years
of age, and (2) indication for new warfarin therapy for at least 3 months with a target INR
range of 2.0 to 3.0. Exclusion criteria were diagnosis of cancer other than nonmelanoma
skin cancer, alcohol or drug abuse, baseline INR > 1.4, known warfarin
allergy/intolerance, terminal disease, prior use of warfarin therapy or vitamin K within 2
weeks before study enrolment, and known or suspected pregnancy.
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Table 4.2.1 Patient characteristics (n=167).
Demographics
Age, y
Sex, male/female, n

60 ± 17
96/74

Weight, kg

84 ± 19

Height, cm

171 ± 10

Ethnicity
White

159 (95.2)

Black

4 (2.4)

Asian

3 (1.8)

Other

1 (0.6)

Prescribed medication
Amiodarone

2 (1.2)

Statins

45 (26.9)

Antiplatelets

55 (32.9)

Antibiotics

6 (3.6)

Antifungals

1 (0.6)

NSAIDs

12 (7.2)

Indication for warfarin
Atrial fibrillation

61 (36.6)

Deep vein thrombosis

77 (46.1)

Pulmonary embolism

21 (12.6)

Other

8 (4.7)

Prescribed warfarin dose
Mean maintenance dose (mg/day)

5.54

CYP2C9
*1/*1

119 (71.3)

62

*1/*2

29 (17.4)

*1/*3

14 (8.4)

*2/*2

3 (1.7)

*2/*3

2 (1.2)

*3/*3

0

VKORC1 -1639
G/G

66 (39.5)

G/A

75 (44.9)

A/A

26 (15.6)

CYP4F2 c.1297
G/G

80 (48.6)

G/A

68 (40.7)

A/A

19 (11.3)

Values are mean ± SD or n (%), unless otherwise indicated.
NSAIDs indicates nonsteroidal anti-inflammatory drugs.
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4.2.2

Clinical data collection and follow-up

Demographic information was obtained at the time of enrolment. Therapy related
information was collected by patient interview and review of medical records. A baseline
venous blood sample was obtained for DNA extraction and assessment of INR.
Subsequent INR measurements, dose adjustments, adverse events, and therapy-related
interventions were recorded at both study sites. The study period was September 2008 to
August 2010.

4.2.3

Genotyping

Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit
according to the manufacturer’s protocol (Qiagen, Alameda, CA). Genotype analysis
included CYP2C9*2, CYP2C9*3, VKORC1 -1639G>A and CYP4F2 c.1297G>A. At
LHSC, genotypes were determined by allelic discrimination with TaqMan drug
metabolism genotyping assays using the 7500 RT-PCR System (assay IDs:
C__25625805_10, C__27104892_10, C__1329189_10, C__16179493_40; Applied
Biosystems, Foster City, CA). At TOH Research Institute, genotypes were determined
with the Luminex 200 system (Luminex Corp). Briefly, forward and reverse primers for
SNPs of interest were designed to amplify regions surrounding each SNP by standard
multiplex PCR protocols. The PCR products were then hybridized with appropriate
xMAP carboxylated microspheres at 52°C, followed by analysis with the Luminex 200.
Genotyping was generally performed within 24 hours of receiving the baseline blood
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sample and used prospectively to determine individualized initiation doses before
warfarin commencement for all study subjects.

4.2.4

Mathematical foundation for a novel pharmacogeneticsbased initiation protocol

Using historical datasets compiled from Vanderbilt University (n = 297) (24) and TOH (n
= 63) (25), we developed a pharmacogenetics-based initiation protocol aimed at
providing a uniform anticoagulation response among all patients. The dosing regimen
comprises of both a loading and maintenance dose algorithm. Development of the
loading and maintenance dose algorithms required the integration of pharmacokinetic
(PK) and pharmacodynamic (PD) factors to predict the time-course of warfarin plasma
levels and response.

In this mechanistic model, the plasma PK of warfarin was described with a simple 1compartment model for warfarin distribution of a set volume (V). The time course of
estimated plasma S-warfarin concentration (Cplasma) arose from the interplay between
drug absorption in the gut (ka) and drug elimination via CYP2C9 metabolism (ke). Values
for kinetic parameters for S-warfarin were obtained from the literature (26-29). Warfarin
metabolism capacity (ke) is mainly dependent on CYP2C9 genotype; thus, the values for
ke were adjusted based on reported clearance reductions in heterozygous and
homozygous variant allele carriers of either CYP2C9*2 or *3 (29). The pooling of
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genotypes into 3 subgroups was performed because of the lack of confidence in the
accuracy of limited available clearance rates reported in literature for the CYP2C9*2/*2,
*2/*3, and *3/*3 genotype groups as a result of low allelic frequencies (29).

Warfarin PD was described by an indirect response model that incorporates the known
delay and magnitude of anticoagulation effects after achieving the required plasma
concentration (30). In this model, the degree of suppression of vitamin K-dependent
clotting factor production is related to the effectiveness of warfarin concentrations to
inhibit vitamin K epoxide reductase. Here, the rate of change in INR is modeled with
zero-order input (K) and first-order output (ko) variables. Plasma warfarin levels dictate
the inhibition of output response according to classic competitive enzyme inhibition
kinetics described by the parameters Imax (enzyme content and intrinsic activity) and IC50
(drug affinity) (31). Imax values corresponding to VKORC1 genotypes were determined
on simulation of maintenance drug administration to stable therapeutic coagulation.
Depiction and parameters of the PK-PD model are shown in supplemental material,
Figure 4.5.

The PK-PD model and corresponding parameter values presented here are preliminary
and served only to guide the establishment of a practical WRAPID dosing protocol for
various VKORC1 and CYP2C9 genotype combinations. A finalized version of the PKPD model with data-derived parameter values based on formal modeling of R/S-warfarin
concentrations and INR measurements obtained in this patient cohort, along with
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identification of key nongenetic and genetic determinants of warfarin kinetics and
responses, will be published elsewhere.

4.2.5

Loading doses

Practical (5, 7.5, and 10 mg) daily loading doses were prescribed for 2 days and were
dependent on VKORC1 and CYP2C9 genotypes (Table 4.2). These doses were used to
obtain sufficient warfarin plasma concentrations to reach and maintain optimal
anticoagulation response (INR 2.0 – 3.0) with similar rapid initial time-course for all
genotype groups (supplemental material, Figure 4.6).

4.2.6

Maintenance doses

To obtain the maintenance dose, key patient clinical parameters that are known to
influence warfarin dose requirement along with genetics were combined in a generalized
linear regression model (Table 4.3). Briefly, warfarin dose was the dependent variable,
the VKORC1 and CYP2C9 genetics-based dose was a constant variable (Table 4.4), and
coefficients of independent variables were varied according to the least-squares linear
regression method.

After the 2-day loading dose, patients were prescribed the calculated maintenance dose to
begin on day 3. On 3 occasions within the first 9 days of therapy (initiation), INR
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measurements were obtained (typically days 3, 5/6 and 7/8/9), because this frequency of
INR measurements has been shown to be practical and efficacious for anticoagulation
management (19). When the INR response at each measurement did not conform to the
predicted trajectory based on the mathematical model, the daily maintenance dose was
further adjusted according to a treatment day specific dose adjustment nomogram (Table
4.5). Adjusted doses were rounded to either the nearest whole number or 0.5.

To make dosing practical, we devised an automated dose calculator for the initiation
phase (supplemental material, Figure 4.7). After initiation, dosing was adjusted by
pharmacists at both centers on the basis of a standardized post initiation nomogram. Once
patients had obtained 2 therapeutic INRs, dosing was assisted by Dawn AC
anticoagulation software (4-S Information Systems Ltd).
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Table 4.2.2 Pharmacogenetics-based loading dose grid according to VKORC1 and
CYP2C9 genotype.
CYP2C9
VKORC1

*1/*1

*1/*2 or *1/*3

*2/*2, *2/*3, *3/*3

G/G

10 mg*

10 mg*

7.5 mg†

G/A

10 mg*

7.5 mg†

5 mg†

A/A

5 mg†

5 mg†

5 mg†

Loading doses are in milligrams.
* Loading dose was adjusted to 7.5 mg for patients with weight < 60 kg.
†

Loading dose was decreased by 2.5 mg for patients with weight < 45 kg.
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Table 4.2.3 Final multiple linear regression for estimation of maintenance dose.
Predictor Variable

B

Standard

P in final model

error
Intercept

-1.46

1.23

0.235

Weight (kg)

0.06

0.01

<0.0001

1

-

<0.0001

Age, y

-0.05

0.01

<0.0001

Sex, female

-0.90

0.34

<0.01

Amiodarone use, yes

-1.97

1.1

0.07

CYP4F2 c.1297G>A, per allele

0.33

0.25

0.199

Genetics-based dose grid
(Table 4.4)
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Table 4.2.4 Genetics-dependent dose grid for maintenance dose regression.
CYP2C9
VKORC1

*1/*1

*1/*2 or *1/*3

*2/*2, *2/*3, *3/*3

G/G

7 mg

5 mg

3.5 mg

G/A

5 mg

4 mg

2.5 mg

A/A

3.5 mg

2.5 mg

1.5 mg

Doses are in milligrams.
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Table 4.2.5 Dose adjustment nomogram during initiation.

Day 3

Day 5/6

Day 7/8/9

INR

Warfarin dose adjustment

<1.3

↑ 10%

1.3 – 1.5

No change

1.6 – 1.8

↓ 10%

1.9 - 2.1

↓ 20%

2.2 – 2.5

↓ 50%

> 2.5

Hold dose for 1 day, then ↓ 50%

<1.3

↑ 50%

1.4– 1.7

↑ 20%

1.8 – 2.5

No change

2.6 – 3.0

↓ 20%

3.1 – 3.9

↓ 50%

≥ 4.0

Hold dose for 1 day, then ↓ 50%

<1.5

↑ 20%

1.5– 1.9

↑ 10%

2.0 – 2.8

No change

2.9 – 3.5

↓ 10%

3.6 – 4.0

Hold dose for 1 day, then ↓ 15%

≥ 4.0

Hold dose, test INR daily until in range (2.0-3.0), then

↑ indicates increase; and ↓, decrease.

↓ 25%
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4.2.7

Refinement of loading and maintenance dose algorithm

It was our objective to refine the loading and maintenance dose algorithm after
monitoring an initial cohort of patients (n = 87) for application in a final cohort. After the
initial cohort, we observed a disproportionate number of out-of-range INR responses in
those patients with a high loading dose-to-weight ratio. Thus, we modified the loading
dose algorithm to consider weight after the first cohort. For patients who weighed 60 kg
who had been given a 10 mg load according to the original loading algorithm, we
decreased the dose to 7.5 mg. For patients who weighed 45 kg, all loading doses were
decreased by 2.5 mg (7.5 - 5 mg, and 5 mg - 2.5 mg).

Planned optimization of the maintenance dose regression was performed by slight
modification of the contribution of clinical parameters to dose, whereas the impact of
VKORC1 and CYP2C9 remained unchanged. In univariate analysis, we observed a
significant relationship between CYP4F2 c.1297G>A genotype and dose, in which A/A
carriers required a 1 mg higher warfarin dose than the wild-type group (P < 0.05). Thus,
we included CYP4F2 genotype in the final regression model to determine maintenance
doses of the final cohort.

4.2.8

Sample size

The WRAPID study was powered to assess the effect of VKORC1 -1639G>A genotype
on anticoagulation response, after pharmacogenetics-guided initiation. A study size of
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150 patients was estimated to have 80% power to detect a response hazard of 2 at a 2sided significance level of 0.05, which allowed for a dropout rate of 10%. A hazard ratio
(HR) of 2 was chosen on the basis of previously published VKORC1-carrier status
hazard risk for primary outcomes.(24) Power analysis was performed with SAS Version
9.2 (SAS Institute).

4.2.9

Primary and secondary outcomes

The primary outcomes of the present study were time to first therapeutic INR and time to
first overanticoagulation (INR ≥ 4). We choose these primary outcomes because they are
critical markers of anticoagulation pace and quality of control. Therapeutic INR was
defined as 2.0 – 3.0 for all patients.

Secondary outcomes were time to first stable anticoagulation, time spent in therapeutic
range, and time spent above therapeutic range during the first 30 days (prestabilization
phase) and after 30 days (stabilization phase). Stable anticoagulation was defined as 2
consecutive in-range INRs, at least 7 days apart, with no dose adjustments. For estimation
of time spent in or out of range, we adopted the Rosendaal linear interpolation method to
calculate the percentage of time each patient spent within and out of the therapeutic range
(32). The difference between one INR value and the subsequent INR value was divided
by the number of days elapsed between the 2 measurements to produce the average daily
increment or decrement of INR.
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Additional secondary outcomes included percentage of patients within range during
initiation, percentage of patients with an INR ≥ 5, percentage of time spent above INR ≥
4, percentage of time spent in therapeutic range, and extended therapeutic range (1.8 3.2), as well as average maintenance dose.

The outcomes were selected to assess the influence of VKORC1 genotype on
anticoagulation response. Although the present study was not powered to evaluate the
individual effects of CYP2C9*2 and *3 genotypes on response, analysis was conducted
to compare wild-type and any CYP2C9 variant-carrier status.

4.2.10

Statistical analysis

Patients were divided into 3 groups for VKORC1 and 2 groups for CYP2C9: VKORC1
wild-type, heterozygous, and homozygous carriers of -1639G>A; CYP2C9 wild-type
(*1/*1) and a CYP2C9 variant group that included 1 or 2 variant allele carriers (*1/*2,
*1/*3; *2/*2, *3/*3 or *2/*3). Hardy-Weinberg equilibrium was assessed for each
genotype with the chi-square goodness-of-fit test.

The influence of VKORC1 and CYP2C9 genotype on the primary outcomes was
evaluated with survival analysis techniques. Kaplan-Meier plots were used to depict the
proportion of subjects without events over time. Comparison between survival curves
was conducted by the log-rank test. Unadjusted HR and its 95% confidence interval (CI)
between genotype groups were computed. The Cox proportional hazard model was
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adopted to adjust for potential confounding effects of age, sex, weight, warfarin dose,
amiodarone use, indication, patient cohort, and VKORC1, CYP2C9 and CYP4F2
genotype to obtain adjusted HRs and their 95% CIs. For comparison of differences in
outcomes between patients with various VKORC1 statuses, G/G genotype was
considered as the reference group, because it is the most warfarin-resistant group.
Statistical analysis of Schoenfeld residuals and visual inspection of log-minus-log plots
revealed no significant variation from the proportional hazards assumption.

Percentages of time spent in therapeutic range and time spent above the therapeutic range
were compared among VKORC1 and CYP2C9 genotype groups with the use of KruskalWallis test followed by Tukey-Kramer posttest or Mann-Whitney test, as appropriate.

All enrolled patients (initial and second cohort) were included for outcome analysis to
obtain at least 80% power to detect the association of VKORC1 genotype and response.
This was acceptable because there were no statistical differences between the 2 cohorts
with respect to primary outcomes of time to first therapeutic INR and time to first INR ≥
4. In addition, potential variations between cohorts because of dosing-regimen
modifications were accounted for as a confounding variable in the Cox regression
analysis of primary survival data and should not interfere with assessment of genetic
variation effects on rate of INR anticoagulation responses. Because no significant
differences were observed between the initial and second cohorts for secondary
outcomes, both patient groups were combined for secondary analysis.
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To assess and compare the predictability of our dosing model, we determined the
association between maintenance dose and model-derived dose. The proportion of
variance explained was calculated as the R2 statistic. In addition, we determined the mean
absolute error of each model for the same purpose.

A 2-tailed P-value < 0.05 was considered significant for all analyses. Statistical analysis
was performed with the use of GraphPad Prism Version 5.0 or SPSS Version 17.0.
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4.3
4.3.1

Results
Population characteristics

Of the 196 patients enrolled, 29 were excluded from analysis for the following reasons: 3
because of entry error, 4 because they self-administered the wrong dose, 1 for failure to
comply with INR measurements, 14 dropouts, 6 because of incomplete follow-up and 1
because of death (cause not attributed to study participation). Of those included for
outcome analysis, 61 and 96 patients were enrolled at the LHSC and TOH, respectively.

The allelic frequencies for VKORC1 -1639G>A and CYP4F2 c.1297G>A were 38.0%
and 31.7%, respectively. The CYP2C9*2 and *3 allelic frequencies were 11.1% and
4.8%, respectively. There were no deviations from the Hardy-Weinberg equilibrium.

4.3.2

Time to first therapeutic INR (2.0-3.0) and
overanticoagulation (INR ≥ 4)

The primary outcomes were compared in terms of VKORC1 and CYP2C9 genotypes.
VKORC1 genotype had no significant effect on time required to reach the first INR
within the therapeutic range (P = 0.52) or time required to obtain an INR ≥ 4, according
to log-rank test (P = 0.64; Figure 4.1A, 4.1C). Similarly, there was no significant
difference between CYP2C9 wild-type and variant genotype for either of these outcomes
(P = 0.28 for first INR, P = 0.96 for first INR ≥ 4; Figure 4.1B, 4.1D). Concordant with
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these findings, HR estimates for the VKORC1 and CYP2C9 genotype groups were not
significantly different from unity before or after adjustment for covariates by Cox
regression analysis (Table 4.6). Because outcomes during the first 30 days would be most
sensitive to the initiation protocol, we compared the time to first INR ≥ 4 during the first
month of therapy among genotype groups.

VKORC1 and CYP2C9 polymorphisms were without influence on this outcome (data not
shown). Importantly, these outcomes were not associated with genotype when we
considered the first and second cohorts of patients independently (data not shown).

4.3.3

Time to stable anticoagulation

The time to first stable anticoagulation was significantly different between VKORC1 (P <
0.05) genotype groups, whereas there were no differences between CYP2C9 groups (P =
0.37; Figure 4.2). However, when adjusted for confounding covariates, neither VKORC1
nor CYP2C9 showed a significant influence on time to stability (Table 4.6).

79

Figure 4.1 The effect of pharmacogenetics-guided dosing on time to primary events.
Kaplan-Meier plots represent the lack of association for attainment of first international
normalized ratio (INR) within therapeutic range (2.0-3.0) and first above-range INR (INR
≥ 4) among VKORC1 (A, C) and CYP2C9 (B, D) genotype groups after initiation with
WRAPID nomogram. The statistic in each panel represents the log-rank P value for
testing the equality of survival functions. WT indicates wild type.
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Figure 4.1 The effect of pharmacogenetics-guided dosing on time to primary events.
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Table 4.3.1 Unadjusted and adjusted HRs for anticoagulation outcomes in patients
with VKORC1 G/A or A/A and CYP2C9 variant genotype.
Genotype and outcome

Unadjusted
HR (95% CI)

Adjusted
P

HR (95% CI)

P

VKORC1 G/A genotype*
Time to first therapeutic INR

0.79
(0.50-1.25)

Time to first above-range

0.71

INR

(0.32-1.59)

Time to stable

1.03

anticoagulation

(0.65-1.63)

0.32

0.40

0.91

0.62
(0.27-1.39)
0.58
(0.11-3.19)
1.11
(0.64-1.90)

0.24

0.53

0.72

VKORC1 A/A genotype*
Time to first therapeutic INR

0.87
(0.55-1.37)

Time to first above-range

0.70

INR

(0.32-1.56)

Time to stable

0.69

anticoagulation

(0.43-1.10)

0.54

0.39

0.12

0.76
(0.34-1.57)
0.56
(0.14-3.15)
0.8
(0.47-1.37)

0.43

0.60

0.41

CYP2C9 variant genotype†
Time to first therapeutic INR

0.85
(0.61-1.19)

Time to first above-range

1.02

INR

(0.53-1.94)

Time to stable

1.17

anticoagulation

(0.83-1.65)

0.34

0.96

0.38

1.04
(0.69-1.57)
0.91
(0.43-1.92)
0.88
(0.60-1.29)

0.86

0.81

0.51
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CI, confidence interval; CYP2C9, cytochrome P450 2C9; HR, hazard ratio; INR,
international normalized ratio; VKORC1, vitamin K epoxide reductase subunit 1.
All Cox regression models were adjusted for age, gender, weight, warfarin dose,
indication for therapy, cohort, VKORC1, CYP2C9, and CYP4F2 genotype.
* Survival function was compared with VKORC1 wild-type G/G genotype group.
† Survival function was compared with CYP2C9 wild-type *1/*1 genotype group.
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Figure 4.2 The effect of pharmacogenetics-guided dosing on time to stability.
Kaplan-Meier plots representing the time to stable anticoagulation among VKORC1 (A)
and CYP2C9 (B) genotype groups. The statistic in each panel represents the log-rank P
value for testing the equality of survival functions. WT indicates wild type.
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4.3.4

Time spent within therapeutic range (INR 2.0-3.0) and above
therapeutic range (INR > 3)

To separate the initiation and stabilization phases of therapy, we considered
prestabilization as day 1 to 30 and the stabilization phase as day 31 to the end of the study
period. We chose 30 days because the median time to stability was 29 days. There was no
significant influence of VKORC1 or CYP2C9 genotype on time spent in therapeutic
range or above range during prestabilization or stabilization phase (supplemental
material, Table 4.8). The present study was not powered to detect secondary outcomes.

4.3.5

INR response time course during first 3 weeks of therapy

With the PK-PD model, the response profiles for various genotype groups were predicted
to be similar during the attainment of therapeutic INR. Our algorithm was developed to
enable patients to reach the first therapeutic response in a steady and safe manner, with a
goal of reaching optimal anticoagulation by the end of initiation. Figure 4.3A illustrates
the average INR time course of patients in the present study up to treatment week 3. The
time-course observed was similar to the model predicted response profile, particularly
during the critical first week. Concordant with our primary outcomes, average INR
during initiation rose to the target range in a similar fashion among VKORC1 and
CYP2C9 genotype groups, and importantly, anticoagulation stability, as represented by
maintenance of INR within range after initiation was comparable (Figure 4.3B, 4.3C).
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Figure 4.3 The effect of genotype-guided dosing on response time course during the
first 3 weeks of warfarin therapy.
(A) The average response observed in patients dosed by the WRAPID nomogram,
represented as mean with 95% CI of the SE, is similar to the PK-PD model-predicted
anticoagulation response time course. The observed INR time courses among VKORC1
(A) and CYP2C9 (B) genotype groups, presented as LOWESS (locally weighted
scatterplot smoothing regression) smoothed plots, rises and is maintained within
therapeutic range in a parallel and similar manner.
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4.3.6

Secondary outcomes

Secondary efficacy and safety outcomes of anticoagulation are summarized in Table 4.7.
By day 6 of therapy, 40.1% of patients enrolled in the present study had an INR within
the therapeutic range, whereas 57.5% had an INR within the therapeutic range by day 9.
The proportion of patients reaching extended INR range of 1.8-3.2 by days 6 and 9 was
60.5% and 78.4%, respectively. Although approximately 20% of patients reached an INR
≥ 4 during the entire study duration, the percentage of time spent with INR ≥ 4 was only
1.2%. Moreover, only 3.6% of patients experienced excessive overanticoagulation with
an INR ≥ 5 during the entire study period. The average maintenance dose was 5.54 mg/d
and followed the known gene-dose relationship (supplemental material, Table 4.9).

4.3.7

Dosing algorithm assessment

The association between observed maintenance dose, algorithm predicted dose, and day
7/8/9 dose was determined. The proportion of variance explained by the final
maintenance regression was 42% (Figure 4.4A), whereas the variance explained
following INR-guided dose adjustments was 70% (Figure 4.4B). In addition, there was
less bias between day 7/8/9 dose and maintenance dose than that of the algorithm
predicted. The mean absolute error (SE) of the final model was 10.4 (0.1) mg/wk,
whereas for the INR-adjusted dose, it was 8.5 (0.9) mg/wk, comparable to that of other
pharmacogenetics-based nomograms (33).
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Table 4.3.2 Secondary outcomes following dosing with pharmacogenetics-based
algorithm.
Initiation phase (Day 1-9), n (%)
INR 2-3 within 3 days

13 (7.8)

INR 2-3 within 6 days

67 (40.1)

INR 2-3 within 9 days

96 (57.5)

INR extended 1.8-3.2 within 3 days

23 (13.8)

INR extended 1.8-3.2 within 6 days

101 (60.5)

INR extended 1.8-3.2 within 9 days

131 (78.4)

INR ≥ 5, No. (%)

0 (0)

90-day follow up period*
Time spent in range, % (SD)

64.8 (19.8)

Time spent in extended therapeutic INR (1.8-3.2), % (SD)

77.3 (14.4)

Time spent in INR ≥ 4, % (SD)

1.2 (2.9)

Number of INR measurements in 90 days, mean±SD

12.3±2.7

INR ≥ 5, n (%)

6 (3.6)

Post 30 day follow up period
Time spent in range, % (SD)

68.1 (25.0)

INR, international normalized ratio; SD, standard deviation.
* Ninety-day follow-up period excludes initiation phase (day 1- 9). The outcomes change
slightly when initiation is included.
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4.4

Discussion

The clinical benefit of warfarin for decreasing stroke risk among AF patients and treating
VTE is well established; however, the unpredictable anticoagulation response for a
significant proportion of patients poses a substantial clinical challenge to optimal
warfarin therapy. Several studies have examined various initiation strategies for treatment
of VTE and AF (1, 34-36). Although several of these studies have incorporated loading
dose nomograms during initiation, most have been in the setting of VTE (19, 20), and
few studies incorporating loading dose strategies for other indications have been reported
(34, 37). Pharmacogenomic studies conducted in the last decade have established the
contribution of both VKORC1 and CYP2C9 genetic variations to maintenance dose
requirements; however, VKORC1 is a more important modulator of early warfarin
response than CYP2C9 (24). Not surprisingly, both genes have recently been reported to
predict therapeutic doses during the initial weeks of therapy (38, 39). With these
considerations, we developed and evaluated a practical and universal pharmacogeneticsbased loading dose algorithm for both AF and VTE patients.

In contrast to the findings previously observed with nonpharmacogenetics-based
dosing,(24) we show that use of the WRAPID algorithm eliminated VKORC1 and
CYP2C9 genotype-related differences in attainment of first therapeutic INR in both AF
and VTE patients. This finding did not change after adjustment for confounding
variables. Interestingly, subanalysis of patients in the initial cohort, in which CYP4F2
was not included as a predictor of dose, demonstrated that the c.1297G>A SNP did not
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significantly influence attainment of therapeutic INR. This was in contrast to a recent
study by Zhang et al. that examined the role of CYP4F2 as a genetic determinant during
initiation in patients dosed according to standard methods (40). The present findings
suggest that dosing according to VKORC1 and CYP2C9 genotype is sufficient. This is
consistent with the fact that CYP4F2 genotype accounts for only a small portion of the
observed maintenance dose variability (0-4%) (12, 41). However, a caveat here is that the
present study was not powered to detect an association between response and CYP4F2
genotype. Thus, the definitive role of CYP4F2 genotype in individualized warfarin
therapy requires further assessment in a powered study of sufficient sample size.

With respect to risk for excessive anticoagulation (INR ≥ 4), several groups have reported
that variant carriers of VKORC1 and CYP2C9 are subject to significantly increased risk
of overanticoagulation (22). After initiation with a pharmacogenetics-based dosing
algorithm, neither the VKORC1 nor the CYP2C9 variant groups had an elevated risk of
supratherapeutic INR during the first month of therapy or throughout the entire study
period. The present findings contrast with those of a study conducted by Voora et al. in
which patients were dosed prospectively only according to CYP2C9 genotype (42). In
that study, carriers of a variant CYP2C9 allele still exhibited an increased risk for
excessive anticoagulation. This may be explained by dosing algorithm and adjustment
differences during initiation compared with the present study.
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An important measure of variability in anticoagulation quality is the time to stability.
Higashi et al. reported that variant carriers of CYP2C9 required significantly longer to
attain stability in the absence of pharmacogenetics-based dosing (8). The present study
demonstrates that differences in time to stability between VKORC1 and CYP2C9
genotype groups can be effectively reduced with the use of pharmacogenetics-guided
dosing. Moreover, Wadelius et al. and Limdi et al. recently reported that the INR
response profile differed between genotype groups during initiation using a standarddosing regimen, in which variant carriers had greater warfarin sensitivity (22, 23). In
contrast, the increase in INR to therapeutic range in the present study was similar among
genotype groups.

It cannot be entirely ruled out that the lack of association observed in the present study
may have been caused by insufficient sample size; however, calculations showed that we
had ample power (> 80%) to detect the association of a causal VKORC1 -1639G>A SNP,
with an allele frequency of 35%, with anticoagulation response, for an HR of 2. Because
we observed no evidence of an association between VKORC1 genotype and
anticoagulation responses, it would be reasonable to conclude that the WRAPID
algorithm eliminated the VKORC1-driven response variation. Although we did not
observe a significant association between CYP2C9*2 or *3 genotype and response, this
may be because of lack of power. When one considers the small proportion of
heterozygous and homozygous carriers of CY2C9*2 and *3 allele, the sample size
required to detect such individual associations would be very large (~ 1000). Thus, we
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assessed the association of pooled CYP2C9 variant status (at least 1 of *2 or *3 allele), a
frequency of 30% in the present study population, with anticoagulation response. In this
case, calculation showed that sufficient power was achieved (> 80%) to detect the
association of CYP2C9 variant status with anticoagulation responses for an HR of 2.
Such pooling of CYP2C9*2 and *3 variants has been used previously by other studies for
similar reasons.(8, 43) In particular, these studies demonstrated that among patients
whose therapy was initiated with standard dosing protocols, CYP2C9 variant carriers
spent more time above therapeutic INR, had an elevated risk of overanticoagulation, and
a lower dose requirement overall.

To the best of our knowledge, the WRAPID nomogram is the first warfarin initiation
algorithm that incorporates both VKORC1 and CYP2C9 genotype-determined loading
doses, which differs from the typical doubling of the maintenance dose. Thus far, there
have been 2 prospective randomized clinical trials (RCTs) in which pharmacogeneticsbased warfarin initiation with loading doses was compared with standard warfarin
loading dose initiation, whereas other studies have not incorporated loading doses. In the
first trial, control patients were loaded with 5 mg, whereas study patients were loaded
according to CYP2C9 genotype (44). In the second trial, control patients were initiated
with 10 mg, whereas study patients were initiated with double the maintenance dose
determined with VKORC1 and CYP2C9 genotype (45). Evidently, there is a lack of
consensus with respect to warfarin initiation and especially concerning loading dose
selection from genetic information. The aforementioned trials, albeit small, indicate that
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pharmacogenetics-guided dosing improves warfarin response in terms of more time spent
within the therapeutic range, decreased bleeding events, and faster attainment of
therapeutic INR, supporting the use of loading doses for initiation. In addition, some
studies recommend that loading dose should be age adjusted because of concern about
warfarin sensitivity (34). However, we did not observe a disproportional number of
elderly patients with excessive anticoagulation with our loading dose regimen, in which
some elderly patients were indeed loaded with 10 mg as per genotype. Thus, the present
data do not support age-modified loading doses. We did, however, observe an effect of
decreased weight on response sensitivity during initiation.

Limitations of the present study include the inability to determine the influence of a
pharmacogenetics-guided dosing algorithm on rare bleeding complications because of
insufficient sample size; however, we can comment on the general safety of our dosing
regimen. The number of INRs over 5 has been used previously as a measure of the safety
of a dosing protocol (19). In the present study, only 3.6% of patients experienced such
excessive anticoagulation, which is lower than that observed with other initiation
protocols (5.6 – 8.6%) (19, 36). Several RCTs involving larger sample sizes are currently
under way to evaluate the safety and efficacy of pharmacogenetics-based dosing
compared with standard-dosing (www.clinicaltrials.gov; NCT01006733, NCT00839657,
and NCT01119300). Interestingly, a proposal has been made for a multicenter trial in
Europe that will test pharmacogenetics-guided initiation with the use of a genotype-based
loading doses to examine the clinical utility of such dosing methods. The present study
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supports the use of genotype-guided loading dose during warfarin initiation. Another
limitation is that because the present study lacked a control group (nongenetics-based
warfarin initiation), the results may be attributed in part to management of warfarin
therapy by anticoagulation clinics. However, the present study was not designed as an
RCT; rather, it had the goal of demonstrating the minimization of genotype-dependent
differences in early anticoagulation response, because this has not been demonstrated
conclusively in the warfarin-pharmacogenetics field. Furthermore, several studies
published to date have described the contribution of genetic variations to initial warfarin
response variability in patients whose treatment was initiated with respective
anticoagulation clinic regimens, likely with similar INR-response monitoring schedules
as WRAPID (22, 23, 43). Thus, we believe that pharmacogenetics-based initiation,
particularly with the use of loading doses, should result in a safe and similar rise to
optimal anticoagulation responses among VKORC1 and CYP2C9 genotype groups.
Supportive of the role of genotype-guided initiation for warfarin therapy, a recent study
suggested that genotyping for patients in whom therapy was being initiated significantly
reduced the hospitalization rate for bleeding or thromboembolic events compared with a
control group.(46) Furthermore, the results of 5 small RCTs (range from 38-200 patients)
completed thus far largely suggest that pharmacogenetics-guided dosing improves
warfarin response, in terms of more time spent within the therapeutic range and decreased
bleeding events compared with standard dosing (44, 45, 47, 48), with the exception of 1
study in orthopaedic patients (49). In that RCT, patients were followed up for only 2-4
weeks, and daily INR monitoring in addition to a similar dose adjustment protocol
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between the 2 arms may have rendered the effect of genotype-guided dosing
nonsignificant. Indeed, larger RCTs that incorporate models such as WRAPID are
required to compare adverse event rates between standard and pharmacogenetics-guided
dosing of warfarin-based anticoagulation.

To the best of our knowledge, this is the first prospective study to demonstrate the utility
of a genotype-guided warfarin initiation algorithm for the minimization of widely
recognized VKORC1 and CYP2C9 genotype-associated differences in anticoagulation
response for both AF and VTE patients. The pharmacogenetics-based algorithm proposed
here is feasible and effective for outpatient management of individuals requiring
warfarin-based anticoagulation.
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Table 4.6.1 Comparison of percent time spent within therapeutic range (2.0-3.0) and
over range (>3) among VKORC1 and CYP2C9 genotype groups.
VKORC1

CYP2C9

G/G

G/A

A/A

P value

53.20

46.60

52.40

0.12

75.04

64.77

68.22

15.80

10.18

6.35

5.37

Wild-

Variant

P value

49.83

50.24

0.90

0.19

66.46

70.86

0.30

16.62

0.11

13.14

14.74

0.45

6.97

0.95

5.74

7.18

0.37

type

Time
within
range (day
1-30), %
Time
within
range (day
30-90), %
Time
above
range (day
1-30), %
Time
above
range (day
30-90), %
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Table 4.6.2 Mean prescribed daily maintenance dose (mg) in relation to VKORC1
and CYP2C9 genotype.
CYP2C9
VKORC1

*1/*1

*1/*2

*1/*3

*2/*2

*2/*3

G/G

7.10

6.71

4.12

6.5

NA*

G/A

5.59

4.60

3.91

2.50

NA*

A/A

4.10

2.35

2.13

NA

1.93

* Not available
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Figure 4.5 A schematic representation of the pharmacokinetic-pharmacodynamic
(PK-PD) model employed to determine loading doses and dose-adjustment
nomogram.
PK of warfarin is described by a one-compartment model with first-order absorption (A)
while PD is described by an indirect response model (B), that accounts for delay in
anticoagulation response. (C) Parameter values used for simulation of drug concentration
and response time course during model development.
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Figure 4.6 Concentration response curves necessary for formulating loading doses.
Loading doses were determined by simulating adequate S-warfarin plasma concentrations
(A-C) to increase international INR response (D) to therapeutic range (2.0 – 3.0) at a
similar trajectory for various VKORC1 and CYP2C9 genotype combinations.
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Figure 4.7 An automated dose calculator that incorporates the WRAPID
pharmacogenetics-based dosing algorithm and adjustment nomogram for warfarin
initiation.
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5

CLINICAL AND GENETIC DETERMINANT OF
WARFARIN PHARMACOKINETICS AND
PHARMACODYNAMICS DURING TREATMENT
INITIATION3

____________________________

3

Reprinted with permission from Gong IY, Schwarz UI, Crown N, Dresser GK, LazoLangner A, Wells PS, Kim RB, Tirona RG. 2011. Clinical and genetic determinants of
warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PloS One,
6(11): e27808. Copyright 2011 Gong et al.
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5.1

Introduction

The vitamin K antagonist, warfarin, is an oral anticoagulant commonly prescribed to
prevent and treat venous thromboembolism (VTE) and decrease the risk of stroke in atrial
fibrillation (AF) (1). Warfarin therapy is complicated by the wide interindividual
variation in response and dose requirements for adequate anticoagulation. Optimal
warfarin therapy is achieved by maintaining the anticoagulation response, international
normalized ratio (INR), within a narrow therapeutic range of 2.0 to 3.0 for most
indications. Due to the unpredictable pharmacokinetic (PK) and pharmacodynamic (PD)
responses to warfarin, initiation of therapy is the most clinically challenging phase as the
optimal dose is often determined iteratively, guided by INR (2).

Warfarin is administered as a racemic drug; however, the S-warfarin enantiomer is 3-5
times more potent than R-warfarin.(3) CYP2C9 is the primary enzyme responsible for
metabolism of S-warfarin (4), and studies have consistently shown that CYP2C9
polymorphisms (*2, c.430C>T, rs1799853; *3, c.1075A>C, rs1057910) significantly
contribute to the variable warfarin response (5). Non-genetic factors of warfarin PK
variability and dose requirements are also important.

For example, age and co-

administration with drugs that inhibit or induce CYP2C9 can alter S-warfarin elimination
(6-10). Moreover, S-warfarin volume of distribution is dependent on weight (11, 12).
Taken together, it has been estimated that PK factors determine 26-40% of warfarin
maintenance dose variability (10, 13, 14).
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Warfarin exerts its anticoagulation effects by inhibiting vitamin K epoxide reductase
(VKOR encoded by the VKORC1 gene), the enzyme responsible for recycling oxidized
vitamin K epoxide to its hydroquinone form, an essential cofactor for activation of
clotting factors II, VII, IX and X (15). It is appreciated that single nucleotide
polymorphisms (SNPs) in VKORC1 result in altered warfarin sensitivity while rare
mutations have been linked to warfarin resistance (8, 16). Of note, the common promoter
SNP (VKORC1 -1639G>A, rs9923231) is likely the causative variation responsible for
greater warfarin sensitivity (17, 18). In addition to CYP2C9 and VKORC1
polymorphisms, several studies have reported that a functional SNP in CYP4F2
(c.1297G>A, rs2108622), the metabolizing enzyme for vitamin K (19), also determines
dose requirement (20, 21). Furthermore, diet has long been considered an important
environmental determinant of warfarin response. Indeed, reduced anticoagulation
response was observed in warfarin-stabilized patients with intake of vitamin K-rich foods
(22, 23), and vitamin K status was associated with warfarin sensitivity at the onset of
treatment (24).

With the intent of improving warfarin anticoagulation therapy, a number of algorithms
have been proposed which incorporate genetics as well as clinical parameters to predict
individualized maintenance dose (8, 25, 26). Many of the factors influencing required
maintenance dose such as age, body surface area, drug interactions and importantly,
CYP2C9 genotype relate to their effects on S-warfarin PK parameters, such as volume of
distribution and clearance (7-9, 27). The influence of genetics and clinical parameters on
S-warfarin PD variability is less clear. Although the influence of VKORC1 genetic
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variations and vitamin K intake on dose and anticoagulation response is evident, the
quantitative and dynamic influence of these variables on PD parameters, such as drug
affinity and maximal inhibition, has not been well established (28). Moreover, there is a
paucity of information regarding the influence of other genetic and clinical variables on
S-warfarin PD variation.

In this study, we aimed to separate warfarin pharmacokinetic factors from intrinsic
pharmacodynamic factors to elucidate crucial covariates of each, and their contribution to
the overall anticoagulation response variation. To this end, PK-PD modeling was applied
to a cohort of patients commencing warfarin therapy using a novel initiation protocol
(29).
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5.2
5.2.1

Experimental Design
Study subjects and design

Patients with AF (n = 61), VTE (n = 98) or other conditions (n = 8) were prospectively
enrolled to evaluate the safety and efficacy of a pharmacogenetics-based warfarin
initiation protocol.

Patient characteristics and clinical outcomes were described

previously in detail (29). The inclusion criteria for study enrolment were minimum of 18
years of age and indication for new warfarin therapy for at least 3 months with a target
INR range of 2.0 to 3.0. Patients were excluded on the basis of diagnosis of cancer other
than non-melanoma skin cancer, alcohol or drug abuse, baseline INR>1.4, known
warfarin allergy/intolerance, terminal disease, prior use of warfarin or vitamin K use
within 2 weeks prior to study enrolment, and pregnancy. The majority of patients were
Caucasian (95%) with mean age of 60 years (range, 19-88) and mean weight of 84 Kg
(43-155). The allelic frequencies for VKORC1 -1639G>A and CYP4F2 c.1297G>A were
38.0% and 31.7%, respectively. The CYP2C9*2 and *3 allelic frequencies were 11.1%
and 4.8%, respectively. There was no homozygous CYP2C9*3 carrier in this population.
Amiodarone, statin, antiplatelet, antibiotic, antifungal and NSAID medication use were
present in 2%, 45%, 55%, 6%, 1% and 12% of the cohort, respectively.

The Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing (WRAPID)
protocol has been described elsewhere (29). Briefly, a 2-day loading dose (according to
VKORC1 and CYP2C9 genotype) was administered, followed by a day 3 INR

112

measurement that was used in combination with the maintenance algorithm to determine
the subsequent dose. Two subsequent INR measurements were obtained within the first 9
days of therapy where the maintenance dose was further adjusted accordingly to the dose
adjustment nomogram. Simultaneous with INR monitoring, additional blood samples
were collected for drug level analysis.

This study was conducted at the London Health Sciences Centre and The Ottawa
Hospital upon approval by Research Ethics Boards at the University of Western Ontario
and Ottawa Hospital. Patients requiring initiation of warfarin therapy were prospectively
screened for study eligibility and informed written consent was acquired.

5.2.2

Genotyping

Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit
(Qiagen, Valencia, CA). At London Health Sciences Center, genotypes were determined
by allelic discrimination using TaqMan Drug Metabolism Genotyping assays with the
7500 RT-PCR System (Applied Biosystems, Carlsbad, CA). At Ottawa Health Research
Institute, genotypes were determined using the Luminex 200 system (Luminex, Austin,
TX).
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5.2.3

Warfarin drug level analysis

Racemic warfarin and internal standard (IS) R/S-para-chloro-warfarin were purchased
from Sigma-Aldrich. Plasma was extracted from patient blood samples within 1 hour of
collection and stored at -80°C until use. Total S-warfarin plasma concentration was
determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Briefly, 300 µL of acetonitrile and 25 µL of IS was added to 100 µL of plasma and
centrifuged at 14,000 rpm for 20 min. The resulting supernatant was added to 5 mM
ammonium acetate pH 4 (1:3 v/v). Warfarin and IS enantiomers were separated with the
Astec CHIROBIOTIC™ V Chiral Column (5 cm × 4.6 mm, 5 µM particle size) using
gradient elution with 5 mM ammonium acetate (pH 4) and acetonitrile (5 to 70%) in a 10
min run time. The MS was set in negative mode for detection of warfarin and IS with
transitions 307.2  160.0 m/z and 340.8  160.0 m/z, respectively. Calibration curves
were prepared by spiking blank plasma with known concentrations of R/S-warfarin. The
lowest limit of quantification was 1 ng/mL for both enantiomers. The interday coefficient
of variation and bias of S-warfarin quality controls was 10.5% and 9.3%.

5.2.4

Proteins induced by vitamin K absence factor II (PIVKA-II)
assay

PIVKA-II concentrations were analyzed with use of an enzyme-linked immunosorbent
assay kit as per manufacturer’s protocols (Diagnostica-Stago, Parsippany, NJ).
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5.2.5

Kidney function

We measured patient plasma creatinine concentrations by LC-MS/MS. Briefly, creatinine
and the IS, creatinine-D3, was purchased from Sigma-Aldrich and Toronto Research
Chemicals, respectively. Creatinine and IS were separated with the reverse-phase
Hypersil Gold column (50 × 5 mm, 5 µM particle size) using isocratic elution with 25%
1% formic acid in water v/v and 75% acetonitrile with 1% formic acid v/v in a 7 min run
time. The MS was set in positive mode for detection of creatinine and IS with transitions
114.1  44.3 m/z and 117.1  47.3 m/z, respectively. The lowest limit of quantification
was 50 ng/mL. The interday coefficient of variation and bias of creatinine quality
controls was 8.7% and 6%. eGFR was estimated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation (30). Renal function was categorized
according the National Kidney Foundation’s classification of chronic kidney disease.

5.2.6

PK-PD modeling

S-warfarin PK was described using a linear one-compartment model with a set volume of
distribution (V; 0.14 L/kg) on a per patient basis (12). The time-course of plasma Swarfarin concentration (Cp) arose from the interplay between first-order drug absorption
(ka) and drug elimination (ke) processes. Parameter values for ka were fixed (28.56 day-1)
based on the literature (31). Bioavailability was assumed to be complete (32). Individual
ke values were obtained by least squares fitting (Scientist, Micromath, St. Louis, MO) of
the concentration data during the first 9 days with prescribed doses as input. Clearance
(CL) was calculated according as the product of V and ke.
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S-warfarin PD was described by an established indirect response model which
incorporates the known delay in anticoagulation effects (33). In this model, the rate of
change in INR was modeled using zero-order input (K) and first-order output (kout)
variables. Plasma S-warfarin levels (Cp) modulate the output response according to
classical inhibition kinetics, described by parameters maximum inhibitory factor (Imax, i.e.
inversely related to enzyme content) and drug affinity (IC50) (34). Since VKORC1 1639G>A promoter SNP has been correlated with altered mRNA expression levels, Imax
values were expected to vary with VKORC1 genotype. Rmax and kout values in the indirect
response model were both fixed at 1. The IC50 for S-warfarin was fixed at 1500 ng/mL, as
reported previously (35). The following equation describes the PD model.


    ·


1 

 · 
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The response analysis was conducted following estimation of individual S-warfarin
plasma concentrations. These estimated drug concentrations were used in combination
with measured INRs to estimate the individual PD parameter, Imax, by least squares
fitting.

We note that clearance and Imax parameter estimates should be considered independent of
the dosing regimen and anticoagulation responses observed in the WRAPID study
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because estimations of individual warfarin clearance and individual drug concentrationresponse profile are unaffected by the doses received.

5.2.7

Vitamin K epoxide reductase protein expression in human
liver

The collection and processing of liver samples was described elsewhere (36). In order to
obtain a positive control for VKOR protein analysis, the enzyme was over-expressed in
cells using previously described protocol (37). For this purpose, human VKORC1 cDNA
was

amplified

from

a

human

liver

cDNA

TGGAGATAATGGGCAGCACCTGGGGG-3’

library
(forward)

using

primers
and

5’5’-

GTTGAGGGCTCAGTGCCTCTTAGCCTTG-3’ (reverse). Samples were separated by
SDS-PAGE on 4-10% gels (Invitrogen, Carlsbad, CA) and subsequently transferred onto
nitrocellulose membranes. Blots were probed with a custom anti-VKOR antibody (kindly
provided by Dr. Kathleen Berkner, Learner Research Institute, Cleveland Clinic (38)) and
subsequently probed with anti-rabbit horseradish peroxidise-labeled secondary antibodies
(Bio-Rad, Hercules, CA). The bands were detected using the BM Chemiluminescence
Western Blotting Substrate (Roche, Indianapolis, IN) and KODAK ImageStation 4000
MM (Carestream, Rochester, NY). Protein expression levels were normalized to a wildtype VKORC1 sample (HLM100), repeated on all blots.
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5.2.8

Determinants of warfarin kinetics and response

Regression analysis was performed to determine factors affecting S-warfarin clearance
and Imax . Since the distribution of both of these parameters in our patient population was
skewed, square-root transformation was adopted to normalize the data. The variables age,
gender, body weight, amiodarone use, other known interacting medications, indication
for warfarin therapy, kidney function, vitamin K status as measured by PIVKA-II,
VKORC1 genotype, CYP2C9*2 and *3 genotype were considered as covariates for both
S-warfarin clearance and Imax. The covariates were added to the model according to the
stepwise forward regression. A P-value < 0.05 was considered as significant and the
variable was subsequently entered into the equation; variables included with P-values >
0.1 in subsequent models were removed. The models with significant covariates were
then internally validated through bootstrapping. Bootstrapping was achieved by random
sampling with replacements to obtain 1000 samples, allowing estimation of the standard
error and the 95% confidence interval (CI) of parameter estimates. Potential collinearity
between variables was assessed using condition indices and variance proportions.

The clearance and Imax regression equations were then integrated with the PK-PD model
in order to predict and compare anticoagulation response profiles following initiation
with various nomograms for typical warfarin patients.
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5.2.9

Statistical analysis

The Kruskal-Wallis one-way analysis of variance followed by Tukey’s test for pairwise
comparisons was employed for the following analysis: S-warfarin concentration
differences with respect to VKORC1 genotype, influence of VKORC1 genotype on
attainment of therapeutic INR and dose, effect of VKORC1 genotype on liver protein
expression, relationship between S-warfarin clearance and CYP2C9 genotype, effect of
kidney function on S-warfarin clearance, relationship between VKORC1 genotype and
Imax. Mann-Whitney U’s test was employed to examine gender effect on S-warfarin
clearance and warfarin indication effect on Imax. A two-tailed P value of less than 0.05
was considered significant for all analyses. Statistical analysis was performed with the
use of GraphPad Prism v.5.0 (GraphPad, La Jolla, CA) or SPSS v. 17.0 (SPSS, Chicago,
IL).
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5.3
5.3.1

Results
PK-PD model performance

We fitted the individual patient S-warfarin plasma levels during the first 9 days of therapy
to a one-compartment PK model (Figure 5.1A) to furnish estimates of S-warfarin
clearance. The S-warfarin clearance estimated here was similar to that previously
observed (39). Moreover, good fits to individual patient levels with the PK model were
obtained (Figure 5.1C). Overall, the PK model was sufficiently accurate in describing the
data as linear regression analysis for predicted and actual S-warfarin concentrations
yielded a coefficient of determination (r2) of 0.91, with a slope of 0.92 (Figure 5.1D). The
mean absolute error (MAE) between estimated and actual was 0.04 µg/mL, and 88% of
these estimated values were within 25% of actual concentrations.

An indirect response model was used to estimate maximal inhibitory factor (Imax), the PD
parameter related to the amount of hepatic VKOR enzyme. Here, the S-warfarin plasma
concentration-INR response relationship is governed by the parameters IC50 (related to
warfarin affinity to VKOR) and Imax, where at constant IC50, increasing Imax enhances
drug sensitivity (Figure 5.1B). Individual predicted S-warfarin concentrations estimated
from the PK model in conjunction with observed INR values served as inputs for the PD
model. Fits to individual patient INRs over the initiation period were good (Figure 5.1E).
Linear regression analysis for predicted and actual INR values of the entire data set
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yielded an r2 of 0.89, with a slope of 0.91 (Figure 5.1F). The MAE was 0.17, and 90% of
these estimated values were within 25% of actual INR.
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Figure 5.1 PK-PD model performance. (A) Model simulated S-warfarin plasma
concentration-time profiles after single dose with CYP2C9 variant alleles. (B) Model
simulated steady-state therapeutic INR (2.5) vs. S-warfarin plasma concentration with
varying Imax corresponding to VKORC1 -1639G>A genotype. (C) Model fit of measured
S-warfarin concentrations in a single patient. (D) Scatter plot of actual vs. predicted Swarfarin plasma concentration throughout the initiation phase (coefficient of
determination, r2 = 0.91, n = 459). The diagonal line represents the unity line. (E) Model
fit of measured anticoagulation INR response values in the same patient as in (C). (F)
Scatter plot of actual vs. predicted INR during the initiation phase (r2 = 0.89, n = 459).
The diagonal line represents the unity line. Imax, maximal inhibitory factor; INR,
international normalized ratio.
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5.3.2

Determinants of S-warfarin clearance

Mean S-warfarin clearance was 7.5 L/day (SD 3.4) with a range of 0.8 to 20.8, indicating
a more than 20-fold interindividual variability in S-warfarin PK (Figure 5.2A). S-warfarin
clearance was significantly associated with CYP2C9 genotype with mean clearance
values of 8.1, 7.0, 4.3, 4.5, and 2 L/day, for CYP2C9 *1/*1, *1/*2, *1/*3, *2/*2, and
*2/*3 genotypes, respectively (Figure 5.2B). Interestingly, lower S-warfarin clearance
was observed in patients with decreased renal function as estimated by glomerular
filtration rate (eGFR) (Figure 5.2C, P<0.0001). The cohort average eGFR was 91
mL/min/1.73 m2 (SD 23) with a range of 22 to 140. Moreover, eGFR was significantly
decreased with increase in age (P<0.0001, data not shown). Gender also had an influence
on S-warfarin clearance, where on average, females had significantly lower clearance
compared to males (Figure 5.2D, P<0.001). With stepwise regression, clearance was
found to be dependent on CYP2C9*3 allele, kidney function, gender, and CYP2C9*2
allele, in order of covariate entry into the regression equation. VKORC1 genotype was
without influence on S-warfarin clearance. The r2 of the final model for clearance
estimation was 36.5%. Parameter estimates of the final clearance model and bootstrap
validation results are given in Table 5.1.
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Figure 5.2 Determinants of S-warfarin clearance. (A) Frequency distribution of estimated
S-warfarin clearance, shown as percent of total patients for each bin. (B) Relationship
between CYP2C9 genotype and S-warfarin clearance. Lines represent mean clearance.
(C) S-warfarin clearance is significantly correlated with kidney function, as defined by
eGFR. (D) Observed S-warfarin clearance segregated by gender. Lines represent mean
clearance. eGFR, estimated glomerular filtration rate. * P < 0.05, ** P < 0.005, ***P <
0.0005
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Table 5.3.1 Multiple linear regression analysis of independent predictors of Swarfarin clearance (L/day).
Entry
into
model
-

1

Predictor
Variable

Intercept
CYP2C9*3,
per allele

B

Standard
error

3.105

0.072

-0.812

0.151

2

eGFRa

-0.278

0.080

3

Gender (F)

-0.357

0.081

-0.274

0.080

4

CYP2C9*2,
per allele

95% CI

2.966,
3.248
-1.093,
-0.510
-0.417,
-0.145
-0.511,
-0.186
-0.427,
-0.113

R2 after

P in

entry

final

(%)

model

-

<0.0001

14.3

<0.0001

24.9

<0.0001

32.3

<0.0001

36.5

<0.0001

CI, confidence interval; CYP2C9, cytochrome P450 2C9; eGFR, estimated glomerular
filtration rate in mL/min/1.73m2; F, female.
a

Coded as follows: ≥ 90 mL/min/1.73 m2, 0; 60-89, 1; 30-59, 2; 15-29, 3; ≤ 15, 4.
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5.3.3

Therapeutic S-warfarin plasma concentration correlates with
VKORC1 genotype

S-warfarin plasma concentrations on day 7/8/9 were statistically different between
VKORC1 -1639G>A genotype groups (P<0.0001) despite similar INR (Figure 5.3A).
Patients carrying at least one -1639G>A allele required lower plasma concentrations than
wild-type patients for similar therapeutic efficacy, and this was gene-dose dependent
(Figure 5.3A, 5.3B). The mean plasma S-warfarin concentrations for VKORC1 A/A, G/A,
and G/G genotype groups were 0.291 ng/mL (SD 0.157), 0.347 ng/mL (0.170), and 0.503
ng/mL (0.217), corresponding to mean warfarin daily doses of 4.4 mg (2.7), 5.0 mg (2.5)
and 7.6 mg (3.0), respectively.

5.3.4

Determinants of S-warfarin PD

The mean Imax value for subjects was 2.7 (SD 1.0), with a range of 0.3 to 6.9,
demonstrating a more than 20-fold interindividual variability in S-warfarin PD (Figure
5.3C). A significant relationship between VKORC1 -1639G>A genotype and Imax (Figure
5.3D, P<0.0001) was observed. The mean Imax values for VKORC1 A/A, G/A, and G/G
genotypes were 3.7 (SD 1.2), 2.8 (1.0) and 2.2 (0.7), respectively.

Stepwise regression analysis indicated that Imax was dependent on VKORC1 genotype,
indication for warfarin, pre-treatment plasma proteins induced by vitamin K absence
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(PIVKA-II) concentration, CYP4F2 1297C>T genotype, and weight, in order of covariate
entry into the regression equation. The r2 of the final model for Imax estimation was 41%.
Parameter estimates of the final Imax model and the bootstrap validation results are given
in Table 5.2. The mean baseline PIVKA-II concentration was 7.1 ng/mL (SD 4.8), with a
range of 1.8 to 30.6, indicating that majority of our patients did not exhibit vitamin K
deficiency. Imax was greater in patients with AF than VTE, denoting that VTE patients
were more resistant to warfarin’s therapeutic effect. Moreover, there was an additive
effect of VKORC1 genotype and indication, where VTE patients had lower Imax than AF
patients irrespective of VKORC1 genotype (Figure 5.3E). VTE patients who were
VKORC1 G/G carriers had the lowest average Imax (2.1) while AF and A/A carriers had
the highest Imax (4.4). These findings imply that differences in INR response would be
evident between patients with AF and VTE when warfarin is initiated by a common
dosing protocol. Indeed, we found a more rapid response in patients with AF in
comparison to VTE over the first week of therapy (Figure 5.3F), despite that the
WRAPID protocol eliminated the previously known genetic and clinical contributors to
early response variability (29).
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Figure 5.3 Determinants of maximal inhibitory factor, Imax. (A) Box-and-whisker plots of
S-warfarin plasma concentration and INR on days 7/8/9 segregated by VKORC1 1639G>A genotype. Box-and-whisker plots representing VKORC1 gene-dose effect
during initiation. The top and bottom of the boxes represents 25th and 75th percentile,
respectively; median is represented by the middle line, whiskers are the 95% CI, and
outliers are identified as closed circles. (B) Warfarin daily dose on days 7/8/9 with
respect to VKORC1 genotype. (C) Frequency distribution of estimated Imax, shown as
percent of total patients for each bin. (D) Association between VKORC1 genotype and
Imax. Results are represented as mean with standard deviation. (E) Additive effect of
indication for warfarin therapy and VKORC1 genotype on Imax. (F) INR time course for
patients with AF and VTE over the initial 10 days of therapy with common geneticsguided dosing protocol. Results are represented as mean with 95% CI of the standard
error. AF, atrial fibrillation; INR, international normalized ratio; VTE, venous
thromboembolism. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

130

A

B
****
****
*

4.0

3.0
1.00

2.5

0.75

2.0
1.5

0.50

1.0
0.25

0.5

0.00

Day 7/8/9 Warfarin Dose (mg/day)

3.5

1.25

G/A

G/G

A/A

G/A

*

**

16

12

8

4

0

0.0
A/A

**

20

Day 7/8/9 INR

Day 7/8/9 Plasma [S-warfarin] (µg/mL)

1.50

A/A

G/G

VKORC1 -1639 G>A Genotype

G/A

G/G

VKORC1 -1639 G>A Genotype

C

D
45
max)

40

Maximum Inhibitory Factor (I

35

Frequency (%)

***

5.0

30
25
20
15
10
5
0
0.5

1.5

2.5

3.5

4.5

5.5

***

3.0

2.0

1.0

0.0

6.5

A/A

Maximum Inhibitory Factor (Imax )

E

***

4.0

G/A

G/G

VKORC1 -1639 G>A Genotype

F
4.0
3.5
4.0

**

3.0
2.5

*

3.0

INR

Maximum Inhibitory Factor (I

max)

5.0

2.0

2.0
1.5
1.0

1.0

0.5
0.0
AF

VTE

A/A

AF

VTE

G/A

AF

VTE

AF

VTE

0.0
0

2

G/G

VKORC1 -1639 G>A Genotype

Figure 5.3 Determinants of maximal inhibitory factor, Imax.

4

6

Treatment Day

8

10

131

Table 5.3.2 Multiple linear regression analysis of independent predictors of Imax.
Entry
into
model
-

1

2

3

4

5

Predictor
Variable

Intercept
VKORC1,
per allele
Indication
(VTE)
PIVKA-II
(ng/mL)
CYP4F2, per
allele
Weight (Kg)

B

Standar
d error

1.383

0.101

0.211

0.030

-0.281

0.049

0.017

0.007

-0.072

0.031

0.002

0.001

95% CI

1.156,
1.570
0.148,
0.267
-0.380,
-0.190
0.005,
0.033
-0.133,
-0.009
0.000,
0.004

R2 after

P in

entry

final

(%)

model

-

<0.0001

26.3

<0.0001

34.9

<0.0001

37.9

<0.05

39.6

<0.05

41.0

<0.05

CI, confidence interval; CYP4F2, cytochrome P450 4F2; Imax, maximal inhibitory factor;
PIVKA-II, proteins induced by vitamin K absence; VKORC1, vitamin K epoxide
reductase complex subunit 1; VTE, venous thromboembolism.
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5.3.5

Correlation of VKORC1 genotype to hepatic VKOR protein
levels

With Western blot analysis, hepatic microsomal VKOR had electrophoretic mobility
consistent with an 18 kDa protein while the two immunoreactive bands observed in overexpressed VKOR control samples likely represent differentially glycosylated forms of the
protein (Figure 5.4A, 5.4B, 5.4C). VKOR protein level was significantly correlated to
VKORC1 genotype (Figure 5.4D, P<0.05), where the VKORC1 G allele was associated
with higher liver enzyme level than the A allele.
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Figure 5.4 The influence of VKORC1 -1639G>A promoter genotype on hepatic
VKOR protein expression levels.
(A, B, C) VKOR expression determined in 17 healthy human livers by Western blot
analysis. The band intensity was normalized to HLM100. A positive control sample was
included on each blot. (D) Semiquantitative measurement of hepatic expression in
relation to VKORC1 genotype. * P < 0.01
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5.3.6

Simulated anticoagulation response with different warfarin
initiation protocols

To demonstrate the utility of the PK-PD model, we simulated and compared INR
response profiles of individuals with different combinations of covariates using different
published dose initiation schemes (25, 29, 40-42). Specifically, we compared responsetime curves of typical patients following initiation with our WRAPID protocol (29), the
Kovacs nomogram (non-pharmacogenetics, validated in VTE) with the day 8 dose
refinement algorithm (42), and finally, initiation with the pharmacogenetics-based as well
as clinical-only maintenance dose algorithms available at www.warfarindosing.org
incorporating the recently published day 4 dose refinement algorithm (25, 40). Doses
were adjusted according to simulated INR values on days 3, 5, and 8 for WRAPID and
Kovacs and on day 4 for warfarindosing.org as per nomogram. Clearance and Imax values
were calculated based on regression equations (Tables 5.1 and 5.2) for various VKORC1
and CYP2C9 genotype combinations in typical AF and VTE patients. Homozygous
CYP2C9*3 patients were not considered in the simulations as we did not encounter such
individuals in our population. We used CYP4F2 wild-type C/C genotype (increased
sensitivity) for all calculations of Imax. Figure 5.5 illustrates the predicted effect of
VKORC1 or CYP2C9 variant allele burden on responses of AF and VTE patients initiated
with WRAPID nomogram (Figure 5.5A, 5.5B), Kovacs nomogram (Figure 5.5C, 5.5D),
warfarindosing.org genetics (Figure 5.5E, 5.5F), and clinical nomogram (Figure 5.5G,
5.5H), respectively. The simulated response curves indicate that increased possession of
variant alleles is associated with slightly greater time above therapeutic INR with fixed
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10 mg loading doses and iterative response-based Kovacs nomogram than initiation
strategies which incorporate genetic and patient factors. In contrast, pharmacogeneticsguided initiation schemes eliminated the genotype-dependent response differences.
Furthermore, pharmacogenetics-guided dosing nomograms resulted in comparable rise to
optimal anticoagulation response among different genotypes within groups of AF and
VTE patients. Evidently, loading dose was not used in simulations of patients initiated
with warfarindosing.org and thus, the time to reach optimal anticoagulation was
approximately 3 days slower as compared to the WRAPID nomogram. Simulations with
the warfarindosing.org clinical algorithm indicate that there would be significant
differences in initial INR responses as the burden of genetic variants increases.
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Figure 5.5 Model predicted response curves following warfarin initiation using various
initiation protocols. Simulations were performed using non-genetics and genetics-based
nomograms for typical AF and VTE patients harbouring variable number of variant
alleles. The genotype of zero-variant patients is VKORC1G/G-CYP2C9*1/*1. Patients
carrying 1 variant allele have one of the following genotype combinations: VKORC1G/ACYP2C9*1/*1, VKORC1G/G-CYP2C9*1/*2, or VKORC1G/G-CYP2C9*1/*3. Patients
carrying 2 variant alleles have one of the following genotype combinations:
VKORC1A/A-CYP2C9*1/*1,

VKORC1G/A-CYP2C9*1/*2,

VKORC1G/A-

CYP2C9*1/*3, or VKORC1G/G-CYP2C9*2/*2. Patients carrying 3 variant alleles have
one

of

the

following

VKORC1A/A-CYP2C9*1/*3,

genotype

combinations:

VKORC1A/A-CYP2C9*1/*2,

VKORC1G/A-CYP2C9*2/*2,

or

VKORC1G/A-

CYP2C9*2/*3. Patients carrying 4 variant alleles have one of the following genotype
combinations: VKORC1A/A-CYP2C9*2/*2, or VKORC1A/A-CYP2C9*2/*3. AF, atrial
fibrillation; VTE, venous thromboembolism.
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Figure 5.5 Model predicted response curves following warfarin initiation using
various initiation protocols.
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5.4

Discussion

Warfarin initiation is a challenging therapeutic phase, associated with the highest
occurrence of major bleeding events and thromboembolism (43-46). Thus, effective
initiation protocols that pre-emptively account and adjust for interindividual variability
have significant potential to improve warfarin anticoagulation therapy.

A major contributor to dose requirement and response is S-warfarin clearance. The
analysis demonstrates that kidney function, gender, CYP2C9*2 and *3 genotype are
major determinants of S-warfarin clearance. The finding that S-warfarin clearance is
reduced in renal impairment supports recent studies that found relationships between both
warfarin dose requirement and propensity for over-anticoagulation with kidney function
(47, 48). Although age has been correlated with decreased warfarin clearance, we failed
to observe this relationship after multivariate regression that included both age and eGFR
(7-9, 27). It is plausible that age, as a contributor to clearance, somewhat reflects agerelated decline in renal function. Indeed, we note that including eGFR as an additional
factor into the regression analysis resulted in 36.5% of clearance variation explained,
while only 27.6% of this variation was accounted for when eGFR was absent and age
included in the analysis. Interestingly, gender was a significant independent contributor
to S-warfarin clearance in this study, with females having 22% lower S-warfarin
clearance than males. While females require lower doses than males for similar
anticoagulation quality and efficacy (49), there remain conflicting reports on the role of

139

gender on S-warfarin pharmacokinetics (7, 8, 27). Drug interactions, particularly with
amiodarone and antifungals, are significant contributors to variable warfarin response
(50-52). Because of the limited number of patients in this cohort taking these
medications, we did not find associations between concomitant drugs and warfarin
clearance. Larger studies in patients are required to better characterize the quantitative
influence of co-administered drugs on warfarin clearance.

While determinants of S-warfarin PK have been studied, less is known regarding
determinants of the S-warfarin plasma concentration-response relationship. We identified
VKORC1, weight, indication for warfarin, PIVKA-II and CYP4F2 genotype as significant
predictors of S-warfarin Imax, the PD parameter that governs the magnitude of observed
anticoagulation INR response. In addition, we demonstrate that promoter -1639G>A SNP
results in lower hepatic VKOR protein expression. In concordance with that previously
observed for warfarin-stabilized patients (53), there was a significant relationship
between VKORC1 genotype and S-warfarin plasma concentrations at the end of the
initiation phase where therapeutic INR was achieved. Taken together, the VKORC1 1639G>A promoter SNP confers lower hepatic expression, thus lower plasma S-warfarin
concentrations and dose required for optimal anticoagulation.

The finding that Imax differences exist between AF and VTE patients, following
adjustment of confounding variables such as age and weight, suggests that indication for
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treatment maybe a prominent contributor to response variability during initiation. This
may be attributed to different coaguability states among patients during therapy initiation,
in addition to inherent disease differences between the two subsets of patients. Further
studies are required to investigate the physiological basis mediating the PD differences
between AF and VTE patients. It is also of interest to know whether this dynamic
difference would diminish or be maintained throughout the course of anticoagulation
therapy. Indeed, indication for anticoagulation was an independent determinant of
maintenance dose in the present cohort and one dose algorithm (warfarindosing.org)
incorporates VTE as a factor requiring higher warfarin maintenance dose (25). In the
present study population, we find a 2.3 mg/day difference in mean maintenance dose
between AF and VTE patients. This value is greater than the 0.7 mg/day difference
predicted by the WRAPID maintenance dose algorithm when accounting for the average
age (21 yrs) and weight (6.5 kg) differences between the AF and VTE groups. While a
component of this maintenance dose difference is likely related to the lack of
consideration of renal function differences among the disease groups with the WRAPID
algorithm, the current PK-PD analysis suggests that indication for anticoagulation
remains a contributor to warfarin dose.

In agreement with previous studies linking CYP4F2 genotype and vitamin K intake to
warfarin dose requirement (18, 23, 24), our data demonstrate that pre-treatment plasma
PIVKA-II levels and CYP4F2 1297G>A genotype affects S-warfarin PD sensitivity
during initiation. PIVKA-II, a des-carboxylated form of prothrombin, is a direct
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biomarker for liver vitamin K status and dietary intake (54). We did not find a
relationship between PIVKA-II level and CYP4F2 genotype during statistical analysis or
collinearity during stepwise regression of Imax for this cohort of patients. Taken together,
our findings highlight the importance of the balance between the VKOR agonist (vitamin
K) and antagonistic (warfarin) concentrations in achievement and maintenance of optimal
anticoagulation, particularly during initiation.

An important outcome of this study was the formulation of an overall PK-PD model that
incorporates the determinants of warfarin kinetics and response. We demonstrate the
utility of the model to predict S-warfarin concentrations and INR response curves in
simulated individuals initiated with different protocols. The simulations predict
substantial differences in initial anticoagulation responses depending on the initiation
scheme, indication for warfarin treatment and burden of genetic variation in CYP2C9 and
VKORC1.

Within all of the initiation protocols examined, AF patients would be

predicted to have greater initial response than VTE.

The indication difference

exaggerates the effect of genetic polymorphisms on response especially for initiation
protocols that do not consider CYP2C9 and VKORC1 genotypes. Interestingly, the
simulations indicate that the Kovacs nomogram results in a safe and rapid initiation in
VTE patients, consistent with the observed good safety profile in real-world patients (41,
55). On the other hand, the Kovacs nomogram is predicted to be less optimal for in AF as
it may pose an over-anticoagulation risk in these patients. Simulations in patients initiated
with pharmacogenetics-based dosing algorithms suggest they would be safe and effective
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for both patient populations and that the response curves of individuals possessing variant
alleles were similar. In comparing initiation with WRAPID and warfarindosing.org, time
to therapeutic range was delayed without the use of loading dose. In the case for VTE,
delayed attainment of therapeutic INR may have economic consequences as bridging
therapy with low molecular weight heparins would need to be extended when loading
doses are not administered. The simulations also forecast the time-course of initial INR
responses in the large multi-centered randomized clinical trial comparing outcomes
between pharmacogenetic and clinical-based warfarin dosing (Clarification of Optimal
Anticoagulation Through Genetics, COAG trial) as defined by warfarindosing.org
algorithms. The model predicts significant differences in INR response between the two
dosing methods during initiation, particularly for patients harbouring variant alleles.

While maintenance dose prediction algorithms typically utilize a number of clinical and
genetic parameters, these models are not designed to delineate how each parameter
affects warfarin PK, PD or both. The formal PK-PD analysis described herein
demonstrates that the interindividual variation in both components of the overall warfarin
response can be separated and quantitatively ascribed to respective combinations of nongenetic and genetic factors. Moreover, our integrated PK-PD model allows for robust
prediction of INR response profiles particularly during initiation phase of therapy
following any initiation-dose scheme, in addition to assessment of covariate effect on
responses by altering PK or PD estimates. It should be noted that based on the current
model form and input parameters, the PK determinants only account for 36.5% of the
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variability observed in S-warfarin clearance, while PD determinants accounted for 41%
of the Imax variation. For this reason, it is expected that the current model would not
provide precise response estimations on an individual patient basis due to the large
variation still unaccounted for.

In conclusion, the data presented here provides additional insight into the combination of
patient characteristics contributing to warfarin PK and PD variability, in turn allowing
better prediction of anticoagulation response outcomes without the need for intensive
sampling of drug concentrations. Until there is a better understanding of additional
determinants of PK and PD variation, and better quantitative characterization of drugdrug interactions, the current model may be useful for predicting outcomes in populations
of patients within the context of comparing the effectiveness of various dosing algorithms
in early attainment and maintenance of therapeutic INR responses and in guiding future
study designs.
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ABSENCE OF BOTH MDR1 (ABCB1) AND BCRP
(ABCG2) TRANSPORTERS SIGNIFICANTLY ALTER
RIVAROXABAN DISPOSITION AND CNS ENTRY4

____________________________

4

Reprinted with permission from Gong IY, Mansell SE, Kim RB. 2013. Absence of both
MDR1 (ABCB1) and BCRP (ABCG2) transporters significantly alter rivaroxaban
disposition and CNS entry. Basic Clin Pharmacol Toxicol, Mar;112(3):164-70. Copyright
2013 John Wiley and Sons Inc.
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6.1

Introduction

Thromboembolic events resulting from blood clotting disorders are a significant source
of mortality and morbidity and thus often require life-long anticoagulation therapy (1).
Although warfarin has been the mainstay of therapy, important limitations in its use have
prompted development of newer agents (2). Rivaroxaban is a reversible factor Xa
inhibitor recently approved for stroke prevention in atrial fibrillation (AF) patients and
treatment of venous thromboembolism (VTE) (3).

Rivaroxaban oral bioavailability was reported to be over 80% and achieves maximal
anticoagulation 2-4 hr after administration (4). Excretion of rivaroxaban occurs through
two main pathways; cytochrome P450 (CYP) 2J2 and CYP3A4-dependent metabolism
are responsible for two-thirds of its elimination while one-third is renally excreted
unchanged (4). However, renal elimination may be greater than currently assumed as
rivaroxaban exposure is 50% higher in patients with renal impairment (4). Furthermore,
bleeding complications were higher in patients with poor renal function (2, 5). Renal
excretion appears to be greater than glomerular filtration rate, suggesting a significant
contribution of active secretory processes to rivaroxaban elimination (2).

There has been growing appreciation of drug transporters expressed in various tissues in
determining the disposition and excretion of a wide range of xenobiotics (6). Pglycoprotein (P-gp), or multi-drug resistance protein 1 (MDR1, ABCB1) and breast
cancer resistance protein (BCRP, ABCG2) belong to the ATP-binding cassette family of
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efflux transporters. Both are expressed in organs important for drug elimination such as
the intestine, liver, and kidney. Moreover, their expression in organs such as the brain and
placenta prevent the entry of substrate drugs (7, 8).

Rivaroxaban was recently reported to be a substrate of P-gp (9), and correspondingly,
concomitant administration of potent P-gp inhibitors in human beings increases plasma
levels

by

over

two

times

(http://www.ema.europa.eu.proxy1.lib.uwo.ca/docs/en_GB/document_library/EPAR_Pro
duct_Information/human/000944/WC500057108.pdf).

However,

rivaroxaban

pharmacokinetics (PK) was not altered in P-gp knockout mice, likely due to involvement
of other efflux transporters (9). It is known that P-gp and BCRP exhibit overlapping
substrate specificity and tissue expression (10). For common drug substrates, the
transporters tend to exhibit a synergistic effect at the blood brain barrier (BBB) (11).
Thus, we suggested that BCRP may be the key compensatory transporter for rivaroxaban.
Accordingly, we investigated the transcellular transport of rivaroxaban in polarized cell
monolayers followed by assessment of the in vivo relevance of P-gp and BCRP to
rivaroxaban disposition using knockout mouse models.
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6.2
6.2.1

Methods
Rivaroxaban permeability in polarized LLCPK, LMDR1 and
Caco-2 monolayers

LLCPK, LMDR1 (LLCPK cells over-expressing MDR1) and Caco-2 cells were grown in
DMEM (Lonza, Walkersville, MD, USA) supplemented with 10% FBS (Invitrogen,
Carlsbad, CA), 2 mM L-glutamine, 50 U/mL penicillin (Invitrogen), 50 µg/mL
streptomycin (Invitrogen), and 1% non-essential amino acids (Invitrogen) and incubated
at 37°C in 5% CO2. LMDR1 cells were cultured with 640 nM vincristine (SigmaAldrich, St. Louis, MO, USA) to maintain MDR1 expression. LLCPK and LMDR1 cells
were seeded at a density of 2 x 105 cells per 12 mm well while Caco-2 cells were seeded
at 3 x 105 cells/mL onto 0.4 µm porous membrane inserts (BD, Franklin Lakes, NJ,
USA). LLCPK and LMDR1 cells were allowed to polarize over a 7-day incubation
period while Caco-2 cells were allowed to polarize for 12 days, with media change every
2 days. Prior to commencement of the transport experiment, cells were washed and
incubated with Opti-MEM (Invitrogen) for 1 hr. To initiate transport, media from either
the basal or apical compartment were replaced with 700 µL Opti-MEM with or without 5
µM rivaroxaban (Toronto Research Chemicals, Toronto, ON, Canada), as appropriate.
Cells were incubated at 37°C in 5% CO2 and transcellular flux was measured in the
apical-basal or basal-apical direction over 4 hr by liquid chromatography-tandem mass
spectrometry (LC-MS/MS). In LLCPK and LMDR1 monolayers, rivaroxaban transport
was also conducted in the presence of the selective P-gp inhibitor LY335979 (12) (1 µM;
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Eli Lilly Pharmaceuticals, Indianapolis, IN, USA). In Caco-2 monolayers, rivaroxaban
transport was also conducted in the presence of LY335979, the selective BCRP inhibitor,
fumitremorgan C (13, 14) (1 µM; Sigma-Aldrich) or both. Digoxin ([3H]-radiolabeled, 1
µM) was used as the positive control. Apparent permeability (Papp) was calculated from
the following equation: Papp = dQ/dt*1/(A*C0), where dQ/dt is the rate of transport over 4
hr, C0 is the resultant rivaroxaban concentration, and A is the surface area of the
membrane insert.

6.2.2

In vivo disposition of rivaroxaban disposition in transporter
knockout mice models

Male 6-12 week old Mdr1a-deficient mice (Mdr1adef), a subpopulation of CF-1 mouse
strain lacking expression of P-glp in the intestine and brain, and age matched male wildtype CF-1 mice were obtained from Charles River Laboratories (Wilmington, MA, USA).
Bcrp knockout (Bcrp-/-), Mdr1a/Mdr1b/Bcrp triple knockout (Mdr1a/Mdr1b-/-/Bcrp-/-)
mice, and age-matched (6-12 weeks old) wild-type FVB mice were obtained from
Taconic Farms (Hudson, NY, USA). Mice were administered 2 mg/kg of rivaroxaban via
oral gavage. Doses were prepared by dissolving rivaroxaban in DMSO (2%) and (1:1 v/v)
PEG-400/sterile water. Serial blood samples (60 – 100 µL) were obtained over 4 hr from
the saphenous vein and centrifuged to obtain plasma. At 4 hr, mice were killed using
isoflurane, blood was collected via cardiac puncture and liver, kidney, and brain tissues
were harvested and flash-frozen. Tissues were weighed and homogenized in 5 mM
ammonium acetate, pH 4.
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6.2.3

Rivaroxaban drug level analysis by LC-MS/MS

Samples from in vitro permeability studies, plasma and tissue homogenates were spiked
with 15 µL of internal standard (D3-rivaroxaban, 500 ng/mL; Toronto Research
Chemicals). Subsequently, acetonitrile was added to samples (3:1 v/v) and centrifuged at
9000 x g for 20 min to precipitate protein. The resulting supernatant was added to two
volumes of 5 mM ammonium acetate pH 4 and injected into the liquid chromatograph.
Analytes were separated with the reverse-phase Hypersil Gold column (50 × 5 mm, 5 µM
particle size) using gradient elution with 5 mM ammonium acetate pH 4 and acetonitrile
(20 to 80%) in a 6 min run time. The MS was set in positive mode for detection of
rivaroxaban and IS with transitions 437  144 m/z and 440  144 m/z, respectively.
The lowest limit of quantification was 1 ng/mL. The interday coefficient of variation and
bias of rivaroxaban quality controls were 10.5% and 9.3%, respectively.

6.2.4

Statistical analysis

The Mann-Whitney non-parametric t-test was used to analyse the statistical difference
between two groups (Graphpad Prism v5.0, La Jolla, CA, USA). Rivaroxaban clearance
was determined by non-compartmental analysis of plasma concentration curves in mice.
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6.3
6.3.1

Results
Permeability of rivaroxaban in LLCPK and LMDR1 cells

The ability of P-gp to transport rivaroxaban was assessed using the parental LLCPK and
LMDR1 cells. Rivaroxaban flux was markedly greater in the basal-apical direction,
where the permeability difference was 5.46 (Figure 6.1A). Modest basal-apical transport
was observed in LLCPK cells (1.68), suggesting transport by an endogenously expressed
transporter. In the presence of a specific P-gp inhibitor, LY335979, the basal-apical flux
in LMDR1 monolayers was attenuated, whereas apical-basal flux was enhanced,
abrogating the net efflux (Figure 6.1B). In contrast, little change was observed in the net
efflux of rivaroxaban in LLCPK cells in the presence of LY335979. As expected, net flux
of digoxin, a well-recognized P-gp substrate, was in the basal-apical direction in LMDR1
cells, which was abrogated with LY335979.

6.3.2

Permeability of rivaroxaban across intestinal Caco-2 cells

Vectorial transport of rivaroxaban was also assessed in the intestinal Caco-2 model,
known to express both MDR1 and BCRP. There was significantly greater permeability of
rivaroxaban in the basal-apical direction, leading to an efflux ratio of 2.82 (Figure 6.1C).
In the presence of either LY335979 or the specific BCRP inhibitor, fumitremorgan C,
rivaroxaban net flux was attenuated, reducing the efflux ratio to 1.61 and 1.88,
respectively (Figure 6.1D, 6.1E). Moreover, co-administration of both LY335979 and
fumitremorgan C with rivaroxaban lead to near complete loss of directional transport
difference (1.29) (Figure 6.1F). The permeability data are summarized in Table 6.1.
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Figure 6.1 In vitro transport of 5 µM rivaroxaban across monolayers. Rivaroxaban
transport was assessed in LMDR1 (A) and Caco-2 cells (C). The flux in LMDR1 cells
was also evaluated with co-administration of 1 µM of the specific MDR1 inhibitor,
LY335979 (B). The flux in Caco-2 cells was also evaluated with co-administration of 1
µM of the specific BCRP inhibitor, fumetrimorgan C (D), 1 µM LY335979 (E) or both
(F). Symbols and bars represent the mean and standard error. All transport experiments
were conducted in triplicates. ** P < 0.01, *** P < 0.001
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Figure 6.1 In vitro transport of 5 µM rivaroxaban across monolayers.
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Table 6.3.1 Apparent permeability of rivaroxaban across cell monolayers.
Papp A-B (SEM)

Papp B-A (SEM)

Efflux Ratio
(PappB-A/PappA-B)

-6

10 cm/s
LLCPK
Rivaroxaban

5.55 (0.49)

9.35 (0.20)

1.68

Rivaroxaban + LY

6.72 (1.16)

8.88 (1.15)

1.32

Rivaroxaban

2.28 (0.67)

12.44 (2.48)

5.46

Rivaroxaban + LY

12.10 (4.61)

10.40 (1.84)

0.86

2.59 (0.30)

7.01 (0.50)

2.70

4.26 (0.29)

4.86 (0.28)

1.14

Rivaroxaban

3.85 (0.44)

10.85 (0.15)

2.82

Rivaroxaban + LY

5.82 (0.56)

9.37 (0.22)

1.61

Rivaroxaban + FTC

5.29 (0.28)

9.93 (0.27)

1.88

Rivaroxaban + LY + FTC

7.26 (0.90)

9.38 (0.76)

1.29

2.44 (0.12)

6.16 (0.28)

2.52

3.57 (0.31)

4.13 (0.45)

1.16

LMDR1

3

[ H]Digoxin
3

[ H]Digoxin + LY
Caco-2

3

[ H]Digoxin
3

[ H]Digoxin + LY

BCRP, breast cancer resistance protein; FTC, fumitremorgan C; LY, LY335979; MDR1,
multi-drug resistance protein 1; Papp, apparent permeability; S.E.M., standard error of the
mean.
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6.3.3

Rivaroxaban in vivo disposition in wildtype and knockout
mice

To determine the relevance of MDR1 and BCRP in vivo, plasma (Table 6.2) and tissue
(Table 6.3) concentrations were assessed after rivaroxaban oral administration (2 mg/kg)
to wild-type, Mdr1adef, Bcrp-/-, and Mdr1a/Mdr1b-/-/Bcrp-/- mice (n = 6 per group). Plasma
concentrations did not significantly differ between wild-type and Mdr1adef or Bcrp-/- mice
(Figure 6.2A, 6.2B). However, the Mdr1a/Mdr1b-/-/Bcrp-/- mice appeared to exhibit
higher rivaroxaban plasma levels (Figure 6.2C). At 4 hr, rivaroxaban liver-to-plasma ratio
was significantly lower in the absence of Mdr1a, while no difference was observed in
Bcrp-/- or Mdr1a/Mdr1b-/-/Bcrp-/- mice compared with wild-type (Figure 6.3A-C).
Rivaroxaban kidney-to-plasma ratio did not differ across the various knockout mice
assessed (Figure 6.3D-F). However, kidney rivaroxaban accumulation was significantly
higher in Mdr1a/Mdr1b-/-/Bcrp-/- mice, likely due to the higher plasma concentration
observed in these mice (data not shown). Importantly, rivaroxaban total apparent
clearance was only significantly reduced in the absence of both Mdr1 and Bcrp compared
with wild-type (Figure 6.2D). Interestingly, rivaroxaban brain-to-plasma ratio was not
increased in Mdr1adef or Bcrp-/- mice, but was significantly elevated in Mdr1a/Mdr1b-//Bcrp-/- mice by over two times (Figure 6.3G-I).
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Table 6.3.2 Mean plasma tissue concentrations of rivaroxaban (ng/mL) after oral
administration of 2 mg/kg rivaroxaban (n = 6) in knockout and wild-type mice.
Time (hr)
0.5

1

2

4

Wildtype

29.3 (14.7)

20.5 (8.5)

12.1 (3.20

9.7 (2.6)

Mdr1adef

32.4 (24.5)

16.8 (7.6)

13.0 (6.2)

7.5 (3.5)

Wildtype

182 (28)

94 (15)

31 (8)

11 (4)

Bcrp-/-

133 (38)

85 (30)

26 (6)

18 (10)

Wildtype

45.8 (23.7)

27.1 (3.4)

12.3 (3.2)

5.0 (2.2)

Mdr1a/Mdr1b-/-/Bcrp-/-

31.6 (12.8)

27.0 (9.4)

19.8 (8.0)

8.5 (2.8)

Mdr1adef

Bcrp-/-

Mdr1a/Mdr1b-/-/Bcrp-/-

Bcrp, breast cancer resistance protein; Mdr1a, multi-drug resistance protein isoform 1a;
Mdr1a, multi-drug resistance protein isoform 1b.
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Table 6.3.3 Mean tissue concentrations of rivaroxaban (ng/mL) 4 hr after oral
administration of 2 mg/kg rivaroxaban (n = 6) in knockout and wild-type mice.
Organ
Liver

Kidney

Brain

Wildtype

12.5 (3.5)

2.9 (2.1)

0.14 (0.05)

Mdr1adef

6.6 (3.0)

4.0 (3.9)

0.18 (0.05)

Wildtype

19.7 (8.2)

3.1 (2.2)

0.7 (0.3)

Bcrp-/-

38.6 (18.0)

4.8 (2.3)

0.7 (0.3)

Wildtype

4.6 (1.7)

2.5 (0.8)

0.05 (0.01)

Mdr1a/Mdr1b-/-/Bcrp-/-

7.7 (1.8)

4.0 (1.0)

0.22 (0.07)

Mdr1adef

Bcrp-/-

Mdr1a/Mdr1b-/-/Bcrp-/-

Bcrp, breast cancer resistance protein; Mdr1a, multi-drug resistance protein isoform 1a;
Mdr1a, multi-drug resistance protein isoform 1b.
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Figure 6.2 Rivaroxaban pharmacokinetics in mice.
Rivaroxaban was administered by oral gavage to wildt-ype, Mdr1a deficient (Mdr1adef),
Bcrp-/-, and Mdr1a/Mdr1b-/-/Bcrp-/- mice (n = 6 for each group). The ratio of rivaroxaban
concentration and apparent systemic clearance in knockout and wild-type mice over 4 hr
was determined. Data are represented as mean with standard error of the mean. * P <
0.05
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Figure 6.3 Rivaroxaban liver, kidney and brain distribution in mice.
Liver to plasma ratios in Mdr1adef (A), Bcrp-/- (B), Mdr1a/Mdr1b-/-/Bcrp-/-(C) are
compared to wild-type. Kidney to plasma ratios in Mdr1adef (D), Bcrp-/- (E),
Mdr1a/Mdr1b-/-/Bcrp-/-(F) are compared to wild-type. Brain to plasma ratios in Mdr1adef
(G), Bcrp-/- (H), Mdr1a/Mdr1b-/-/Bcrp-/-(I) are compared to wild-type. Data are
represented as mean with standard deviation. * P < 0.05
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6.4

Discussion

In this report, we demonstrate that rivaroxaban is a shared substrate of both P-gp and
BCRP. In vivo relevance and interplay of both transporters are demonstrated through the
observation of a lack of any impact to rivaroxaban clearance in the individual transporter
knockout mice, but significantly reduced in the Mdr1a/Mdr1b-/-/Bcrp-/- mice. Similar to
certain tyrosine kinase inhibitors (11), rivaroxaban accumulation in the brain was
considerably higher when both transporters were absent than either one alone, suggesting
the collective effect of P-gp and Bcrp in determining rivaroxaban brain exposure in brain.

Although drug interaction studies have traditionally been focused on metabolizing
enzyme-mediated interactions, emerging evidence in recent years indicates the important
role of drug transporters in modulating pharmacokinetics and hence, efficacy and toxicity
(6, 15). Therefore, identification of drug transporters involved in rivaroxaban disposition
in addition to metabolizing enzymes is crucial for optimal efficacy while reducing side
effects. Accordingly, our findings are of particular importance in predicting rivaroxaban
exposure and certain drug drug interactions (DDIs) involving P-gp and BCRP. While
anticoagulation therapy effectively reduces ischaemic strokes, the elevated risk of
haemorrhage complications paradoxically causes intracranial bleeding, including the lifethreatening haemorrhagic stroke in some patients (16). Moreover, the risk of rivaroxabanassociated adverse events was compounded by poor renal function, driven by increased
systemic levels of the drug (5). Thus, exposure to rivaroxaban is expected to modulate the
extent of bleeding risk in patients. Our findings would suggest that patients at the highest
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bleeding risk likely have not only poor renal function but also reduced P-gp and BCRP
function, where the net effect would be increased gastrointestinal rivaroxaban absorption
leading to increased bioavailability, made worse through reduced rivaroxaban renal
secretion.

The lack of dramatic change in rivaroxaban disposition in vivo in mice lacking P-gp
function is in concordance with a previous report (9). Moreover, there may be rodent and
human differences in substrate specificity of P-gp, leading to differential P-gp-mediated
transport efficiency (17). Consequently, caution should be used for translating results
found in animal models to human beings, particularly for weak substrates of P-gp.
Nonetheless, mice deficient in P-gp has been used as a powerful tool for assessing the
role of P-gp in vivo, likely attributed to the overlapping expression pattern and function
between rodents and human P-gp (18). Despite this, the role of P-gp in modulating
rivaroxaban efficacy and risk of bleeding complications in human beings should not be
overlooked. In fact, concurrent use of rivaroxaban and P-gp inhibitors is contraindicated
due to prolonged anticoagulation and increased bleeding risk as a result of elevated
plasma levels, as observed with ketoconazole and ritonavir. Given that the bioavailability
of rivaroxaban is high, it is likely that the observed clinical interaction is owing to
inhibition of metabolism and excretion of rivaroxaban rather than affecting its absorption.
We know that P-gp and CYP3A4 share a large number of common inhibitors (19), and
thus the over two times increase in rivaroxaban exposure in human beings with coadministration of ketoconazole and ritonavir is likely a result of dual inhibition of P-gp
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and CYP3A4. In addition, it is possible that the inability to translate from deficient mouse
model to the observed P-gp interaction in human beings is due to the less prominent role
of renal excretion to overall rivaroxaban disposition in rodents (20). Thus, although our
data indicated that the overall clearance was only modestly reduced even in the
Mdr1a/Mdr1b-/-/Bcrp-/- knockout mice, the relevance of P-gp and BCRP-mediated
rivaroxaban excretion in humans should not be disregarded and requires further
assessment.

Drug interactions with BCRP are less likely as a large fraction of BCRP substrates and
inhibitors are chemotherapeutic agents (21). However, there are clinically relevant
polymorphisms that exist in MDR1 and BCRP, particularly the common reduced function
polymorphisms in BCRP (c.34 G>A, c.421 C>T) recognized for affecting the PK of its
substrates (22, 23). Thus, genetic variations in efflux transporters may play an important
role in determining rivaroxaban exposure, efficacy, and toxicity. Collectively, we
postulate that homozygous carriers of BCRP variants concomitantly taking Pgp/CYP3A4 inhibitors likely possess the greatest risk for haemorrhage. This is especially
a concern for AF patients, the predominant disease of the elderly with declining renal
function, whereby comorbidities and concomitant use of P-gp/CYP3A4 inhibiting
medications may be difficult to avoid. Our findings would suggest that the highest at risk
subset of such patients would be those who carry loss of function polymorphisms in
BCRP.
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Additionally, higher rivaroxaban entry in central nervous system (CNS) in Mdr1a/Mdr1b/-

/Bcrp-/- mice suggests that patients with attenuated P-gp and BCRP transport function

could potentially be at greater risk of intracranial haemorrhage. Modulation of P-gp
function with use of inhibitors has indeed been shown to allow greater CNS access for Pgp substrates, such as HIV protease inhibitors and loperamide (12, 24). The mechanisms
underlying haemorrhagic strokes have not been clearly delineated; however, oral
anticoagulant-associated haemorrhage has been suspected to be due to increased
haematoma expansion, particularly in patients with over-anticoagulation as a result of
elevated systemic exposure of the drug (25). Moreover, rivaroxaban was developed with
the intent of eliminating routine response monitoring. Hence, evaluation of
anticoagulation efficacy and bleeding risk in patients will likely be problematic in realworld patients without the use of a standardized test. Furthermore, the lack of a validated
antidote for reversing rivaroxaban overdose will likely potentiate the danger of bleeding
events (26). Thus, similar to other new anticoagulant agents (27), there is a need for postmarketing surveillance of adverse events, including analysis of bleeding events within the
context of drug transporter pharmacogenetics, to more fully delineate rivaroxaban safety
and efficacy. Future clinical studies are required to elucidate the combined effect of P-gp
and BCRP in modulating rivaroxaban exposure in plasma, bleeding complications, and
anticoagulation efficacy.
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7

CLARIFYING THE IMPORTANCE OF CYP2C19 AND
PON1 IN THE MECHANISM OF CLOPIDOGREL
BIOACTIVATION AND IN VIVO ANTIPLATELET
RESPONSE5

____________________________

5
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Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel
bioactivation and in vivo antiplatelet response. Eur Heart J, 33(22):2856-2464a.
Copyright 2012 European Society of Cardiology.
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7.1

Introduction

Antiplatelet therapy is an important therapeutic intervention for prevention of ischaemic
events in patients with high-risk cardiovascular disease, particularly for those who
undergo percutaneous coronary intervention (PCI) (1). Currently, the standard of care for
managing such patients is dual antiplatelet therapy with a P2Y12 receptor antagonist and
the cyclooxygenase I inhibitor aspirin. Clopidogrel is the most widely prescribed
thienopyridine that exerts its pharmacological effect by irreversibly binding to P2Y12
receptors on platelets, thereby diminishing adenosine diphosphate (ADP)-mediated
platelet aggregation (2). Although benefits from clopidogrel have been widely
documented in large clinical trials, marked interpatient variation in platelet
responsiveness has meant that 21% of the patients remain at risk for coronary artery and
stent thrombosis (3).

Clopidogrel is a prodrug and its clinical efficacy appears to be a function of the amount
of enzymatically derived active thiol metabolite formed (4, 5). Previous in vitro studies
have delineated that this bioactivation is a two-step process, catalysed by several
cytochrome P450 (CYP) isozymes (6-8). Clopidogrel is first metabolized to the
intermediate metabolite, 2-oxo-clopidogrel, followed by metabolism to a number of thiol
metabolite stereoisomers, only one of which (H4) is active in vivo (2, 5, 9). Notably, both
metabolic steps leading to H4 formation have been shown to be predominantly dependent
on CYP2C19 and to a lesser extent CYP3A4 (6). Importantly, in large clinical trials,
CYP2C19*2 or *3 loss-of-function single nucleotide polymorphisms (SNPs) have been
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associated with lower platelet inhibition and consequently, an increased risk of major
cardiovascular events (10-12).

In contrast, Bouman et al. recently demonstrated that a non-CYP enzyme, paraoxonase-1
(PON1) was the key determinant of clopidogrel active metabolite formation (13).
Importantly, they showed that plasma PON1 activity as well as the Q192R SNP (rs662)
in PON1, but not CYP2C19 SNPs was predictive of antiplatelet response and risk for
stent thrombosis in clopidogrel-treated patients. These findings fundamentally challenged
our prior understanding of clopidogrel metabolism and efficacy. In the report, we set out
to define a mechanistic link between clopidogrel metabolism and antiplatelet action to
clarify the clinical relevance of PON1 and CYP2C19 to clopidogrel response.
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7.2
7.2.1

Methods
Clinical study design

The study was approved by the Research Ethics Board at the University of Western
Ontario. All subjects (age 18-65) were non-smokers, not taking concomitant medications,
without previous exposure to clopidogrel, and deemed healthy per medical exam. Healthy
volunteers who met the eligibility criteria were enrolled upon provision of written
informed consent (n = 21; supplemental material, Table 7.3).

Overnight fasted subjects received a single oral dose of clopidogrel (75 mg). In addition,
100 µg of midazolam was administered orally as an in vivo probe for CYP3A4 activity.
For pharmacokinetic analysis, blood samples were collected over an 8 h period.
Clopidogrel thiol metabolites were stabilized for analysis using EDTA tubes containing
50 µL of 125 mM 2-bromo-3-methoxyacetophenone (MPB) (Sigma-Aldrich, Oakville,
Canada).

To determine antiplatelet response, blood was collected using a 1.8 ml sodium citrate
(3.2%) tube at baseline and 4 hours post-clopidogrel dose and subjected to the
VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA), as per the manufacturer’s
protocol.
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Genotype analysis and plasma paraoxonase activity were determined as described in
supplemental materials.

7.2.2

Clopidogrel bioactivation

The in vitro metabolic profiling of clopidogrel metabolism was conducted in microsomes
(supplemental material).

7.2.3

Liquid Chromatography Tandem Mass Spectrometry (LCMS/MS) analysis

Quantitation of midazolam and clopidogrel metabolites (in vivo and in vitro) was
performed as described in supplemental materials.

7.2.4

Data analysis

All data analyses are as described in supplemental material.
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7.3
7.3.1

Results
Influence of CYP2C19, PON1, and CYP3A4 on clopidogrel
kinetics and response

Following a 75 mg dose, carriers of at least one reduced function CYP2C19 allele
[CYP2C19*2 or *3 allele, reduced metabolizers (RMs); 38% of the study population] had
significantly decreased total plasma exposure (area under the plasma concentration curve,
AUC) of the H4 active metabolite when compared with the non-carrier extensive
metabolizers (EMs) (Figure 7.1A; supplemental material, Figure 7.6). Similarly, the
maximum plasma concentration (Cmax) was higher in EMs than RMs (Table 7.1). Prior to
administration of clopidogrel, the mean platelet responsiveness [platelet reactive units
(PRU)] induced by 20 µmol/L ADP and 22 nM prostaglandin E1 (PGE1) was similar
between EMs and RMs (VerifyNow P2Y12 assay; Table 7.2). Four hours following
clopidogrel administration, the absolute percentage change in PRU was significantly
lower in RMs when compared with EMs (Figure 7.1B). In fact, we observed a strong
correlation between H4 plasma exposure and platelet inhibition, demonstrating that
individuals with highest exposure to H4 active metabolite have the greatest antiplatelet
response (Figure 7.1C). Interestingly, we did not observe any correlation between gainof-function PON1 Q192R polymorphism and clopidogrel pharmacokinetics or response,
despite the fact that PON1 plasma activity, assessed ex vivo using paraoxon as the
prototypical substrate, in the same healthy volunteers correlated well with the PON1
Q192R genotype (Figure 7.1D, 7.1E; supplemental material, Figure 7.6). In addition, no
significant correlation was found between paraoxonase plasma activity and antiplatelet

178

response (Figure 7.1F). Of note, exclusion of non-Caucasian participants in these
analyses does not modify the above findings (data not shown).

Midazolam plasma AUC was not related to H4 AUC or antiplatelet response (P = 0.91,
0.65) (Figure 7.2).
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Figure 7.1 The role of CYP2C19 and PON1 genetic polymorphisms in clopidogrel
pharmacokinetic and pharmacodynamic responses.
(A and B) Box-and-whisker plots of total active metabolite H4 plasma exposure (AUC)
and antiplatelet response according to CYP2C19 genotype. (C) Scatter plot of H4 AUC
and antiplatelet response (r2 = 0.78). (D and E) Box-and-whisker plots of H4 AUC,
paraoxonase plasma activity, and antiplatelet response according to the PON1 genotype.
(F) Scatter plot of plasma paraoxonase activity and antiplatelet response. Boxes indicate
25th and 75th percentile, whiskers denote the 95% confidence interval, and ‘+’ represents
the mean. *P < 0.05; **P < 0.01.
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Table

7.3.1

H4

active

metabolite

pharmacokinetic

parameters

following

administration of a single 75 mg oral dose of clopidogrel.
Cmax, (ng/mL)

33.9 (21.0)

P-Value

CYP2C19
EM

40.2 (23.3)

RM

25.5 (13.7)

0.05

PON1
Q192Q

30.34 (19.80)

Q192R

41.84 (30.67)

R192R

27.70 (6.08)

tmax, (h)

0.55

0.73 (0.18)

CYP2C19
EM

0.77 (0.16)

RM

0.67 (0.17)

Q192Q

0.78 (0.16)

Q192R

0.68 (0.19)

R192R

0.65 (0.13)

0.18

PON1

t1/2 (h)

0.33

0.67 (0.19)

CYP2C19

PON1

EM

0.67 (0.20)

RM

0.68 (0.19)

0.91
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Q192Q

0.63 (0.25)

Q192R

0.69 (0.20)

R192R

0.67 (0.16)

AUC0-8 hr (ng h/mL)

37.40 (21.97)

0.77

CYP2C19
EM

44.79 (25.09)

RM

27.54 (12.27)

Q192Q

35.31 (21.57)

Q192R

43.27 (28.33)

R192R

27.47 (6.64)

0.03

PON1

0.66

Cmax, maximum plasma concentration; EM, extensive metabolizers (CYP2C19 *1/*1 or
*1/*17); RM, reduced metabolizers (*1/*2, *2/*2 or *1/*3); tmax, time to Cmax; t1/2, halflife; AUC08 hr , area under the plasma concentration curve. Data are represented as mean
with standard deviation.
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Table 7.3.2 Platelet response pre- and 4 h post-clopidogrel administration.
P-value

Pre-dose PRU
CYP2C19
EM

348 (32)

RM

315 (43)

0.30

PON1
Q192Q

343 (41)

Q192R

306 (34)

R192R

361 (29)

0.07

Antiplatelet response (absolute % change PRU)
CYP2C19
EM

24.5 (19.0)

RM

11.31 (14.82)

0.02

PON1
Q192Q

15.4 (13.4)

Q192R

24.8 (28.2)

R192R

14.51 (4.5)

0.55

EM, extensive metabolizers; RM, reduced metabolizers; PRU, platelet reactive units.
Data are represented as mean with standard deviation.
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Figure 7.2 The role of CYP3A4 activity in clopidogrel pharmacokinetics and
pharmacodynamics.
(A and B) Scatter plot of total midazolam plasma exposure and H4 active metabolite
exposure, or antiplatelet response, respectively.
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7.3.2

Identification of other clopidogrel thiol metabolites in plasma

Using an ultra-high-performance liquid chromatography-tandem mass spectrometry
(UHPLC-MS/MS) method, we were able to detect and quantify other clopidogrel thiol
metabolites isobaric to H4 in the plasma of study subjects (Figure 7.3A) (9). One
metabolite, known to be inactive is termed H3, is stereochemically similar to H4 except
being diastereomeric at the carbon 4 position. Another observed thiol metabolite is
termed Endo, which differs from H3/H4 in that the carbon double bond is in the
endocyclic position. In addition to chromatographic separation of H3, H4 and Endo
(Figure 7.3C, 7.3E), the MS fragmentation signatures of the H3/H4 and Endo thiol
metabolite were distinct (Figure 7.3D, 7.3F), ensuring analytical specificity of the
isomers being analysed.
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Figure 7.3 Representative chromatograms of derivatized H4 and Endo metabolite. (A)
Chromatogram

of

a

human

plasma

sample

derivatized

with

2-bromo-3-

methoxyacetophenone. (B) Chromatogram of a sample derived from PON1-mediated
hydrolysis of 2-oxo-clopidogrel. (C and D) Chromatogram of Endo standard and its
MS/MS fragmentation signature. (E and F) Chromatogram of H4 standard and its
MS/MS fragmentation signature.
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7.3.3

Biotransformation of clopidogrel to 2-oxo-clopidogrel

In the first step of the bioactivation process, the intrinsic clearances (CLint) calculated
from estimated Km and Vmax values show that CYP2C19 is more efficient in forming the
intermediate metabolite than CYP3A4 in vitro (Figure 7.4A; supplemental material,
Table 7.4).

7.3.4

Biotransformation of 2-oxo-clopidogrel to H3 and H4 thiol
metabolites

In the second step of the bioactivation process, the CLint for H4 formation from 2-oxoclopidogrel by CYP2C19 was greater than that with CYP3A4 (Figure 7.4B; see
Supplemental material, Table 7.4). Notably, the formation of H4 from 2-oxo-clopidogrel
was dependent on the presence of 5 mM reduced glutathione (GSH) (data not shown).
Based on lower H4 formation compared with 2-oxo-clopidogrel formation, it appears that
the second reaction is the rate-limiting step of the overall clopidogrel bioactivation. We
observed that the inactive metabolite, H3, was also formed from 2-oxo-clopidogrel by
CYP2C19 at a relatively similar efficiency as H4 (supplemental material, Table 7.4).
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7.3.5

Biotransformation of 2-oxo-clopidogrel to Endo thiol
metabolite

We incubated a range of 2-oxo-clopidogrel concentrations with baculovirus microsomes
heterologously expressing CYP2C19 and HeLa cell-derived microsomes constitutively
expressing PON1 while lacking any drug-metabolizing CYP enzymes. In the baculovirus
microsomes, Endo metabolite formation was greater with CYP2C19 than in control
baculovirus microsomes (Figure 7.4C; supplemental material, Table 7.5). In addition,
HeLa cell microsomes constitutively expressing PON1 were capable of forming Endo
metabolite but not H4 (Figure 7.3B, 7.4D; supplemental material, Table 7.5). We further
confirmed the ability of PON1 to hydrolyse 2-oxo-clopidogrel using an adenovirus
overexpressing system in HeLa cells, where Endo formation was 3.5-fold higher than
vector control (LacZ) and no H4 was detected (Figure 7.4E). Moreover, Endo formation
by PON1 was attenuated by the specific PON1 inhibitor 2-hydroxyquinoline (Figure
7.4E). We note that PON1-mediated Endo formation was not dependent on GSH (data
not shown). Overall, our data suggests that PON1 can hydrolyse 2-oxo-clopidogrel to
form Endo metabolite while unable to mediate H4 formation and that CYP2C19 also
catalyses Endo formation. Analysis of total Endo plasma exposure in healthy volunteers
demonstrated that its levels were more than 20-fold lower than H4 (data not shown), and
unlike H4 (Figure 7.1C), Endo AUC did not correlate with antiplatelet response (Figure
7.4F).
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Figure 7.4 Clopidogrel bioactivation in vitro. (A) Formation of 2-oxo-clopidogrel by
CYP2C19 and CYP3A4. (B) Formation of H4 active metabolite by CYP2C19 and
CYP3A4. (C) Formation of the Endo metabolite by CYP2C19 and CYP-lacking
baculovirus insect-cell microsomes. (D) 2-oxo-clopidogrel metabolism to Endo
metabolite by HeLa cell-line derived microsomes. (e) PON1-mediated hydrolysis of 2oxo-clopidogrel to the Endo metabolite in the absence or presence of PON1 inhibitor, 2hydroxyquinoline. Symbols and bars represent means and standard errors. (F) Scatter plot
of Endo metabolite plasma exposure and antiplatelet response. *P < 0.001.
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7.4

Discussion

The impact of CYP2C19 genetic variations on clopidogrel antiplatelet response has been
documented in a number of studies (11, 14). In fact, a recent meta-analysis reported that
carriers of CYP2C19*2 allele had a higher risk for major adverse cardiovascular events,
increased mortality and stent thrombosis compared with non-carriers, independent of
baseline cardiovascular risk (14). We note that in contrast to these studies, one trial
(CURE) reported similar clopidogrel efficacy irrespective of the CYP2C19 genotype
(15). A potential explanation for the disparate findings is the difference in rate of PCI
with stenting, where only 14.5% of the population underwent stenting in the CURE trial
while majority of patients underwent stenting in other CYP2C19-supportive trials.
Indeed, it has been consistently shown that the greatest clinical benefit with clopidogrel
use is the reduction in stent thrombosis rate (16). Moreover, several prospective trials
have restored diminished H4 exposure and poor antiplatelet response in CYP2C19 variant
carriers by increasing clopidogrel dose, including one recently published multi-centre
double-blinded randomized clinical trial (17-19). However, our understanding of
clopidogrel response in the context of pharmacogenomics was further complicated when
Bouman et al. challenged the aforementioned findings by identifying the PON1 Q192R
polymorphism as the only genetic marker associated with stent thrombosis, accounting
for 72.5% of the response variation.
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In the present study, we aimed to determine the influence of CYP2C19 and PON1 on
clopidogrel metabolism and antiplatelet response. In contrast to Bouman et al., our results
support the notion that decreased CYP2C19 function reduces the formation of
clopidogrel active thiol metabolite, while PON1 showed no effect on active metabolite
exposure. It should be noted that there are several challenges to accurate quantification of
the active metabolite, H4. First, H4 is one of several diastereomeric thiol metabolites of
clopidogrel observed during in vitro metabolomic analysis that requires analytical
techniques capable of distinguishing the related species (5, 9). Secondly, due to the
reactive nature of the free thiol metabolites, derivatization using alkylating agents, such
as MPB, has been required to trap the metabolite for quantitation (9). In the current study,
we followed a recently published stereoselective UHPLC-MS/MS method to determine
plasma concentrations of clopidogrel thiol metabolites (H4, H3, and Endo) in our cohort
(9). In the study by Bouman et al., stereo-specific separation of H3, H4, and Endo was
not demonstrated, thus resulting in inaccurate clopidogrel pharmacokinetic analysis (13).
Furthermore, they used an alternative method of stabilizing the active metabolite for
quantitation and thus, these technical discrepancies may in part explain the discordant
findings with regards to contribution of CYP2C19 and PON1 to clopidogrel
pharmacokinetics.

Similar to a number of recent studies that refuted a clinically relevant role of PON1
genotypes to clopidogrel response, we show that CYP2C19 but not PON1 genotype is
related to ADP-induced antiplatelet response (20-22). This agrees well with a recently
published genome-wide association study in a healthy Amish population showing that the
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CYP2C19*2 allele had a significant association with clopidogrel platelet aggregation,
while the PON1 genotype did not (23). The strong correlation between H4 exposure and
antiplatelet response (r2=0.78) presented here suggests that known genetic variation in
CYP2C19 as well as interpatient variation in expression and activity of this enzyme likely
account for clopidogrel resistance observed in nonresponders.

The role of CYP3A4 in clopidogrel pharmacokinetics and pharmacodynamics remains
unclear. While some studies postulate that CYP3A4 genotype and inhibition modulates
clopidogrel pharmacokinetics and action (24), many others do not (25). Midazolam has
been well documented as an in vivo probe drug for CYP3A4 activity (26). Thus,
administration of a microdose of midazolam was used here to measure CYP3A4
phenotype in subjects. To the extent of our knowledge, we demonstrate for the first time
that CYP3A4 activity, as measured by midazolam exposure, is not an important driver of
clopidogrel pharmacokinetics or antiplatelet response.

Recently, a correspondence from Dansette et al. questioned the validity of the original
findings of Bouman and colleagues (27). Specifically, they report that the Endo
metabolite, but not other thiol metabolites is formed in human liver microsomes
incubated with 2-oxo-clopidogrel in the absence of CYP-requiring NADPH. This Endo
formation was attenuated in the presence of the PON1 substrate paraoxon but unaffected
by the presence of a CYP inhibitor. Moreover, Dansette and colleagues found that the
Endo metabolite was generated in serum (devoid of CYP enzymes) upon ex vivo
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incubation with 2-oxo-clopidogrel. Those results indicate a role for PON1 in the
formation of the Endo metabolite but not in the bioactivation to H4. The results from the
current study not only confirm the findings of Dansette et al., but solidify PON1 as the
key player in Endo but not H4 generation through systematic and definitive metabolic
experiments that include a PON1 overexpression system and recombinant CYP enzymes.

We believe that lack of analytical specificity, followed by misidentification of the
synthesized analytical standard used to quantify clopidogrel active metabolite levels may
have been the critical missteps which led to the conclusion by Bouman et al. that PON1
generates the active metabolites 16. First, the conditions for the separation of H4 from
other

structurally

similar,

but

inactive

metabolites

requires

high-resolution

chromatographic techniques such as UHPLC coupled with MS/MS. The liquid
chromatographic method used by Bouman et al. was likely insufficient for discriminating
between active H4 from the inactive H3 and Endo metabolites. It is also not certain
whether the analytical method used could quantify non-Endo thiol metabolites such as
H4. Secondly, Bouman et al. obtained their thiol metabolite reference standard from
purification of PON1-mediated 2-oxo-clopidogrel hydrolysis

16

. They suggest that this

product was active based on platelet reactivity experiments. However, those experiments
were performed at purified thiol metabolite concentrations of 2 mg/L, which is 100 times
greater than the reported plasma thiol metabolite concentration. Since we clearly show
that PON1 can only generate Endo and not H4, it is clear that the thiol metabolite they
had used as analytical standard to represent the active metabolite was in fact the inactive
Endo metabolite. Bouman and colleagues admit that their analytical methods did not
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distinguish between different thiol metabolites derived from PON1, human liver
microsomes, or human serum in vitro (27). They argue that the ratio of produced active
thiol metabolites to total thiol metabolites was constant between enzyme preparations
based on platelet reactivity studies of purified thiols, suggesting that PON1 creates a
similar degree of active metabolites as human liver microsomes. Again, it is important to
note that those platelet incubations were performed at purified thiol metabolite
concentrations of 0.5 - 5 mg/L, values that are 25 - 250 times greater than their reported
concentration of thiol metabolites patient plasma, bringing to question the relevance of
such experiments as an argument for not requiring greater analytical specificity. Without
identification and quantitation of these unknown PON1-derived active metabolites in
relation to the amount of H4 active metabolite known to be found at significant levels in
patient/subject plasma, it would seem that Bouman and colleagues have not clarified a
role for PON1 in clopidogrel bioactivation.

Here, the in vitro data are consistent with previous studies that demonstrated the
importance of CYP isozymes in clopidogrel bioactivation (6, 7, 27). In addition, the
mechanism by which the 2-oxo-clopidogrel ring opens to expose the free thiol in H4
metabolite has been shown to be dependent on the presence of a reducing agent such as
GSH (7, 8). Consistent with such data, we see a lack of H4 formation by CYP enzymes in
the absence of GSH. Overall, we propose that both steps of clopidogrel bioactivation are
mainly driven by CYP2C19, ultimately generating active H4, while PON1-mediated
hydrolysis of 2-oxo-clopidogrel generates the Endo metabolite (Figure 7.5). Notably, we
show that the estimated enzyme affinity (Km) of 2-oxo-clopidogrel to CYP2C19 is much
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higher than that of PON1, concordant with the low 2-oxo-clopidogrel affinity for PON1
demonstrated by Bouman et al. Accordingly, in hepatocytes, where clopidogrel
bioactivation occurs, CYP2C19-mediated oxidation of 2-oxo-clopiodgrel would be the
preferred pathway at therapeutic concentrations of the drug. Importantly, to the extent of
our knowledge, this is the first study to quantify Endo and H4 concentrations
simultaneously in humans. We demonstrate that Endo levels are nearly 20-fold lower
compared with H4; thus, Endo is unlikely to contribute substantially to clopidogrel
antiplatelet response, in addition to the lack of association between Endo levels and
antiplatelet response. Moreover, these results are further substantiated by our findings of
no association between PON1 plasma activity and genotype with H4 levels or antiplatelet
activity.

There are several noteworthy limitations to our study. First, the current clinical study was
conducted in a relatively small cohort of study subjects. Therefore, we combined carriers
of one or two alleles of CYP2C19*2 or CYP2C19*3 into one group and cannot comment
on the differential influence of these alleles or its gene-dose effect on clopidogrel
pharmacokinetics and pharmacodynamics. Such pooling of CYP2C19 variant carriers has
been done previously for similar reasons (28). It should be noted that in terms of sample
size, an 80% power was achieved to detect a 40% difference in antiplatelet response
between CYP2C19 EM and RM genotype groups with a two-sided significance level of
0.05, and a standard deviation of 20%. With respect to PON1 analysis, the high
interindividual variability observed within PON1 genotype groups lead to reduction in
power below 80%. However, the lack of PON1 Q192R genetic influence on clopidogrel
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response is in agreement with recently published studies of large sample sizes. Secondly,
this study used the point-of-care VerifyNow P2Y12 assay to measure clopidogrel
antiplatelet response. While VerifyNow utilizes ADP and PGE1 to induce and measure
global platelet aggregation, it is not as direct a measure of platelet P2Y12 signalling
activity as the vasodilator-stimulated phosphoprotein (VASP) assay or even direct
receptor occupancy assays using 33P-2MeS-ADP (29). Indeed, clopidogrel H4 metabolite
plasma exposure tracks with the VASP phosphorylation platelet reactivity index (17).
Whether the H4 metabolite level is associated with VerifyNow PRU response has not
been well described until now. Although some studies show high correlation between
VASP and VerifyNow measured antiplatelet response(19, 30, 31), others did not (32).
Nevertheless, clopidogrel response as measured by VerifyNow has consistently been
shown to predict therapy resistance and clinical outcomes in a number of large trials and
thus represents a feasible alternative technique for monitoring clopidogrel response (30,
33). Indeed, the more pressing issue to address is delineating relevant cut-off thresholds
for distinguishing between responders and non-responders, which will then allow
clinicians to increase clopidogrel dose as appropriate. A standardized optimal cut-off
value for each P2Y12 activity assay remains to be evaluated and defined. Lastly, since this
is a proof-of-principle study in healthy subjects given a single 75 mg dose of clopidogrel,
designed to delineate the role of PON1 relative to that of CYP2C19, we cannot directly
extrapolate our findings to clopidogrel responsiveness in patients but it should be noted
that the influence of CYP2C19 and PON1 on clopidogrel platelet aggregation has been
assessed large patient cohorts in multiple studies (20-22). However, a key advantage of
our study population and design is the ability to more clearly delineate the effect of

198

pharmacogenetic markers on clopidogrel pharmacokinetics and response and elimination
of the potentially confounding effects of concomitant medications and existing disease
states. In addition, quantification of the active H4 thiol metabolite here allowed for a
more precise assessment of the role of genetics on clopidogrel pharmacokinetics.

In conclusion, we show that PON1, unlike CYP2C19, is incapable of generating the
clopidogrel active metabolite H4 in vitro. In human subjects, the CYP2C19 loss-offunction genotype is a major driver of H4 exposure, corresponding to lowered ADPinduced antiplatelet response. Furthermore, we demonstrated that PON1 generates the
Endo metabolite; however, no correlation existed between plasma paraoxonase activity
and Endo levels to antiplatelet response. Accordingly, although it remains likely that
there are other genetic and non-genetic determinants of clopidogrel efficacy, our study
suggests that CYP2C19 but not PON1 or CYP3A4 is a mechanistic determinant of
interpatient antiplatelet response variability to clopidogrel therapy.
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Figure 7.5 Schematic summary of clopidogrel bioactivation.
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7.6
7.6.1

Supplemental material
Genotyping

Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit as
per manufacturer’s protocol (Qiagen, Alameda, CA). Genotype analysis included
CYP2C19*2(rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 (rs12248560), and
PON1 Q192R (rs662). Genotypes were determined by allelic discrimination using
TaqMan Drug Metabolism Genotyping assays with the 7500 RT-PCR System (assay IDs:
C_25986767_70, C_27861809_10, C_469857_10, C_2548962_20; Applied Biosystems,
Foster City, CA). Genotype analysis was conducted in parallel with known, sequenceverified wild-type, heterozygous, and variant controls for each SNP.

7.6.2

Kinetics of clopidogrel metabolism

Microsomes from baculovirus cells overexpressing human cytochrome P450 2C19 and
3A4 as well as NADPH CYP Oxidoreductase (BD Biosciences, Mississauga, Ontario)
were used to examine the formation of 2-oxo-clopidogrel. Clopidogrel (0 – 45 µM) was
incubated with microsomes at 37°C for 5 min, followed by addition of NADPHregenerating system to start the reaction, yielding a final volume of 100 µL in potassium
phosphate buffer (100 mM pH 7.4). After incubation at 37°C for 10 min, the reaction was
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terminated by adding 2-fold volume of acetonitrile with 125 mM MPB and 500 ng/mL
D4-clopidogrel carboxylic acid as the internal standard (IS).

7.6.3

Kinetics of 2-oxo-clopidogrel metabolism

CYP2C19, CYP3A4 and control baculovirus microsomes were used to characterize the
metabolism of 2-oxo-clopidogrel. 2-oxo-clopidogrel (0 – 50 µM) was incubated with
microsomes at 37°C for 5 min, followed by addition of NADPH-regenerating system and
5 mM reduced glutathione (GSH) to start the reaction, yielding a final volume of 100 µL
in potassium phosphate buffer (100 mM pH 7.4). After incubation at 37°C for 30 min, the
reaction was terminated by adding 2-fold volume of acetonitrile with 125 mM MPB and
500 ng/mL IS.

7.6.4

PON1-mediated hydrolysis of 2-oxo-clopidogrel

LacZ control and PON1 overexpressing HeLa microsomes (Supplemental Methods) were
pre-incubated with 100 mM Tris buffer (pH 7.4), 1 mM calcium chloride, and 5 mM
GSH at 37°C for 5 min, followed by addition of 2-oxo-clopidogrel to start the reaction
(total volume of 50 µL) in presence or absence of specific PON1 inhibitor, 2hydroxyquinoline (400 µM). After incubation at 37°C for 15 min, the reaction was
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terminated by adding 2-fold volume of acetonitrile with 125 mM MPB and 500 ng/mL
IS.

7.6.5

UHPLC-MS/MS analysis

Clopidogrel active metabolite H4-MPB derivative, Endo-MPB derivative, and internal
standard (IS) D4-clopidogrel carboxylic acid were purchased from Toronto Research
Chemicals (Toronto, Canada). H4 and Endo concentrations were determined using ultra
high pressure liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS,
Agilent 1290 UPLC coupled with ThermoScientific TSQ Quantum). Briefly, 200 µL of
acetonitrile and 10 µL of IS (0.5 µg/mL) were added to 100 µL of MPB-treated plasma
and centrifuged at 14,000 rpm for 20 min. The resulting supernatant was added to water
(1:2 v/v) prior to injection into the chromatograph. Analytes were separated by reversephase chromatography (Hypersil Gold Column 100 × 2 mm, 1.9 µM; or Shimpack XRODS II 75 mm x 2.0 mm, 2.2 µM) using gradient elution of 0.1% formic acid in water
v/v and 0.1% formic acid in acetonitrile (35 to 70%) with a flow rate of 0.3 mL/min in an
8 min run time. The MS was equipped with heated electrospray ionization in positive
mode for detection of H4, Endo, and IS with transitions 504  354 m/z, 504  155 m/z
and 312  212 m/z, with collision energies of 44 eV, 22 eV and 20 eV, respectively. The
lowest limit of quantification was 1 ng/mL for all analytes. The interday coefficient of
variation of H4 and Endo quality controls were 10.3% and 7%, respectively.
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7.6.6

Midazolam LC-MS/MS analysis

Midazolam and the IS, alprazolam, were purchased from Diagnostix (ThermoFisher,
Mississauga, Canada). Midazolam plasma concentrations were determined using LCMS/MS (Agilent 1200 coupled with ThermoScientific TSQ Vantage). Midazolam was
extracted using solid-phase extraction (SPE), using a Waters Extraction Plate manifold
coupled with Oasis Hydrophilic-Lipophilic-Balanced µElution 96-well plates. Briefly,
column packings were conditioned with 200 µL of acetonitrile and equilibrated with 200
µL of water, followed by 200 µL of 0.1% formic acid in water. Subsequently, each
column was loaded with 500 µL of 0.1% formic acid in water and alprazolam (10 ng/mL)
mixed with 500 µL of plasma. The sample was washed with 200 µL of 10 mM
ammonium acetate and eluted with 100 µL of 0.1% formic acid in acetonitrile. The
resulting elutant was added to 0.1% formic acid in water (1:2 v/v). Upon injection into
the liquid chromatograph, analytes were separated with the reverse-phase Hypersil Gold
Column (50 × 5 mm, 5 µM particle size) using gradient elution of 0.1% formic acid in
water and 0.1% formic acid in acetonitrile (20 to 80%) in a 6.5 min run time. The MS
was set in positive ionization mode for detection of midazolam and alprazolam of
respective transitions 309  281 m/z and 326  291 m/z, with collision energy of 30 eV.
The lowest limit of quantification was 0.025 ng/mL. The interday coefficient of variation
of midazolam quality controls was 12.1%.

208

7.6.7

Determination of paraoxonase activity

Plasma paraoxonase activity was measured by UV spectrophotometry in a 96-well plate
format using paraoxon as the substrate, as previously described.(34) Briefly, the reaction
mixture composed of 9 mM Tris hydrochloride pH 8, 1 mM calcium chloride, 1 M
sodium chloride, 1.5 mM paraoxon, and 40-fold diluted plasma. The rate of paranitrophenol generation was monitored at 405 nm over 10 mins at 25°C, in 30 sec
intervals. An extinction coefficient of 17000 M-1 cm-1 was used to calculate units of
paraoxonase activity, expressed as nmol/mL/min para-nitrophenol produced.

7.6.8

PON1 overexpression in an adenovirus system

Microsomes from HeLa cells overexpressing human PON1 was used to study PON1mediated 2-oxo-clopidogrel hydrolysis. Briefly, the full open reading frame of human
PON1 cDNA was amplified by PCR from a pooled human liver cDNA library using the
oligonucleotide

primers

5’-

ctatccccgaccatggcgaagctgattg-3’

and

5’-

catgggtgcaaatcggtctgttagagctc-3’, and subsequently cloned into expression vectors pEF
and pENT (Invitrogen, Carlsbad, CA). Adenoviral expression vector containing PON1
was generated in pAD/CMV/V5-DEST using the ViraPower adenoviral expression
system (Invitrogen, Carlsbad, CA). Adenovirus containing LacZ was used as a negative
control. Following a 48-hour adenovirus transduction, HeLa cells were lysed with
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hypotonic buffer (5 mM Tris HCl) and subsequently sonicated. Microsomes were
prepared using differential centrifugation methods.

7.6.9

Western blot analysis

Microsome samples were separated by SDS-PAGE on 4-10% gels (Invitrogen, Carlsbad,
CA) and subsequently transferred onto nitrocellulose membranes. Blots were probed with
a mouse anti-PON1 antibody (Abcam, Cambridge, MA) and subsequently probed with
anti-mouse horseradish peroxidise-labeled secondary antibodies (Bio-Rad, Hercules,
CA). The bands were detected using BM Chemiluminescence Western Blotting Substrate
(Roche, Indianapolis, IN).

7.6.10

Data analysis

In the clinical study, the PK parameters maximum observed plasma concentration (Cmax),
time to reach Cmax (tmax), area under the plasma concentration vs time curve from time 0
to 8 hr (AUC0-8hr), and half-life (t1/2) were calculated using noncompartmental analysis
techniques with GraphPad Prism v5.0 (GraphPad, La Jolla, CA) and PKSolver v2.0.
Briefly, AUC0-8hr was calculated using the linear trapezoidal rule while t1/2 was defined as
Ln2/ke, where ke represents the slope of the elimination phase of the log plasma
concentration profile.
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For evaluation of genetic variation on clopidogrel disposition and response, subjects were
divided into 2 groups for CYP2C19 and 3 groups for PON1: CYP2C19 extensive
metabolizers, EMs (*1/*1 or *1/*17) and CYP2C19 reduced metabolizers, RMs (*1/*2,
*1/*3 or *2/*2); PON1 wild-type, heterozygous, and homozygous carriers of Q192R. The
independent effect of CYP2C19*2 and *3 variation could be not be evaluated due to
insufficient subjects with heterozygous and homozygous variant status of each. However,
a dominant model for PON1, comparing PON1 wild-type Q192Q carriers to those
subjects with either Q192R or R192R genotype, was assessed to further evaluate the
influence of PON1 on clopidogrel response. Hardy-Weinberg equilibrium was assessed
for each genotype using the chi-square goodness-of-fit test. No genotype deviated from
Hardy-Weinberg equilibrium.

For all in vitro experiments, the Michaelis-Menten enzyme kinetic parameters Km and
Vmax were calculated using GraphPad Prism v5.0. The calculated Km and Vmax values
were expressed as mean ± standard error (SEM). The intrinsic clearance (CLint) was
calculated as Vmax/Km.

The Mann-Whitney test and Kruskal-Wallis test one-way analysis of variance followed
by Tukey’s test for pairwise comparisons was employed to test the differences between
two or three groups of data, respectively. Linear regression analysis was used to examine
the association between two variables. A two-tailed P value of less than 0.05 was
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considered significant for all analysis. Statistical analysis was performed with the use of
GraphPad Prism v.5.0.
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Table 7.6.1 Healthy volunteer baseline demographics (n = 21).
Age, mean (SD) years

35 (13)

Men, n (%)

11 (52)

Ethnicity, n (%)
Caucasian

17 (81)

Black

1 (5)

Asian

2 (10)

Other

1 (5)

Weight, mean (SD) Kg

70 (15)

Height, mean (SD) cm

169 (10)

CYP2C19, n (%)
*1/*1

11 (52)

*1/*2

6 (28)

*1/*3

1 (5)

*2/*2

1 (5)

*1/*17

2 (10)

PON1 Q192R, n (%)
QQ

8 (38)

QR

8 (38)

RR

5 (24)
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Table 7.6.2 Kinetic parameters of clopidogrel metabolism determined in vitro.
Vmax (SEM)

Km (SEM)

Vmax/Km

CYP2C19

2.869 (0.094)

3.008 (0.414)

0.954

CYP3A4

0.263 (0.039)

18.870 (6.366)

0.014

0.016 (0.0005)

2.696 (0.353)

0.006

0.012 (0.0004)

1.729 (0.373)

0.007

Clopidogrel to 2-oxo-clopidogrel

2-oxo-clopidogrel to H4 active
metabolite
CYP2C19
2-oxo-clopidogrel to H3 metabolite
CYP2C19

Vmax represents maximum rate achieved by enzymatic system; Km represents substrate
concentration required to reach half the value of Vmax; Vmax/Km represents the intrinsic
clearance (CLint). Units are as follows: pmol/pmol P450/min for Vmax; µM for Km;
µL/pmol P450/min for intrinsic clearance. Data represented as mean (standard error,
SEM).
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Table 7.6.3 Kinetic parameters of 2-oxo-clopidogrel metabolism to Endo metabolite
determined in vitro.
Vmax (SEM)

Km (SEM)

Vmax/Km

CYP2C19

0.3544 (0.024)

8.036 (1.631)

0.044

Control (insect cell) microsomes

0.108 (0.009)

15.38 (3.434)

0.007

HeLa cell microsomes

250.5 (30.9)

732.9 (109.7)

0.342

2-oxo-clopidogrel to Endo metabolite

Vmax represents maximum rate achieved by enzymatic system; Km represents substrate
concentration required to reach half the value of Vmax; Vmax/Km represents the intrinsic
clearance. Units are as follows: pmol/mg protein/min for Vmax; µM for Km; mL/mg
protein/min for intrinsic clearance (CLint). Data represented as mean (standard error,
SEM).
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Figure 7.6 Plasma concentration curves of H4 active metabolite measured over 8
hours following 75 mg oral administration of clopidogrel in healthy volunteer study
subjects.
(A, B) Curves grouped by CYP2C19 and PON1 Q192R genotype respectively. Symbols
represent mean and error bars represent the standard deviation.
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8.1
8.1.1

Summary and Discussion
Chapter Four

Single nucleotide polymorphisms in genes that affect warfarin metabolism (cytochrome
P450 2C9 gene, CYP2C9) and response (vitamin K epoxide reductase complex 1 gene,
VKORC1) have an important influence on warfarin therapy, particularly during initiation;
however, there is a lack of consensus regarding the optimal pharmacogenetics-based
initiation strategy. The aim of Chapter Four was to develop a novel pharmacogeneticsbased initiation protocol that incorporates loading and maintenance doses calculated
based on individual patient genetics, clinical variables, and anticoagulation response
(WRAPID). Subsequently, the clinical utility of this initiation protocol was evaluated in
atrial fibrillation (AF) and venous thromboembolism (VTE) patients. We hypothesized
that the use of a pharmacogenetics-based dosing algorithm for initiating patients
requiring new anticoagulation therapy should effectively eliminate genotype-driven
differences in anticoagulation response to provide a safe, rapid, and uniform
anticoagulation response in patients. Indeed, application of the WRAPID algorithm
resulted in a negligible influence of genetic variation in VKORC1 or CYP2C9 on time to
achievement of therapeutic response and risk of overanticoagulation. After adjustment for
covariates, time to stable anticoagulation was not influenced by VKORC1 or CYP2C9
genotype. Importantly, time spent within or above the therapeutic range did not differ
among VKORC1 and CYP2C9 genotype groups. Moreover, the overall time course of the
anticoagulation response among the genotype groups was similar and predictable.
Collectively, these findings demonstrate the clinical utility of genetics-guided warfarin
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initiation with the WRAPID protocol to eliminate genotype-driven differences in
anticoagulation response, in turn providing safe and optimal anticoagulation therapy for
patients with AF or VTE.

8.1.2

Chapter Five

While the influence of factors affecting S-warfarin PK parameters have been identified
(ie, age, drug interactions, and CYP2C9 genotype), the influence of genetics and clinical
parameters on S-warfarin PD variability is less clear. We hypothesized that genetic
variations in CYP2C9 and VKORC1, as well as clinical variables contributes to
interindividual variation in S-warfarin PK and PD parameters. Indeed, regression analysis
demonstrated that CYP2C9 genotype, kidney function, and gender were independent
determinants of S-warfarin clearance. The values for Imax were dependent on VKORC1
and CYP4F2 genotypes, vitamin K status (as measured by plasma concentrations of
proteins induced by vitamin K absence, PIVKA-II), and weight. Importantly, indication
for warfarin was a major independent determinant of Imax during initiation, where PD
sensitivity was greater in AF than VTE. To demonstrate the utility of the global PK-PD
model, we compared the predicted initial anticoagulation responses with previously
established warfarin dosing algorithms. These insights and modeling approaches support
our hypothesis and have important implications for personalized warfarin therapy.
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8.1.3

Chapter Six

Rivaroxaban is a new oral anticoagulant (factor Xa inhibitor), where 30-40% of the
administered drug is excreted unchanged through the kidney via a combination of
glomerular filtration and active tubular secretion. As such, we hypothesized that the
efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP)
contributes to the overall disposition of rivaroxaban. The ability of MDR1 and BCRP
efflux transporters to mediate rivaroxaban transport in vitro was demonstrated in that
significantly greater vectorial transport of rivaroxaban was observed in the basal to apical
direction in Caco-2 cells, which was attenuated in the presence of the selective inhibitors.
Thus, rivaroxaban is a shared substrate of MDR1 and BCRP. Following oral
administration of 2 mg/kg rivaroxaban, plasma concentrations did not significantly differ
between wild-type and Mdr1adef or Bcrp-/- mice (n = 6 per group). However, rivaroxaban
clearance was significantly reduced in the triple knockout mice, Mdr1a/Mdr1b-/-/Bcrp-/-.
Interestingly, rivaroxaban brain to plasma ratio did not differ in mice lacking only Mdr1a
or Bcrp, but more than two times higher in the Mdr1a/Mdr1b-/-/Bcrp-/- mice. Overall,
supportive of our hypothesis, MDR and BCRP likely function synergistically to modulate
rivaroxaban disposition in vivo and appear to be particularly relevant to limiting its
central nervous system entry. These data have important implications for safety and
efficacy of anticoagulation therapy with rivaroxaban as many drugs in clinical use are
known MDR1 inhibitors and loss-of-function polymorphisms in BCRP are common.
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8.1.4

Chapter Seven

It is thought that clopidogrel bioactivation and antiplatelet response are related to
cytochrome P450 2C19 (CYP2C19). However, a recent study challenged this notion by
proposing CYP2C19 as wholly irrelevant, while identifying paraoxonase-1 (PON1) and
its Q192R polymorphism as the major driver of clopidogrel bioactivation and efficacy.
The aim of Chapter Seven was to systematically elucidate the mechanism and relative
contribution of PON1 in comparison to CYP2C19 to clopidogrel bioactivation and
antiplatelet response. Indeed, we found a remarkably good correlation between
clopidogrel active metabolite (H4) area under the plasma concentration curve (AUC0 - 8
hours)

and antiplatelet response (r2 = 0.78). Interestingly, CYP2C19 but not PON1

genotype was predictive of H4 levels and antiplatelet response. Furthermore, there was
no correlation between plasma paraoxonase activity and H4 levels. Metabolic profiling of
clopidogrel in vitro confirmed the role of CYP2C19 in bioactivating clopidogrel to H4.
However, heterologous expression of PON1 in cell-based systems revealed that PON1
cannot generate the H4 active metabolite from its parent compound, but mediates the
formation of another thiol metabolite, termed Endo. Importantly, Endo plasma levels in
humans are nearly 20-fold lower than H4 and were not associated with any antiplatelet
response. Our results demonstrate that PON1 does not mediate clopidogrel active
metabolite formation or antiplatelet action, while CYP2C19 activity and genotype
remains a predictor of clopidogrel pharmacokinetics and antiplatelet response.
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8.2

Therapeutic Implications

The occurrence of adverse drug reactions (ADRs) is a prominent matter of concern in
medicine and drug therapy today (1). In many cases ADRs are caused by inappropriately
or often inadvertently high doses of prescribed drugs, particularly worrisome for drugs
with narrow therapeutic window and large interindividual variability in response. Indeed,
interindividual variation in drug exposure and efficacy has meant that subsets of patients
experience drug-related toxicities and inadequate therapeutic benefit. The one-dose-fitsall paradigm for drug therapy is increasingly recognized as inappropriate for many drugs
in clinical use. Alternative dosing models should be considered to provide and ensure
therapeutic benefit for the vast majority of patients while reducing ADRs. In the past
decade, a substantial amount of pharmacogenomics research has unraveled many genetic
variants affecting cardiovascular treatment response. Accordingly, personalized medicine
represents an exciting emerging field that integrates genetic makeup with environmental
influences and disease states to determine a precise individualized dose regimen.

To the best of our knowledge, the WRAPID nomogram represents the first warfarin
initiation algorithm that incorporates both VKORC1 and CYP2C9 genotype-determined
loading doses, which differs from the typical doubling of the maintenance dose. We
demonstrated that the use of such an algorithm for warfarin initiation is not only practical
in the ambulatory setting, but also effectively minimized interindividual variation in
anticoagulation response to provide similar efficacy in a cohort of genotype-defined
patients. A better understanding of pharmacogenomics and in vivo mechanisms
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responsible for the observed variation in combination with a priori predictive modeling
constitute the foundation for evaluating optimal pharmacogenetics-based dosing
algorithms.

One of the limitations of the study outlined in Chapter Four is that we did not evaluate
the use of pharmacogenetics-based warfarin dosing in the randomized clinical trial (RCT)
setting. However, the recent COUMAGEN-II RCT showed the superiority of
pharmacogenetics-based warfarin dosing over standard care with respective to greater
time spent in therapeutic range and reduced occurrence of ADRs (2). Moreover, a recent
study in real-world patients found that genotyping during warfarin therapy reduced the
hospitalization rate for bleeding or thromboembolic event by 30% compared to a
historical control group (3). These results are well aligned with our findings. Indeed, we
expect that personalized warfarin therapy will ultimately result in a more cost-effective,
safer, and faster treatment outcome to maximize anticoagulation efficacy while
minimizing life-threatening bleeding events. A number of additional RCTs involving
larger sample sizes are currently underway to confirm these encouraging results.

Although cost-effective analysis for use of warfarin pharmacogenetics has been
controversial, there is consensus in that genotyping for CYP2C9 and VKORC1 for
patients with higher risk of thromboembolic events or bleeding will be cost-effective
resulting in increased quality-adjusted life years (QALYs) (4, 5). Indeed, additional costeffective analysis will be required as more convincing data from RCTs become available.
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Nevertheless, given the richness of evidence for warfarin, it will likely be the first widely
adopted pharmacogenetic application in cardiovascular medicine.

The limitations of warfarin therapy have prompted the clinical development of novel oral
anticoagulants that have more predictable response. The factor Xa inhibitor rivaroxaban
is a new oral anticoagulant with direct mechanism of action by inhibiting the clotting
cascade. It is known that rivaroxaban depends on the kidney for excretion of unchanged
drug as well as its metabolites. Not surprisingly, elevated bleeding risk in patients with
renal impairment is of particular concern with rivaroxaban therapy. In the past decade,
remarkable progress has been made in the field of drug transporters in elucidating their
importance in determining the disposition and efficacy of many drugs in clinical use.
Indeed, we demonstrate in Chapter Six that the new oral anticoagulant rivaroxaban is a
shared substrate of the efflux transporters MDR1 and BCRP.

As functional

polymorphisms exist in both MDR1 and BCRP genes, in addition to the wide array of
MDR1 drug inhibitors in clinical use, genetic variations as well as drug interactions will
likely play an important role in modulating rivaroxaban exposure and thus efficacy.
While the clinical experience with rivaroxaban is currently very limited, the full spectrum
of factors determining efficacy and safety within the context of pharmacogenetics,
demographics, concomitant medications, and comorbidities should be evaluated as it is
used more frequently in real-world patients.

The antiplatelet drug clopidogrel is used to treat patients with acute coronary syndrome,
particularly for prevention of stent thrombosis in those undergoing percutaneous coronary
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intervention. Similar to warfarin, pharmacogenetic studies have demonstrated clinically
relevant implications on clopidogrel antiplatelet response and thrombosis event rates. A
layer of complexity in defining optimal genetic markers for predicting clopidogrel
response is that the mechanistic enzymes potentially involved in bioactivating inactive
clopidogrel to its active metabolite has been under scrutiny. In Chapter Seven, we
conducted a proof-of-principle healthy volunteer study powered sufficiently to delineate
the effect of PON1 genetic variation in comparison to CYP2C19 polymorphisms on
clopidogrel bioactivation and antiplatelet response. There was a lack of correlation
between either PON1 genotypes or paraoxinase activity to clopidogrel active metabolite
formation or antiplatelet effect. Rather, we observed an excellent correlation in
antiplatelet effect with CYP2C19 polymorphisms, the enzyme that has been long
appreciated as the key player for clopidogrel bioactivation. Subsequently, systematic in
vitro metabolism studies confirmed that PON1 does not generate the active metabolite
while CYP2C19 does, providing the mechanistic basis for the clinical significance of
CYP2C19 polymorphisms. PON1, on the other hand, generates an inactive metabolite
that likely does not confer any measureable antiplatelet effect in vivo. This data is in line
with analysis of clinical trials data demonstrating the lack of association of PON1 genetic
variation with clopidogrel antiplatelet response or risk of stent thrombosis (6-8). Overall,
Chapter Seven highlights the importance of elucidating underlying molecular
mechanisms of drug metabolism, disposition, and response for accurate interpretation of
the clinical significance of candidate genetic markers. Indeed, recent RCT using point-ofcare CYP2C19*2 genotyping showed that guidance using genetic information led to
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better antiplatelet response, setting the stage for personalized clopidogrel therapy to
improve efficacy (9).

8.3

Future Directions

Warfarin has been the mainstay oral anticoagulant (OAC) prescribed for stroke
prevention in AF patients. However, warfarin therapy is challenging due to marked
interindividual variability in dose and response, requiring frequent monitoring and dose
titration. These limitations have prompted the clinical development of new OACs
(NOACs) that directly target the coagulation cascade with rapid onset/offset of action,
lower risk for drug-drug interactions, and more predictable response. Recently, NOACs
dabigatran (direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors)
have gained regulatory approval as alternative therapies to warfarin. While the
anticoagulation efficacy of these NOACs has been characterized, differences in their
pharmacokinetic and pharmacodynamic profiles have become a significant consideration
in terms of drug selection and dosing. Moreover, interindividual variability in plasma
exposure/response of NOACs and bleeding risk associated with anticoagulation therapy
remains a pertinent question. Indeed, even in a clinical trial setting with stringent
enrollment criteria, the one-dose-fits-all dosing regimen strategy did not appear
successful for NOACs, likely due to the various clinical covariates that significantly
affected extent of drug exposure and response. It is evident that variability in NOAC
plasma exposure will have significant impact on anticoagulation efficacy given the direct
PK-PD relationship and its association with clinical outcomes. Thus, quantifying NOAC
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plasma concentration is likely the most reliable assessment of response and bleeding risk.
Collectively, studies in real-world patients treated with NOACs are required to better
understand the effect of variables such as age, renal/hepatic function, dosing interval, as
well as drug metabolism and transport pharmacogenetics and interactions on the
variability in NOAC drug exposure. These proposed studies would allow for prediction
of patients at risk for sub- and supra-therapeutic anticoagulation response and
individualize OAC selection and dosing. Appendix C highlights in greater detail the
clinical implications of the availability of NOACs in treating AF patients.

Antiplatelet therapy with clopidogrel has emerged as a major success in the treatment of
cardiovascular disease, particularly in reducing the risk for myocardial infarctions
associated with coronary artery disease. Despite the well-known clinical benefit of
clopidogrel in prevention of coronary ischemic events and stent thrombosis, the large
interindividual variability observed with clopidogrel antiplatelet response results in
therapy complexity. According to a recent genome-wide association (GWAS) study,
CYP2C19 genotype only explains 12% of the variation in response (10). Thus, further
delineation of additional genetic and nongenetic markers is required to better explain and
predict response variation, which may in turn define optimal individualized doses for
patients. In addition, the first evidence of a therapeutic window range for clopidogrel
antiplatelet efficacy has recently been proposed to classify responders and nonresponders, and more importantly, early identification of patients not achieving optimal
platelet inhibition (11). Consensus on defining the optimal clopidogrel therapeutic
window has been challenging due to the lack of a standardized platelet-function assay.
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The point-of-care VerifyNow P2Y12 assay has recently been used as a feasible and
reliable method of measuring antiplatelet response (12). However, VerifyNow is not as
direct a measure of platelet P2Y12 signalling activity as the vasodilator-stimulated
phosphoprotein (VASP) assay or even direct receptor occupancy assays using 33P-2MeSADP (13). Although some studies show high correlation between VASP and VerifyNow
measured antiplatelet response, others did not (14). Thus, the relationship between the
gold-standard VASP assay and VerifyNow point-of-care assay in relation to optimal
therapeutic response remains to be evaluated and defined. Furthermore, the stent
thrombosis risk has been demonstrated to be the highest during initiation of clopidogrel
therapy (15). Accordingly, the intra-individual variability in platelet response during this
critical period is another area to be assessed to evaluate consistency of the responder and
non-responder phenotypes. Moreover, quantification of active metabolite H4 plasma
levels will aid in defining the relationship between the proposed therapeutic response
window and a ‘therapeutic H4 concentration window’.

As with warfarin, new antiplatelet agents (prasugrel, ticagrelor) are now available as
alternative agents to clopidogrel. Both prasugrel and ticagrelor do not require extensive
bioactivation by CYP2C19. However, CYP3A4 and CYP2B6 are responsible for
bioactivation of prasugrel to its active metabolite and the influence of polymorphisms in
these enzymes to prasugrel platelet efficacy remains to be delineated. Similarly,
ticagrelor is a substrate of MDR1 and the influence of drug interactions as well as ABCB1
polymorphisms remain to be addressed.
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8.4

Conclusions

Physicians have long sought over the phenomenon that patients respond variably to the
same standard drug treatment. Over half a century ago, Dr Werner Kalow of University
of Toronto (1917-2008) was one of the pioneering physicians to recognize interpatient
variability in drug responsiveness following standard therapeutic doses (16). Werner
Kalow’s work along with others set precedence for studying the link between genetic
variations and pharmacology. Subsequently, the term pharmacogenetics was coined for
describing this phenomenon. In fact, the first monograph of pharmacogenetics was by
Werner Kalow in 1962 entitled “Pharmacogenetics: Heredity and Response to Drugs”,
highlighting his work on the relationship between genetic polymorphisms of
butyrylcholinesterase and the risk of prolonged apnea to standard doses of
succinylcholine due to differential ability to hydrolyze succinylcholine (17).

The field of pharmacogenetics has evolved significantly since the initial observations;
however, the fundamental principles remain the same and that is to delineate the genetic
basis of interindividual variation in drug pharmacokinetics, pharmacodynamics and
ADRs. Indeed, remarkable process has been made in the past decade using a variety of
study designs to unveil the genetic contribution to variable drug responsiveness for a
variety of medications. Moreover, pharmacogenetic studies form the foundation and
evidence needed to implement personalized medicine, an emerging drug treatment
paradigm utilizing individual genetic makeup to guide the appropriate drug therapy and
dosages. This in turn will allow for the greatest therapeutic benefit to be seen while
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reducing risk for toxicity. Many classes of cardiovascular drugs exemplify how heritable
genetic variations influence its efficacy.

The first section of the thesis focused on the development of a novel pharmacogeneticsbased initiation protocol for warfarin therapy. We demonstrated its clinical utility in
eliminating genotype-driven variability in anticoagulation response during the critical
initiation phase, as well as sustaining optimal efficacy throughout maintenance therapy
for AF and VTE patients. Additionally, we defined the genetic and non-genetic
determinants of warfarin PK and PD parameters by use of mathematical PK-PD modeling
to estimate individual clearance and anticoagulation responsiveness. The integration of
elucidated variables contributing to PK and PD variability with modeling techniques
represents a powerful tool for a priori prediction of anticoagulation outcomes in a variety
of clinical scenarios. The availability of NOACs has meant that clinicians now have
alternatives to warfarin; however, interindividual variation in anticoagulation efficacy
remains a concern for NOACs. We determined that both efflux drug transporters MDR1
and BCRP are involved in rivaroxaban active renal secretion, which likely play a
synergistic role in modulating rivaroxaban accumulation and elimination in humans. The
last part of the thesis involved elucidating the metabolic enzymes involved in clopidogrel
bioactivation. We evaluated the impact of relevant genetic variations on the observed
active metabolite plasma concentration and antiplatelet response in a healthy volunteer
setting. Indeed, individuals harbouring reduced function CYP2C19 polymorphism have a
reduced capacity to generate clopidogrel active metabolite and lower antiplatelet
response.
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It is evident that many factors contribute to variability in drug responsiveness, including
renal and hepatic function, underlying disease mechanisms, drug interactions, and
pharmacogenomics. Improvement in our understanding of interindividual variation in
drug responsiveness allows for better prediction of patients at risk for lack of therapeutic
efficacy or adverse event, setting the stage for personalized therapy. One of the major
barriers to the widespread clinical implementation of personalized therapy is the
requirement

from

trialists

to

demonstrate

outcome

and

safety

benefit

of

pharmacogenetics-directed therapy in randomized clinical trials (RCTs). However, these
RCTs are too expensive, not feasible, and unethical in many clinical scenarios. Thus, it is
necessary to resort to pragmatic trials and prospective cohort studies where early adopters
of pharmacogenetics are needed to develop evidence for better efficacy and safety. As
results from pharmacogenetic studies emerge, pharmacoeconomics should be
continuously conducted to evaluate the health-economic benefit and cost-effectiveness of
adopting pharmacogenetics into standard patient care.

The studies presented herein demonstrate pragmatic translational medicine by bridging
the necessary interplay between understanding molecular mechanisms and evaluating
their impact on clinically important endpoints in the real-world setting. It is important to
note that as we recognize that an individual patient’s drug response phenotype is the
ultimate clinical endpoint, the use of pharmacogenomics should be integrated in context
with other patient-specific parameters such as drug exposure, biomarkers, and other
measures of response and toxicity, in the practice of personalized medicine. Overall, our
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studies support the use of pharmacogenetics-guided care for delivery of personalized
medicine to maximize efficacy while reducing toxicity by selecting the right drug at the
right dose for the right patient.
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Introduction
Atrial fibrillation (AF) is associated with a fivefold increase in risk of disabling stroke
(1). Therefore, antithrombotic therapy is required for stroke and systemic embolism
(SSE) prophylaxis. Until recently, the vitamin-K antagonist warfarin was the primary
treatment choice for long-term oral anticoagulation (OAC) as stroke risk is reduced by
60% in nonvalvular AF patients (1). However, warfarin has a number of limitations
including delayed onset of action, large interindividual variability in response,
unpredictable pharmacokinetics (PK), drug-drug interactions, and genetic polymorphisms
in genes affecting metabolism and pharmacodynamics (PD). Intensive monitoring using
international normalized ratio (INR) and frequent dose adjustments are necessary to
provide adequate anticoagulation within warfarin’s narrow therapeutic window.

Significant effort has been made to develop new OACs (NOACs) with direct mechanisms
of action with a sufficiently wide therapeutic window to allow for fixed dose
administrations without the need for routine response monitoring. NOACs directly inhibit
the coagulation pathway, either factor Xa or thrombin, for rapid onset of antithrombotic
effects. The PK and pharmacology of these NOACs are distinct from that of warfarin
(Table C.1, Figure C.1). In the present review, we will highlight the PK and PD features
of the three NOACs that have recently been approved for stroke prevention in AF
patients and provide NOAC selection and dosing recommendations based on their PK-PD
profiles.
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Table C.1 Comparison of pharmacokinetic features of warfarin, dabigatran,
rivaroxaban and apixaban.
Parameter

Warfarin

Dabigatran

Rivaroxaban

Apixaban

Factor Xa

Factor Xa

inhibitor (free

inhibitor (free

or bound),

or bound),

reversible

reversible

Fast

Fast

Fast

Short

Short

Short

Rapid

Rapid

Direct
Mechanism of

Inhibition of

action

VKOR

thrombin
inhibitor (free
or bound),
reversible

Slow, indirect
Onset of action

inhibition of
clotting factor
synthesis

Offset of action

Long

Absorption

Rapid

Bioavailability (%)

100

6.5

80a

50

tmax (hr)

2.0 – 4.0

1.0 - 3.0

2.5 - 4.0

1.0 - 3.0

Vd (L)

10

60 - 70

50 - 55

21

99

35

95

87

t1/2β (hr)

40

12 - 17

9 - 13

8 - 15

Renal excretion

None

80

33

25

Fecal excretion

None

20

28

50 - 70

CL/F (L/hr)

0.35

70 - 140

10

5

None

None

1.3 - 1.9

Protein Binding
(%)

Rapid, acid
dependent

Dependent on
Accumulation in

CYP2C9

plasma

metabolic
efficiency
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Delayed
absorption
Food effect

None

with food with
no influence
on
bioavailability

Age

Yes, lower CL/F
as age increases

Delayed
absorption
with food
with
increased
bioavailabilit
y

Yes, lower
CL/F as age

Yes, lower
None

increases

for increased

Yes, higher
None

None

weight

Gender

Yes, lower CL/F
in females

Ethnicity

dose in African-

Yes, lower
CL/F in

None

CYP3A4,

metabolism

CYP2C19,

None

exposure in
females

Lower dose
None

in Japanese

None

patients
P-gp

P-gp, BCRP

P-gp, BCRP
CYP3A4/5,

CYP2C9,
CYP-mediated

increased

Yes, higher

females

Americans
Drug transporter

exposure with

weight

Lower dose in
Asians; Higher

CL/F as age
increases

Yes, higher dose
Bodyweight

None

None

CYP1A2

CYP3A4/5,

CYP2J2

CYP2J2

(minor),

(equal)

CYP1A2
(minor)

Potent P-gp

Potent

Potent

Drug-drug

Many; affecting

inhibitors;

CYP3A4 and

CYP3A4 and

interactions

metabolism

affecting

P-gp

P-gp

absorption

inhibitors;

inhibitors;
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Variable
Dosing for AF

(0.5 – 16 mg
OD)

Coagulation
measurement

affecting

absorption,

absorption,

metabolism,

metabolism,

and excretion

and excretion

150, 110 mg

20, 15 mg

BID

OD

TT >
INR

affecting

Hemoclot >
ECT > aPTT

anti-FXa >
PT

5, 2.5 mg BID

anti-FXa

AF, atrial fibrillation; aPTT, activated partial thromboplastin test; BCRP, breast cancer
resistance protein; BID, twice daily; CL/F, apparent clearance; CYP, cytochrom P450
isozymes; ECT, ecarin clotting time; OD, once daily; P-gp, P-glycoprotein; PD,
pharmacodynamics; PT, prothrombin time; tmax, time to maximum plasma concentration;
t1/2β, terminal half-life; TT, thrombin time; Vd, volume of distribution; VKOR, vitamin K
epoxide reductase enzyme.
a

Bioavailability is dependent on dose (over 10 mg) and food intake. Thus, rivaroxaban

doses over 10 mg OD should be administered with food. However, 10 mg rivaroxaban is
only licensed for prophylaxis of thromboembolism following elective hip or knee
surgery.
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Figure C.1 Summary of absorption, metabolism, and excretion of dabigatran,
rivaroxaban, and apixaban.
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Clinical outcomes data comparing NOACs to warfarin
Dabigatran etexilate is the first oral direct thrombin inhibitors (DTIs) to be approved for
its clinical use in AF patients (2). In the RE-LY trial (open-label; n = 18,133), 150 mg
dabigatran twice daily (BID) was associated with lower rates of stroke/SSE, achieving
superiority, but a similar rate of major bleeding while 110 mg BID was associated with
similar rates of stroke/SSE but fewer bleeds compared to warfarin (3). Rivaroxaban and
apixaban are the first and second oral direct factor Xa (FXa) inhibitors approved for AF
(4). In the ROCKET-AF trial (double-blinded, n = 14,264), rivaroxaban was noninferior
to warfarin where 20 mg rivaroxaban once daily (OD) resulted in similar rates of
stroke/SSE and major bleeding (5). In the ARISTOTLE trial (double-blinded; n = 18,
201), the reduction in stroke/SSE by 5 mg BID apixaban was superior to warfarin (both
ischemic and haemorrhagic, driven by haemorrhagic) (6). Interestingly, all three NOACs
were associated with less intracranial bleeding compared to warfarin irrespective of time
spent in therapeutic range (TTR) in the warfarin arm. However, more gastrointestinal
(GI) bleeding was observed with dabigatran and rivaroxaban.

Importance of renal function and NOAC clearance
The extent of renal excretion is an important distinguishing feature of NOACs. Up to
80% of circulating dabigatran is eliminated renally, whereas only 33% and 25% of
unchanged rivaroxaban and apixaban is cleared by the kidney (7-9). Following 150 mg
administration, total dabigatran AUC was increased by 1.5-, 3.1-, and 6.3-fold in
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individuals with mild, moderate and severe renal impairment, respectively, compared to
healthy individuals, leading to increased terminal half-life (t1/2β) to 15, 18, and 27 hours
(10). For rivaroxaban, subjects with mild, moderate, and severe impairment exhibited an
increase in AUC of 44, 52, and 65 %, respectively (11). The coagulation parameter
prothrombin time (PT) was affected in a similar fashion. For apixaban, while no changes
were observed in apixaban anti-FXa activity, overall AUC increased by 16, 29, and 44 %
in individuals with mild, moderate and severe renal impairment compared to individuals
with normal renal function (12).

Importance of drug metabolism and transport processes for NOACs
Dabigatran etexilate is the prodrug of dabigatran, and a substrate of efflux transporter Pglycogprotein (P-gp, encoded by ABCB1), with an absolute bioavailability of only 6.5%
(13, 14). Bioavailable dabigatran etexilate is converted entirely to dabigatran by
nonspecific ubiquitously expressed carboxylesterases in the enterocytes, portal
circulation, and hepatocytes (7, 13, 15). Very recently, a genome-wide subanalysis of the
RE-LY trial demonstrated that a single nucleotide polymorphism (SNP) in the
carboxyesterase 1 gene (CES1; rs2244613) attenuated dabigatran formation leading to
lower trough concentrations while the ABCB1 SNP rs4148738 and CES1 SNP rs8192935
were associated with higher and lower peak dabigatran concentrations, respectively (16).
Rivaroxaban’s bioavailability is dose-dependent; the absolute bioavailability of 10 mg
rivaroxaban ranged from 80 to 100 %, while bioavailability of 20 mg under fasting
conditions was 66% (17). Coadministration of 15 or 20 mg rivaroxaban with food
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increased the AUC by 39% (18). The low bioavailability in fasting conditions may result
in risk of inadequate anticoagulation and thus, rivaroxaban should be administered with
food. Apixaban’s absolute bioavailability is 50% and not affected by food intake (9).

Dabigatran is not metabolized by the cytochrome P450 (CYP) isoenzymes; rather, it is
conjugated to acylglucuronides (19). In patients with moderate hepatic impairment, the
bioconversion from prodrug to dabigatran was slightly slower when compared to healthy
subjects although the AUC and extent of dabigatran glucuronidation was unchanged (20).
Conversely, rivaroxaban and apixaban are both subject to CYP-mediated metabolism
whereby CYP3A4/5 and CYP2J2 accounts for clearance of two-thirds of rivaroxaban (8,
21), and apixaban metabolism is predominantly driven by CYP3A4/5 (22). Patients with
mild (Child-Pugh A) hepatic impairment showed no difference in rivaroxaban PK and PD
(23). However, patients with moderate (Child-Pugh B) hepatic impairment exhibited
reduced clearance of rivaroxaban. Therefore, rivaroxaban is not recommended in patients
with moderate or severe (Child-Pugh C) hepatic impairment. The PK and anti-Fxa
activity of 5 mg apixaban was not altered in subjects with either mild or moderate liver
impairment when compared to healthy individuals (12).

Both rivaroxaban and apixaban are substrates of efflux transporters P-gp and breast
cancer resistance protein (BCRP, encoded by ABCG2); thus, active secretion likely
contributes significantly to their renal elimination and systemic exposure (24-26).
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NOAC drug-drug Interactions result from inhibitors or inducers of
CYP3A4 and P-glycoprotein
CYP3A4 located in the intestine and liver plays a pivotal role in governing metabolic
pathways of 50% of all drugs (27). Similarly, many drugs are P-gp substrates, one of the
most important efflux transporters in modulating drug disposition by preventing
absorption and enhancing excretion into the bile and urine (28). Interestingly, there is a
high degree of overlap in CYP3A4 and P-gp drug substrates (29), as the case for
rivaroxaban and apixaban. In addition, the coexpression of these proteins in the gut, liver,
and kidney means that CYP3A4 and P-gp play a concerted role in modulating excretion
of NOACs.

When dabigatran was coadministered with amiodarone or ketoconazole (P-gp and strong
CYP3A4 inhibitor), AUC was increased by about 50% (30). Similarly, the potent P-gp
inhibitor verapamil increased AUC by 2.4-fold when administered 1 hour before
dabigatran while AUC increased by 71% when coadministered (31). Interestingly,
patients of the RE-LY trial coadministered with amiodarone and verapamil only had a
13% and 23% increased bioavailability, respectively (3). Coadministration of
ketoconazole with rivaroxaban increased the AUC by 160% along with similar increases
in coagulation measurements (26). The strong P-gp/CYP3A4 inhibitor ritonavir elevated
rivaroxaban AUC by 150%. Coadministration of ketoconazole increased apixaban AUC
by twofold (32). Overall, coadministration of rivaroxaban and apixaban with Pgp/CYP3A4 inhibitors (namely azoles and protease inhibitors) should be avoided while
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coadministration with moderate inhibitors (ie., erythromycin) should be exercised with
caution (Table C.2).

Inducers of CYP3A4/P-gp such as rifampin has been show to result in 65% reduction in
dabigatran bioavailbility and 50% decrease in AUC and clotting parameters for
rivaroxabin and apixaban (26, 32, 33). Thus, concomitant use of rivaroxaban/apxiaban
with strong CYP3A4/P-gp inducers is contraindicated due to concern of reduced
anticoagulation efficacy.

We note that the clinical significance of concomitant use of multiple moderate inhibitors
in the same patient, a particular concern in elderly AF patients where polypharmacy is
common, remains to be established as it is unknown whether the effect on NOAC PK-PD
would be equivalent to use of a single potent inhibitor. The full spectrum of these
interactions remains to be addressed in the real-world population. Until then, dose
lowering adjustments in conjunction with anticoagulation monitoring should be used to
ensure efficacy and safety.
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Table C.2 List of dual substrates, inhibitors, and inducers of CYP3A4 and Pglycoprotein.
Substrates

Inhibitors

Inducers

Apixaban

Amiodarone

Carbamazepine

Atorvastatin

Cimetidine

Phenobarbital

Celiprolol

Clarithromycin

Rifampicin

Cyclosporine

Erythromycin

St. John's wort

Docetaxel

Fluconazole

Paclitaxel

Ketoconazole

Rivaroxaban

Itraconazole

Tacrolimus

Nifedipine
Nelfinavir
Ritonavir
Saquinavir
Verapamil
Voriconazole
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Why understanding the pharmacokinetic profile of NOACs is essential
for predicting anticoagulation efficacy
The predictable PK/PD of NOACs does not necessitate routine monitoring; however, the
ability to accurately measure their efficacy is highly desirable in a variety of scenarios
including assessment of compliance, and identifying patients at risk for overanticoagulation/bleeding or lack of efficacy. Although standardized coagulation assays
are unavailable, several assays have been evaluated to determine their validity as a
surrogate marker of NOAC plasma exposure and anticoagulation response. Generally, a
parallel relationship exists between NOACs plasma exposure and anticoagulation effects
in a concentration-dependent manner (13, 17, 34-37).

The anticoagulant effect of dabigatran can be measured by activated partial
thromboplastin time (aPTT), PT, thrombin time (TT), ecarin clotting time (ECT), and the
diluted version of TT (Hemoclot). The TT, Hemoclot and ECT are most sensitive and
precise for measuring dabigatran anticoagulation. However, TT is likely too sensitive for
dabigatran efficacy and Hemoclot is currently considered more suitable to quantitate
dabigatran concentrations (38). Unfortunately, these assays are not widely available and
in emergency situations, aPTT may be most accessible for measuring anticoagulation.
The clinical relevance of plasma concentrations was demonstrated in the RE-LY trial
where dabigatran trough plasma concentrations were significantly associated with risk of
stroke/SSE (30). Patients with lower trough plasma levels had substantially greater
probability of ischemic stroke/SSE (<50 ng/mL) (39). Similarly, strong association was
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found between increased dabigatran trough concentrations and bleeding risk. The mean
dabigatran exposure in patients with major or minor bleeding was 50% and 20% greater
than patients without. Bleeding risk was also dependent on age and renal impairment
owing to modulation of dabigatran PK.

For rivaroxaban and apxiaban, the anti-FXa activity assay is a direct measure of
anticoagulation intensity, and thus, the most sensitive and consistent assay for
quantitating plasma concentrations (40, 41). The PT and HepTest also demonstrated
sensitivity for rivaroxaban response and may be used as a more readily available measure
of response (17). Apixaban concentrations was correlated with INR, PT, and aPTT with
less sensitivity (36). A dedicated study of 161 patients embedded into the ROCKET-AF
trial confirmed the linear relationship between PT and anti-FXa activity to rivaroxaban
plasma exposure (42). However, PT did not predict the occurrence of ischemic strokes in
the ROCKET-AF trial (42). Conversely, a linear relationship was demonstrated between
PT prolongation and risk of major bleeding (42). The linear relationship between
apixaban plasma concentrations and anti-FXa activity was confirmed in elective hip/knee
replacement patients (12).

It is important to keep in mind that the sensitivity and precision of different reagents and
instruments used for these coagulation assays is yet to be established. Further validation
of these coagulation assays in measuring NOAC anticoagulation response is required in
the real-world clinical setting. Moreover, is it evident that variability in NOAC plasma
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exposure will have significant impact on anticoagulation efficacy given the direct PK-PD
relationship and its association with clinical outcomes; thus, quantifying NOAC plasma
concentration is likely the most reliable assessment of response and bleeding risk.

Selecting the right OAC
Although the NOACs have shown similar or greater efficacy to warfarin, it is unlikely
that they will fully replace warfarin. The interindividual variability in exposure/response
of NOACs and bleeding risk associated with anticoagulation therapy remains a pertinent
issue. Indeed, even in a clinical trial setting with stringent enrollment criteria, the onedose-fits-all dosing regimen strategy did not appear successful for NOACs, likely due to
the various clinical covariates that significantly affected extent of drug exposure and
response (Figure C.2) (41, 43-46). Moreover, dabigatran and rivaroxaban use outside of
the clinical trial setting has recently been noted to exhibit large interindividual variability
in concentration and response (43, 47). The same trend is likely to be observed with
apixaban as its clinical use increases.

Nevertheless, the emergence of multiple NOACs has meant greater therapeutic options
for treating physicians. However, we are now starting to face the question of how to
select the most appropriate NOAC for individual patients. Factors to be assessed for
deciding the right anticoagulant include patient bleeding risk (HAS-BLED) and benefit
(CHADS2) as recommended by the Canadian Cardiovascular Society (48), lack of an
antidote for NOACs, GI bleeding, renal/hepatic function, age, and concomitant
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medications, relevant genetic variations, of which all have been demonstrated to
influence the PK and PD of OACs.
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Figure C.2 Plasma concentration profiles of dabigatran, rivaroxaban, and apixaban in
atrial fibrillation patients. (A) Mean steady-state dabigatran plasma concentrations
following 150 mg twice-daily administration is represented by the dashed black line
(digitized from Dansirikul et al.) (49). Colored solid lines represent the predicted effect
of various clinical variables and a genetic variation in the carboxylesterase 1 (CES1) gene
on dabigatran concentration based on known area under the concentration curve (AUC)
change (45). The shaded area represents Ctrough dabigatran concentrations associated with
increased antithrombotic efficacy and decreased major bleeding risk according to
population pharmacokinetics modeling of the RE-LY trial data. (B) Mean steady-state
rivaroxaban plasma concentrations following 20 mg once daily administration is
represented by the dashed black line (digitized from Mueck et al.) (44). Colored solid
lines represent the predicted effect of various clinical variables on rivaroxaban
concentration based on known AUC change (44). Although the optimal plasma Ctrough of
rivaroxaban has not been well-defined as of yet, the shaded area represents the 5% - 95%
confidence interval (CI) of Ctrough observed in the ROCKET-AF trial and the dashed line
represents the average Ctrough. (C) Predicted mean steady-state apixaban plasma
concentrations following 5 mg twice-daily administration is represented by the dashed
black line (digitized from Leil et al.) (46). Colored solid lines represent the predicted
effect of various clinical variables on apixaban concentration based on known AUC
change (12). The shaded area represents the population pharmacokinetics model
predicted 5% - 95% CI of Ctrough in atrial fibrillation patients. AF, atrial fibrillation; CrCl,
creatinine clearance; P-gp, P-glycoprotein.
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* Please refer to the figure legend for outline of data source.

Figure C.2 Plasma concentration profiles of dabigatran, rivaroxaban, and apixaban
in atrial fibrillation patients.
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A potential decision tree for selecting the right oral anticoagulant based on individual
patient characteristics (summarized in Figure C.3): The first question to address is
whether the patient is a better candidate for NOAC or warfarin. For patients requiring
new OAC therapy , the factors to consider in this regard include high cost of NOACs
(dependent on patient insurance policy), convenient and accessibility of INR response
monitoring, renal function, and potential drug-drug interactions (Table C.3). Patients who
are already stably anticoagulated on warfarin achieving optimal TTR need not to be
switched, given the familiarity of its use and ability to monitor anticoagulation efficacy.
Indeed, the benefits of NOACs over warfarin are less impressive for patients achieving
well-controlled TTR (> 65%) as evident in the finding that 150 mg BID dabigatran was
no longer superior to warfarin for prevention with stroke (50). However, we note that no
significant interaction was found between TTR and stroke/SSE rates in sub-analysis of
the RE-LY, ROCKET-AF, and ARISTOTLE trial.

In suspected noncompliant patients, warfarin will likely be the better choice because
missed doses of NOACs with short half-lives will be more detrimental to efficacy than
missed doses of warfarin. Moreover, adherence to drug therapy decreases by 10% when
comparing OD to BID dosing, leading to unknowable consequences, especially without
active monitoring of efficacy. Of the NOACs, rivaroxaban is the only one with OD
dosing, preferred for suspected noncompliant patients. We note however, based on the
t1/2β of rivaroxaban (Figure C.2), when strictly considering optimal dosing interval,
splitting the total daily dose to BID dosing interval would be predicted to result in a more
consistent exposure and response.
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Since NOACs are dependent on renal excretion at varying extents, estimated CrCl
(creatinine clearance) should be determined in all patients prior to initiating NOACs.
Moreover, risk of bleeding associated with use of the new agents is compounded by poor
renal function; more than 50% of AF patients over the age of 80 have moderate renal
impairment (51). Although dosing adjustments in renal insufficiency has been
recommended, a recent report indicated that the dose reduction did not obviate elevated
bleeding risk completely (52). Thus, patients with CrCl below 30 mL/min are not suitable
for NOACs; however, if NOAC in patients with renal impairment is preferred, apixaban
is more appropriate than rivaroxaban and dabigatran, otherwise, warfarin should be used.
Elderly patients and those with renal impairment should be assessed regularly for renal
function throughout treatment to ensure that CrCl remains greater than 30 mL/min.

Elevated GI bleeding risk is an important concern for dabigatran and rivaroxaban, and
apixaban is a better choice in patients with a recent and/or recurrent history of GI bleed as
well as patients with disease condition(s) predisposing higher risk of GI bleed (active
peptic ulcer disease, recent biopsy or trauma, gastritis). However, in the case that the site
of GI bleed is identified and the underlying condition adequately treated without
suspected recurrence, any OAC may be considered for therapy if the patient is otherwise
deemed suitable. Dose reduction is required for patients > 75 years old on dabigatran due
to increased bleeding risk with age. The stability of dabigatran may be compromised

267

when stored in humid conditions, and once the bottle is opened the tablets should be used
within 4 months. Patient education in this regard may be important.

Since all NOACs depend on the liver for hepatic metabolism to some degree, patients
with hepatic dysfunction are not candidates for NOACs. Moreover, both rivaoxaban and
apixaban are substrates of CYP3A4, rendering these NOACs susceptible to drug-drug
interactions whereby dose reduction is required in presence of strong inhibitors. Lastly,
for AF patients with recent acute coronary syndrome or percutaneous coronary
intervention requiring triple therapy with antiplatelets and OAC (warfarin or NOACs),
caution is warranted as the benefit in terms of decreased stroke and myocardial infarction
risk with triple therapy may be offset by the near two-fold increase in bleeding risk (53).
Warfarin may be the better choice for these patients owing to the ability to conduct
routine INR monitoring as well as tailoring dose to a lower anticoagulant intensity (lower
INR target) to reduce bleeding risk.
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Figure C.3 Guide for choosing an oral anticoagulation based on influence of patient
characteristics on drug pharmacokinetics. API, apixaban; DAB, dabigatran; RIV,
rivaroxaban. BID, twice daily dosing, OD, once daily dosing. CrCl, creatinine clearance;
ERSD, end-stage renal disease; DDI, drug-drug interaction; GI, gastrointestinal; mod,
moderate; NOAC, new oral anticoagulant. Renal function classification based on
estimated CrCl is in accordance with the product monographs for dabigatran,
rivaroxaban, and apixaban.(12, 54, 55) †Moderate renal impairment is defined as CrCl 30
– 50 mL/min for dabigatran and apixaban, while moderate renal impairment is defined as
CrCl 30 – 49 mL/min for rivaroxaban. *History of GI bleed refers to recent and/or
recurrent GI bleeding events. Disease condition(s) predisposing higher risk of GI bleed
include but not exclusive to active peptic ulcer disease, ulcerative gastrointestinal disease,
recent biopsy or trauma, and gastritis.
Disclaimer: The information presented herein represents the opinion of the authors based
on currently available data and should not serve as substitute for clinical judgment.
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Selection of warfarin vs new oral anticoagulant (NOAC) for AF patients
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•
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* refer to Table 3 for detailed criteria
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Figure C.3 Guide for choosing an oral anticoagulation based on influence of patient
characteristics on drug pharmacokinetics.
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Table C.3 Summary of patient criteria for selecting warfarin vs new oral
anticoagulants (NOACs).
Select warfarin
stable and well controlled INR

Select NOACs
previously on warfarin with poor INR
control

CrCl < 30 mL/min

normal renal function or mild renal
dysfunction

low cost to patient/lack of insurance

high cost of drug affordable

coverage
good compliance

inadequate access to routine INR
monitoring

history of gastrointestinal bleeding

require rapid onset of action

require rapid reversal (antidote)

harboring multiple variant alleles in
CYP2C9 and VKORC1 known to confer
warfarin sensitivity *

concomitant use of P-gp/CYP3A4

patient preference

inhibitor or inducer
CrCl, creatinine clearance; CYP, cytochrome P450; INR, international normalized ratio;
P-gp, P-glycoprotein; VKORC1, vitamin K epoxide reductase enzyme subunit 1.
* particularly CYP2C9 poor metabolizer genotype combined with VKORC1 sensitive
genotype.
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Dosing adjustments
Dosing adjustments are summarized in Figure C.3 and Table C.4. As noted earlier,
kidney is the predominant pathway of excretion for dabigatran while to a lesser extent for
rivaroxaban and apixaban. Renal function is an important variable that must be
considered carefully in AF patients, particularly because age-related decline in renal
function and variation introduced by comorbidities has been well-characterized. The
impact of renal function and demographics has been evaluated in RE-LY AF patients.
The median CrCl of the trial was 69 mL/min; patients with CrCl of 30 and 50 mL/min
had a 1.8- and 1.2- fold increase in dabigatran AUC, respectively (45). Not surprisingly,
age reduced apparent clearance (CL/F) by 0.41% per year from median age of 72. Based
on these data, age and renal function warrants dose adjustment. The standard dabigatran
dose for AF patients with normal renal function is 150 mg BID while approved doses for
patients with CrCl < 30 mL/min differs between countries. In the United States, a dose of
75 mg is approved for patients with CrCl 15 - 29 mL/min. However, these
recommendations were approved on the basis of PK modeling studies and clinical data
supporting this is lacking, limiting the creditability of its use in real-world patients (45).
In other countries including Canada, dabigatran use is contraindicated in patients with
CrCl < 30 mL/min. For patients over 75 years old at increased bleeding risk, previous
history of GI/intracerebral bleeding, or receiving concomitant antiplatelet or P-gp potent
inhibitor, 110 mg BID should be used (a dose not available in the United States).

The typical rivaroxaban dose for most AF patients is 20 mg OD. Based on PK modeling,
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15 mg OD of rivaroxaban in individuals with moderate or severe renal impairment would
have similar plasma levels as individuals with normal renal function taking 20 mg (42,
44). In the ROCKET-AF trial, safety and efficacy of this dosing regimen in patients with
moderate renal impairment was demonstrated in the comparable stroke and bleeding rates
irrespective of renal impairment (56). Similar to dabigatran, approved doses of
rivaroxaban is country-specific. In United States, 20 mg rivaroxaban is approved for
patients with CrCl > 50 mL/min while 15 mg is approved for patients with CrCl 15 – 49
mL/min. In all other countries, 15 mg is approved only for those with CrCl 30 – 49
mL/min and contraindicated in those with severe impairment. Unlike dabigatran, patient
age doesn’t appear to elevate bleeding risk and no dosing adjustments is suggested.
Lower dose of 15 mg should be used with coadministration of a strong CYP3A4/P-gp
inhibitor or multiple moderate inhibitors.

The dose of apixaban to be administered to the average patient is 5 mg BID. In patients
with mild or moderate renal impairment, no dose adjustment is necessary. Patients with
severe renal impairment (CrCl 15 - 29 mL/min) require 2.5 mg BID and use in patients
with CrCl < 15 mL/min is contraindicated. While no dose adjustment is required in
patients with mild or moderate hepatic impairment, apixaban use should be used with
caution in such patients. Individuals with body weight < 50 Kg had 30% greater exposure
than individuals weighing 65 to 85 kg, whom had 30% lower exposure compared to
individuals weighing > 120 kg (12). Elderly patients above 65 years-of-age exhibited
32% greater AUC than younger patients (12). Accordingly, dose reduction to 2.5 mg BID
is warranted for patients concomitantly taking CYP3A4/P-gp inhibitors or meeting at
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least two of the following criteria: > 80 years old, body weight ≤ 60 kg, and creatinine >
133 µmol/L.

Ethnic differences in dosing requirement have only been found for rivaroxaban. The JROCKET trial was conducted to evaluate rivaroxaban use in Japanese patients (57). This
was due to the observation that healthy Japanese subjects had a 20-40% increase in
rivaroxaban exposure compared to Caucasian subjects (57). Thus, 15 mg rivaroxaban in
J-ROCKET patients resulted in similar efficacy and exposures as that observed in nonJapanese patients. Similar reductions in rivaroxaban dose should be considered for
patients of Asian ancestry, and not limited to those of Japanese ancestry.

Notably, we are starting to realize the role of genetic variation to interindividual
variability of NOAC exposure and clinical outcomes. The CES1 rs2244613 SNP was not
only associated with lower dabigatran exposure but also with reduced bleeding risk,
indicating the potential for pharmacogenetics-based dosing adjustments using this
intronic SNP (16). As clinically relevant polymorphisms also exist in CYP3A4/5, P-gp,
and BCRP, these genetic variations may also play an important role in determining
NOAC exposure. Overall, the full spectrum of NOAC efficacy and safety within the
context of pharmacogenetics, demographics, concomitant medications, and comorbidities
should be characterized as the use of these new agents increase in AF patients outside of
the clinical trial setting.
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Table C.4 Dosing adjustments based on pharmacokinetic considerations.
Dabigatran

Rivaroxaban

Apixaban

(mg BID)

(mg OD)

(mg BID)

Mild (CrCl 51 – 80 mL/min)

150

20

5

Moderate (CrCl 30 – 50

110

15

5

n.r.

15

2.5

Mild (Child-Pugh A)

150

20

5

Moderate (Child-Pugh B)

150

n.r.

5

Severe (Child-Pugh C)

n.r.

n.r.

n.r.

Hepatic dysfunction

n.r.

n.r.

n.r.

Ethnicity, Asian

150

15

5

Age, > 75 - 80 yr

110

20

2.5

Weight, < 50 kg

150

20

2.5

P-gp inhibitor

110

15

2.5

CYP3A4 inhibitor

150

15

2.5

P-gp/CYP3A4 inducer

n.r. *

n.r.

n.r.

Renal impairment

mL/min)
Severe (CrCl < 30 mL/min)
Hepatic impairment

Demographic variables

Drug-drug interactions

n.r., not recommended. CYP, cytochrome P450; P-gp, P-glycoprotein.
* CYP3A4 and P-gp are both transcriptionally regulated by xenobiotic sensing nuclear
receptors such as Pregnane X Receptor (PXR) and Constitutive Androstane Receptor
(CAR) (58). Therefore, inducers listed in Table C.2 would lower the plasma level of all
the NOACs outlined in this review.
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Limitations of NOACs
A major limitation of NOAC use is the lack of standardized coagulation tests for
monitoring anticoagulation response. The need for monitoring has been heavily debated
and regulators recently stated that monitoring is necessary in specific clinical
circumstances: renal/liver dysfunction, overdose, prior to invasive surgery, noncompliance, bleeding or thrombosis/stroke, drug-drug interaction and suspected variation
in drug exposure (59). Although some assays have been suggested as surrogate markers
of exposure, limitations in their use include accuracy and clinical experience/availability.
More importantly, meaningful interpretation of the results is difficult owing to lack of
guidance on extrapolating coagulation results to bleeding and thrombosis risk.
Accordingly, directly measuring plasma NOAC drug concentrations may be more
desirable and more accurate for monitoring anticoagulation. An important consideration
for measuring either coagulation or NOAC drug exposure is the standardization of
sampling time from the last dose. The Ctrough level is preferred over the Cmax, avoiding
misinterpretation of results due to variability in absorption phase.

The second limitation is the lack of a validated antidote for rapidly reversing NOACs’
effects. Hemodialysis of dabigatran may be an option given its relatively low protein
binding, but not for rivaroxaban and apixaban which have high protein binding. Potential
reversal agents that have shown promise for reversing NOAC anticoagulation include
prothrombin complex concentrate and recombinant factor VIIa (60, 61). Until better
guidelines are available, NOACs should be used with caution, particularly in patients
with elevated bleeding risk.
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Switching from warfarin to NOAC and vice versa
Patients without adequate INR control will likely benefit from transitioning from
warfarin to one of the NOACs for enhanced efficacy and reduced risk of intracranial
bleeding. It has been recommended that NOAC should be started after INR decreases to
< 2.3 following warfarin discontinuation (62). For patients unable to continue NOAC
therapy and require transitioning to warfarin, it is necessary to consider the delayed onset
of warfarin and allow attainment of therapeutic INR prior to discontinuation of NOAC.

Conclusions
NOACs are promising alternatives to warfarin, demonstrating at least similar
antithrombotic efficacy and decreased rate of intracranial hemorrhage. However, the
availability of multiple NOACs has introduced difficulty in deciding the best agent since
head-to-head trials are unavailable and unlikely to be performed. Rather, clinicians are
required to make informed decisions in selecting the appropriate agent based on
characteristics of the patient and OAC pharmacology. As the clinical use of NOACs
increases, surveillance using therapeutic monitoring (measurement of plasma drug
concentration or anticoagulation response) throughout the treatment period may be
valuable in minimizing risk of bleeding and lack of efficacy. Finally, due to the extent of
interindividual variation in the metabolism and clearance of NOACs, it is likely a greater
range of NOAC doses will be needed to more precisely treat our patients.
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Elucidate the PK-PD relationship of clopidogrel active metabolite to platelet reactivity.
Antiplatelet therapy: (in collaboration with cardiologists)
Role: Lead; enrollment of patients on clopidogrel and new antiplatelet agent ticagrelor
Objective:
Evaluate the interpatient variability in pharmacokinetics of patients on clopidogrel and
ticagrelor, as well as delineating biomarkers of drug-related side effects.
Assessment and compare endothelial function in patients treated with clopidogrel and
ticagrelor.
Immunosuppressant therapy: (in collaboration with nephrologists)
Role: Lead; enrollment of patients on tacrolimus following organ transplantation
Objective:
Assessment of genetic markers of tacrolimus response, pharmacokinetics, and toxicities
to design a precise protocol for individualized loading and maintenance tacrolimus
dosing regimen.

Invited Oral Presentations
“Genetic and clinical determinants of CYP3A4 activity in patients using 4βhydroxycholesterol as an in vivo probe” Gong IY, DeGorter MK, Schwarz UI, Choi YH,
Yin P, Tirona RG, Kim RB. American Society of Pharmacology and Experimental
Therapeutics 2013, Boston, Massachusetts, April 2013.
“Pharmacogenetics of oral anticoagulants and antiplatelets: implications on clinical
practice” Gong IY. Department of Physiology and Pharmacology Seminar Series, the
University of Western Ontario, London, Ontario, January 2013.
“Learn and confirm: Evaluation of CYP3A4 Mediated Drug-Drug Interaction Potential
Between PI3K Inhibitor GDC-0941 and Ketoconazole Using Simcyp” Gong IY.
Department of Clinical Pharmacology Seminar Series, Genentech, South San Francisco,
California, December 2011.
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“Role of Efflux Transporters MDR1 and BCRP to Rivaroxaban Disposition” Gong IY,
Kim RB. Canadian Society of Pharmacology and Therapeutics Meeting 2011, Montreal,
Quebec, May 2011.
“Warfarin pharmacogenetics and better patient care: the importance of teamwork in
patient oriented research” Gong IY, Crown N, Dresser GK, Schwarz UI, Tirona RG, Kim
RB. Medical Grand Rounds, Department of Medicine, London Health Sciences Centre,
London, Ontario, January - February 2011.
“Molecular Determinants of Warfarin Pharmacokinetics and Pharmacological Response”
Gong IY, Schwarz UI, Tirona RG, Crown N, LaRue S, Langlois N, Dresser G, LazoLangner A, Zou GY, Wells P, Kim RB. Canadian Society of Pharmacology and
Therapeutics Meeting 2010, Toronto, Ontario, June 2010.
“Drug disposition and dosing strategies of old and new oral anticoagulants” Gong IY.
Division of Clinical Pharmacology Grand Rounds, University Hospital, London, Ontario,
January 2010.
“Liquid chromatography mass spectrometry: Basic Principals and Application to Clinical
Pharmacology” Gong IY, Urquhart BL. Academic Teaching for Post-Graduate Medical
Residents, University Hospital, London, Ontario, September 2009.
“Personalized Medicine and Warfarin Initiation: UWO Experience and Preliminary
Data” Kim RB, Tirona RG, Schwarz UI, Gong IY. Pharmacogenetics Research Network
Webinar, April 2009.
External Poster Presentations
“CYP3A4*22 single nucleotide polymorphism is an important determinant of endoxifen
plasma concentration” Gong IY, Teft WA, Dingle B, Potvin K, Younus J, Vandenberg
TA, Brackstone M, Perera FE, Choi Y, Zou G, Legan RM, Tirona RG, Kim RB.
American Society of Clinical Pharmacology and Therapeutics Meeting 2013,
Indianapolis, Indiana, March 2013.
“Role of Efflux Transporters MDR1 and BCRP to Rivaroxaban Disposition” Gong IY,
Kim RB. 19th International Symposium on Microsomes and Drug Oxidations and 12th
European International Society for the Study of Xenobiotics Meeting, Noordwijk Aan
Zee, Netherlands, June 2012.
“CYP2C19, PON1, and the role of PPIs to clopidogrel bioactivation and in vivo
antiplatelet response” Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer
MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB. Canadian Society of
Pharmacology and Therapeutics Meeting 2012, Toronto, Ontario, June 2012.
“Pharmacokinetic-Pharmacodynamic Modeling Reveals Novel Determinants of Warfarin
Response During Initiation of Therapy” Gong IY, Schwarz UI, Crown N, Dresser GK,
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Lazo-Langner A, Zou G, Roden DM, Stein CM, Wells PS, Kim RB, Tirona RG.
American Society of Clinical Pharmacology and Therapeutics Meeting 2011, Dallas,
Texas, March 2011.
“Molecular determinants of warfarin pharmacokinetics and response” Gong IY, Schwarz
UI, Tirona RG, Crown N, LaRue S, Langlois N, Dresser G, Lazo-Langner A, Zou GY,
Wells P, Kim RB. 16th World Congress of Basic and Clinical Pharmacology,
Copenhagen, Denmark, July 2010.
“Pharmacokinetic and Pharmacodynamic Determinants of Warfarin Anticoagulation
Response” Gong IY, Schwarz UI, Tirona RG, Crown N, LaRue S, Langlois N, Dresser
G, Lazo-Langner A, Zou GY, Wells P, Kim RB. 16th Annual Meeting of the International
Society for the Study of Xenobiotics, Baltimore, Maryland, October 2009.
“Warfarin oral anticoagulation therapy: R/S-warfarin and vitamin K levels as
determinants of maintenance dose.” Gong IY, Schwarz UI, Tirona RG, Kim RB.
Canadian Society of Pharmacology and Therapeutics Meeting 2009, Saskatoon,
Saskatchewan, May 2009.
“Prediction of CYP3A4 mediated drug-drug interaction potential between PI3K inhibitor
GDC-0941 and ketoconazole through physiologically-based pharmacokinetics modeling”
Jin JY, Gong IY, Chen Y, Salphati L, Budha N, West DA, Mukadam S, Holden S, Ware
JA, Dresser MJ. American Society of Clinical Pharmacology and Therapeutics Meeting
2012, Washington, Maryland, March 2012.
“Regulation of Cytochrome P450 3A4 in Non-Alcoholic Fatty Liver Disease by
Fibroblast Growth Factor 21” Woolsey SJ, Gong IY, Stein S, Kim RB, Levstik M,
Beaton MD, Tirona RG. American Association for the Study of Liver Diseases Meeting
2012, Boston, Massachusetts, November 2012.

